	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S103-PMC2290997	PMC2290997	4/2008	S103-PMC2290997	['additionally, solely Breastfed infants whose mothers were Vitamin D deficient during Pregnancy have smaller reserves of the Nutrient and are at greater risk of developing rickets.']	N/A	N/A	[('GO_0007567', 'parturition', 21, 'breastfed'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('CHEBI_33284', 'nutrient', 124, 'nutrient')]
S4-PMC2606998	PMC2606998	6/2007	S4-PMC2606998	['absolute intakes were below recommended intake (ri) according to nnr for Folate, Vitamin D, Selenium, Vitamin E and iron both before and at mid-Gestation.']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 73, 'folate'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 92, 'selenium'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin E'), ('GO_0007565', 'female pregnancy', 144, 'gestation')]
S6-PMC2606998	PMC2606998	6/2007	S6-PMC2606998	['twenty-three women were below li for Selenium before Pregnancy and five for each of Vitamin D and Selenium at mid-Gestation.']	N/A	N/A	[('CHEBI_27568', 'selenium atom', 37, 'selenium'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 98, 'selenium'), ('GO_0007565', 'female pregnancy', 114, 'gestation')]
S7-PMC2606998	PMC2606998	6/2007	S7-PMC2606998	['when expressed as Nutrient densities (amount of Nutrient per energy unit), intakes were below nnr for Folate, Vitamin D and Selenium before Pregnancy, and for folate, Vitamin D and iron at mid-Gestation.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 18, 'nutrient'), ('CHEBI_33284', 'nutrient', 48, 'nutrient'), ('CHEBI_30863', '5-azaorotic acid', 102, 'folate'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 124, 'selenium'), ('GO_0007565', 'female pregnancy', 140, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'gestation')]
S75-PMC2606998	PMC2606998	6/2007	S75-PMC2606998	['intakes were also expressed as Nutrient densities (amount per mj) and were shown to be lower than ri for Folate, Vitamin\u2009D and Selenium in the Pregestational diet, and for Folate, Vitamin\u2009D and iron at mid-Gestation (table5).']	N/A	N/A	[('CHEBI_33284', 'nutrient', 31, 'nutrient'), ('CHEBI_30863', '5-azaorotic acid', 105, 'folate'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 127, 'selenium'), ('GO_0007565', 'female pregnancy', 143, 'pregestational'), ('CHEBI_30863', '5-azaorotic acid', 172, 'folate'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('GO_0007565', 'female pregnancy', 206, 'gestation')]
S89-PMC2606998	PMC2606998	6/2007	S89-PMC2606998	['at mid-Gestation five women were below li for Vitamin\u2009D and Selenium.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'gestation'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 60, 'selenium')]
S103-PMC2716336	PMC2716336	7/2009	S103-PMC2716336	['caption (table-wrap): table 3\n\nmedian Intake and percentage of inadequate Intake of selected Nutrients in rural shaanxi china 2004median intakeear*increment for Pregnancy<ear + increment (%)energy (kcal)2234.62100†20054protein (g)60.638‡1231calcium (mg)412.9525¶070zinc (mg)8.58.3591riboflavin (mg)0.881.00.4591vitamin C (mg)89.475-934folate (μg)244.232020097\n* estimated average requirement for non-Pregnant women aged above 18 with low physical activity, china nutrition society, 2001\n† ear for energy shown in the table is the figure rni for energy\n‡ the figure shown is the ear for protein for non-Pregnant women aged from 19–50 in usa with the addition of an increment for Pregnancy (ear for groups Food and nutrition board, institute of medicine, national academies)\n¶the figure shown is the ear for Calcium for non-Pregnant women aged 19–50 years in united kingdom with the addition of an increment for Pregnancy (ear; department of health, 1991)\nthe median intakes of energy, protein, calcium, iron, zinc, riboflavin, Vitamin C and Folate were compared between bmi and household wealth sub-groups (table4).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 38, 'intake'), ('GO_0007631', 'feeding behavior', 74, 'intake'), ('CHEBI_33284', 'nutrient', 93, 'nutrients'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy'), ('CHEBI_18245', 'carboxylato group', 319, 'C'), ('GO_0007565', 'female pregnancy', 400, 'pregnant'), ('GO_0007565', 'female pregnancy', 602, 'pregnant'), ('GO_0007565', 'female pregnancy', 678, 'pregnancy'), ('CHEBI_33290', 'food', 704, 'Food'), ('CHEBI_22313', 'alkaline earth metal atom', 806, 'calcium'), ('GO_0007565', 'female pregnancy', 822, 'pregnant'), ('GO_0007565', 'female pregnancy', 910, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1026, 'vitamin C'), ('CHEBI_30863', '5-azaorotic acid', 1040, 'folate')]
S113-PMC2716336	PMC2716336	7/2009	S113-PMC2716336	['comparison of dietary Intakes of Vitamin C (mg) and iron (mg) based on the Food frequency questionnaire by Pregnant women in rural shaanxi china 2004 by season of third Trimester.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 22, 'intakes'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin C'), ('CHEBI_33290', 'food', 75, 'food'), ('GO_0007565', 'female pregnancy', 107, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 169, 'trimester')]
S36-PMC2798111	PMC2798111	12/2010	S36-PMC2798111	['following written informed consent, mothers were randomized to one of three Vitamin D supplementation regimens: group 1: 400\u2009iu Vitamin D3/day (0\u2009iu vitamin D3—placebo and 1 Prenatal Vitamin containing 400\u2009iu Vitamin D3), group 2: 2,400\u2009iu Vitamin D3/day (2,000\u2009iu Vitamin D3And 1 Prenatal Vitamin containing 400\u2009iu Vitamin D3), or group 3: 6,400\u2009iu Vitamin D3/day (6,000\u2009iu Vitamin D3And 1 Prenatal Vitamin containing 400\u2009iu Vitamin D3).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 128, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 128, 'vitamin D3'), ('CHEBI_29238', 'tritium atom', 157, 'D3'), ('PR_000001177', 'D(2) dopamine receptor', 157, 'D3'), ('GO_0007565', 'female pregnancy', 174, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 183, 'vitamin'), ('CHEBI_33279', 'vitamin D5', 209, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 209, 'vitamin D3'), ('CHEBI_33279', 'vitamin D5', 240, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 240, 'vitamin D3'), ('CHEBI_61991', 'maltotriose trisaccharide', 265, 'vitamin D3and'), ('PR_000006317', 'mRNA-decapping enzyme 1A', 273, 'D3and'), ('GO_0007565', 'female pregnancy', 281, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 290, 'vitamin'), ('CHEBI_33279', 'vitamin D5', 316, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 316, 'vitamin D3'), ('CHEBI_33279', 'vitamin D5', 350, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 350, 'vitamin D3'), ('CHEBI_61991', 'maltotriose trisaccharide', 375, 'vitamin D3and'), ('PR_000027594', 'histone H3', 375, 'vitamin D3and'), ('GO_0007565', 'female pregnancy', 391, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 400, 'vitamin'), ('CHEBI_33279', 'vitamin D5', 426, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 426, 'vitamin D3')]
S4-PMC2821652	PMC2821652	2/2010	S4-PMC2821652	['data were obtained from a Prenatal Vitamin D supplementation trial where subjects were stratified by race and randomized into three dosing groups: 400 (control), 2000, or 4000 iu Vitamin D3/day.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 179, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 179, 'vitamin D3')]
S48-PMC2821652	PMC2821652	2/2010	S48-PMC2821652	['study design\ndata were obtained from a large nih-supported (#r01 hd043921) randomized, double-blind, Placebo-control trial of Vitamin D supplements in Pregnant women that took place at the medical university of south carolina (musc).']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 101, 'placebo'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnant')]
S126-PMC2821652	PMC2821652	2/2010	S126-PMC2821652	['because maternal circulating 25(Oh)D is not affected by Gestational age per se, the stability of Vitamin D during Pregnancy allowed for analysis of adherence once steady state was achieved throughout Gestation [15,16].']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 35, 'D'), ('GO_0007565', 'female pregnancy', 56, 'gestational'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('GO_0007565', 'female pregnancy', 200, 'gestation')]
S62-PMC2849017	PMC2849017	9/2007	S62-PMC2849017	['in the hungarian study, women (n=4,156) without a previous ntd-affected Pregnancy and Planning to Become Pregnant again were randomly assigned to receive a multivitamin-Mineral supplement (including 0.8mg of Folic Acid) or a placebo (no Folic Acid but contained copper, manganese, zinc and Vitamin C) (czeizel, 1993).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('GO_0006260', 'DNA replication', 86, 'planning'), ('GO_0007567', 'parturition', 98, 'become'), ('GO_0007565', 'female pregnancy', 105, 'pregnant'), ('CHEBI_46662', 'mineral', 169, 'mineral'), ('CHEBI_30751', 'formic acid', 208, 'folic acid'), ('CHEBI_30751', 'formic acid', 237, 'folic acid'), ('CHEBI_27300', 'vitamin D', 290, 'vitamin C'), ('PR_000004900', 'complement C3', 298, 'C')]
S89-PMC2872349	PMC2872349	4/2010	S89-PMC2872349	['in this study 31% of the mothers had insufficient and 18% had deficient circulating concentrations of 25(Oh) Vitamin D during late Pregnancy (11–20 and <11 μg/l respectively).']	N/A	N/A	[('CHEBI_30778', 'gallic acid', 102, '25(OH)'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy')]
S58-PMC2874518	PMC2874518	6/2010	S58-PMC2874518	['dietary recall\nbased on midwife-administered 24-hour recall dietary assessment at 8–12 weeks of Gestation, women in our cohort had average dietary intakes from Food above the reference Nutrient intake values for most Vitamins and minerals21except Vitamin D, iron, Folate, Selenium and Iodine (table 2).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 96, 'gestation'), ('CHEBI_33290', 'food', 160, 'food'), ('CHEBI_33284', 'nutrient', 185, 'nutrient'), ('CHEBI_33277', 'gamma-tocotrienol', 217, 'vitamins'), ('CHEBI_27300', 'vitamin D', 247, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 264, 'folate'), ('CHEBI_27568', 'selenium atom', 272, 'selenium'), ('CHEBI_24859', 'iodine atom', 285, 'iodine')]
S61-PMC2874518	PMC2874518	6/2010	S61-PMC2874518	['caption (table-wrap): table 2\n\naverage daily intakes of Vitamins and Minerals (from diet alone) based on 24-hour dietary recall at 8–12 weeks of Pregnancy, leeds, uk, 2003–06 ( n = 1257)Micronutrientmean (sd)rni*recommended increment to rni during Pregnancy**proportion of women with Intakes above the Pregnancy rni (95% ci)Thiamin (mg/day)2.4 (7.7)0.8+0.185 (83, 87)riboflavin (mg/day)1.7 (0.8)1.1+0.358 (55, 61)niacin (mg/day)20 (10)13–75 (72, 77)Vitamin B6 (mg/day)2.1 (1.0)1.2–85 (82, 86)Vitamin B12 (μg/day)3.9 (3.7)1.5–79 (77, 82)Folate (μg/day)257 (119)200+10032 (29, 35)vitamin c (μg/day)143 (129)40+1075 (73, 78)Vitamin A (μg Retinol equivalent/day)803 (665)600+10045 (42, 48)Vitamin D (μg/day)2.5 (2.7)–102 (1, 3)Vitamin E (mg/day)7.9 (5.4)–****–Calcium (mg/day)938 (471)700***65 (62, 68)Phosphorus (mg/day)1344 (501)550***98 (97, 99)magnesium (mg/day)283 (112)270***49 (46, 52)iron (mg/day)11.5 (5.3)14.8***20 (18, 23)Zinc (mg/day)8.6 (4.3)7***59 (56, 62)copper (mg/day)1.1 (0.6)1.2***32 (29, 35)Selenium (μg/day)58 (37)60***40 (38, 43)Iodine (μg/day)118 (82)140***28 (24, 29)\nreference Nutrient intakes (rni) for women aged 19–50 years in the uk.21\nreference Nutrient intakes for Pregnant women.21\nno increment.21\nsafe intake – above 3 mg/day for women.21\n\ntype of supplements\nwomen reported taking 22 different types of supplements including Folic Acid, iron, combined Folic Acid–iron preparations, multivitamin–Mineral preparations (six brands), evening primrose, cod Liver oil, Omega 3, Vitamin C, Vitamin B, Vitamin D, Vitamin E, Vitamin A, calcium, zinc, magnesium and Selenium preparations (table 3).']	N/A	N/A	"[('CHEBI_33277', 'gamma-tocotrienol', 56, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 69, 'minerals'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('CHEBI_6923', 'miconazole', 186, 'MicronutrientMean'), ('GO_0007565', 'female pregnancy', 248, 'pregnancy'), ('GO_0007631', 'feeding behavior', 284, 'intakes'), ('GO_0007565', 'female pregnancy', 302, 'pregnancy'), ('CHEBI_9544', 'thiethylperazine', 324, 'Thiamin'), ('CHEBI_27306', 'vitamin B6', 449, 'Vitamin B6'), ('PR_000017269', 'ventral anterior homeobox 2', 449, 'Vitamin B6'), ('CHEBI_28334', 'malonamoyl-CoA', 492, 'Vitamin B12'), ('PR_000017279', 'testis-specific basic protein Y 1', 492, 'Vitamin B12'), ('CHEBI_81245', 'Vulpecholate', 536, 'Folate'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 621, 'Vitamin A'), ('CHEBI_26536', 'retinoic acid', 635, 'retinol'), ('CHEBI_28384', 'vitamin K', 685, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 723, 'Vitamin E'), ('CHEBI_31341', 'calcium dihydroxide', 756, 'Calcium'), ('CHEBI_30207', 'phosphorus(.)', 798, 'Phosphorus'), ('CHEBI_27377', ""Unsym-bis(4'-chlorophenyl)ethylene"", 929, 'Zinc'), ('CHEBI_27568', 'selenium atom', 1007, 'Selenium'), ('CHEBI_31719', 'ipriflavone', 1047, 'Iodine'), ('CHEBI_33284', 'nutrient', 1098, 'nutrient'), ('CHEBI_33284', 'nutrient', 1171, 'nutrient'), ('GO_0007565', 'female pregnancy', 1192, 'pregnant'), ('CHEBI_30751', 'formic acid', 1355, 'folic acid'), ('CHEBI_30751', 'formic acid', 1382, 'folic acid'), ('CHEBI_46662', 'mineral', 1425, 'mineral'), ('UBERON_0002107', 'liver', 1482, 'liver'), ('CHEBI_30823', 'oleate', 1493, 'omega'), ('CHEBI_27300', 'vitamin D', 1502, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 1513, 'vitamin B'), ('CHEBI_27300', 'vitamin D', 1524, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1535, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 1546, 'vitamin A'), ('CHEBI_27568', 'selenium atom', 1586, 'selenium')]"
S109-PMC2874518	PMC2874518	6/2010	S109-PMC2874518	['both brands included Folate and Vitamin C exceeding the current recommended minimum during Pregnancy (table 2).']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 21, 'folate'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin C'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy')]
S0-PMC3004407	PMC3004407	12/2010	S0-PMC3004407	['profound Vitamin D deficiency in a diverse group of women during Pregnancy living in a sun-rich environment at latitude 32°n\n\nabstract\nobjective : determine prevalence of Vitamin D deficiency (vdd) in a diverse group of women presenting for obstetrical care at two community health centers in south carolina at latitude 32°n.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 9, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D')]
S34-PMC3004407	PMC3004407	12/2010	S34-PMC3004407	['each woman had been prescribed a Prenatal Vitamin containing 400\u2009iu of Vitamin D at her first Prenatal visit; compliance with the Prenatal vitamin regimen at the time of the Blood sampling was also recorded.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 33, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 42, 'vitamin'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'prenatal'), ('GO_0007565', 'female pregnancy', 130, 'prenatal'), ('UBERON_0000178', 'blood', 174, 'blood')]
S97-PMC3004407	PMC3004407	12/2010	S97-PMC3004407	['after controlling for race, Prenatal/multivitamin use (containing 400\u2009iu Vitamin D/day) was not associated with 25(Oh)D concentration ( p = .11).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 28, 'prenatal'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 81, 'D'), ('CHEBI_71657', 'versiconol acetate', 112, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 112, '25(OH)D')]
S148-PMC3004407	PMC3004407	12/2010	S148-PMC3004407	['at its most basic concentration, such a burden of deficiency sets the stage of subsequent deficiency for the neonate and infant whose stores of Vitamin D were set during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 170, 'pregnancy')]
S0-PMC3032617	PMC3032617	5/2010	S0-PMC3032617	['regular Vitamin C supplementation during Pregnancy reduces hospitalization: outcomes of a ugandan rural cohort study\n\nabstract:executive-summary\n\nbackground\nvitamin c or Ascorbic Acid is a hydro-soluble Lactone (synthesized from Glucose) essential to Human body and available from diet.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin C'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('CHEBI_22652', 'ascorbic acid', 170, 'ascorbic acid'), ('CHEBI_25000', 'lactone', 203, 'lactone'), ('CHEBI_17234', 'glucose', 229, 'glucose'), ('NCBITaxon_9606', 'Homo sapiens', 251, 'human')]
S4-PMC3032617	PMC3032617	5/2010	S4-PMC3032617	['methods\n384 Pregnant women met the inclusion criteria and were randomly assigned to receive either 400 mg of Vitamin C daily (187) or not (197) in addition to their standard Antenatal Vitamins until Delivery.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 12, 'pregnant'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin C'), ('GO_0007567', 'parturition', 174, 'antenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 184, 'vitamins'), ('GO_0007567', 'parturition', 199, 'delivery')]
S7-PMC3032617	PMC3032617	5/2010	S7-PMC3032617	['results\n42.2% women in the Vitamin C group and 27.9% in the control group were not hospitalized during Pregnancy; this difference was found statistically significant.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin C'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy')]
S63-PMC3032617	PMC3032617	5/2010	S63-PMC3032617	['fisher’s exact test was employed to compare the Vitamin C group vs. controls with respect to: need or not for hospitalization, term Pregnancy, preterm Delivery, Miscarriage and child low Birth weight.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 48, 'vitamin C'), ('GO_0007565', 'female pregnancy', 132, 'pregnancy'), ('GO_0007567', 'parturition', 151, 'delivery'), ('GO_0046660', 'female sex differentiation', 161, 'miscarriage'), ('GO_0007567', 'parturition', 187, 'birth')]
S78-PMC3032617	PMC3032617	5/2010	S78-PMC3032617	['during Pregnancy, 79 out of 187 (42.2%) in the Vitamin C group and 55 out of 197 (27.9%) in the control group were not hospitalized and this difference was considered statistically significant.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin C')]
S79-PMC3032617	PMC3032617	5/2010	S79-PMC3032617	['term Pregnancy was achieved by 143 out of 187 women in the Vitamin C group and 152 out of 197 in the control group, the difference was considered not significant.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin C')]
S80-PMC3032617	PMC3032617	5/2010	S80-PMC3032617	['for the Preterm Delivery, 15 vs.18 in the Vitamin C group and in the control group respectively were recorded and no statistical difference was found.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 8, 'preterm'), ('GO_0007567', 'parturition', 16, 'delivery'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin C')]
S84-PMC3032617	PMC3032617	5/2010	S84-PMC3032617	['average weight gain during Pregnancy was of 14kg in the Vitamin C group of women and 15 kg in the control group, this difference was found statistically not significant (table 1).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin C')]
S9-PMC3034879	PMC3034879	12/2010	S9-PMC3034879	['results\nthe children were divided into two groups based on Vitamin D status during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy')]
S37-PMC3034879	PMC3034879	12/2010	S37-PMC3034879	['maternal Vitamin D status was assessed in communal Prenatal clinics during the first trimesters as part of normal follow-up.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'prenatal')]
S91-PMC3034879	PMC3034879	12/2010	S91-PMC3034879	['for data analysis, the participants were divided into two groups based on maternal Vitamin D status during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy')]
S139-PMC3034879	PMC3034879	12/2010	S139-PMC3034879	['firstly, distal Tibia csa remained larger at 14\xa0months in infants with higher maternal Vitamin D status during Pregnancy than in infants with lower maternal Vitamin D status.']	N/A	N/A	[('UBERON_0000979', 'tibia', 16, 'tibia'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D')]
S140-PMC3034879	PMC3034879	12/2010	S140-PMC3034879	['secondly, the increment in Tibial bmc from Birth to 14\xa0months was higher in those with inferior maternal Vitamin D status during Pregnancy.']	N/A	N/A	[('UBERON_0002101', 'limb', 27, 'tibial'), ('GO_0007567', 'parturition', 43, 'birth'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]
S31-PMC3039633	PMC3039633	2/2011	S31-PMC3039633	['the search syntax included four key parts: 1) terms defining the population of interest (Pregnancy, Pregnant women, Prenatal, Perinatal, Antenatal); 2) terms for Micronutrients (supplement, Micronutrient, dietary supplement, Vitamin, Mineral, Folic Acid/Folate, iron, Iodine, b complex, b12, selenium, zinc, Vitamin A, Vitamin D); 3) terms for developmental outcomes (Infant Development, Child Development, Mental Development, Brain Development, Neurodevelopment, Cognitive Development, psychomotor, iq, behavior); and 4) terms for study design (rct, pseudo-experimental, clinical trial, longitudinal cohort).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('GO_0007565', 'female pregnancy', 100, 'pregnant'), ('GO_0007565', 'female pregnancy', 116, 'prenatal'), ('GO_0036268', 'swimming', 126, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 126, 'perinatal'), ('GO_0007567', 'parturition', 137, 'antenatal'), ('CHEBI_33839', 'macromolecule', 162, 'micronutrients'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 190, 'micronutrient'), ('CHEBI_33229', 'vitamin (role)', 225, 'vitamin'), ('CHEBI_46662', 'mineral', 234, 'mineral'), ('CHEBI_30751', 'formic acid', 243, 'folic acid'), ('CHEBI_30863', '5-azaorotic acid', 254, 'folate'), ('CHEBI_24859', 'iodine atom', 268, 'iodine'), ('CHEBI_27300', 'vitamin D', 308, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 319, 'vitamin D'), ('GO_0060119', 'inner ear receptor cell development', 368, 'infant development'), ('GO_0001410', 'chlamydospore formation', 388, 'child development'), ('GO_0030901', 'midbrain development', 407, 'mental development'), ('GO_0007420', 'brain development', 427, 'brain development'), ('UBERON_0000955', 'brain', 427, 'brain'), ('GO_0007399', 'nervous system development', 446, 'neurodevelopment'), ('GO_0050787', 'detoxification of mercury ion', 464, 'cognitive development')]
S71-PMC3039633	PMC3039633	2/2011	S71-PMC3039633	['[28]276 infants(rural indonesia)1,2(at 6 and 12 mo)bayley scales of infant developmentiron + Folic Acid + Vitamin A vs. Iron + Folic Acid vs. ld iron + ld Folic Acid20 weeks Gestation to Birth∅ 1, 214/21tamura et al.']	N/A	N/A	[('CHEBI_30751', 'formic acid', 93, 'folic acid'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin A'), ('CHEBI_24870', 'ion', 120, 'iron'), ('CHEBI_30751', 'formic acid', 127, 'folic acid'), ('CHEBI_70616', '4-hydroxybenzoic acid 4-(6-O-sulfo)glucopyranoside', 155, 'folic acid20'), ('GO_0007565', 'female pregnancy', 174, 'gestation'), ('GO_0007567', 'parturition', 187, 'birth'), ('GO_0007567', 'parturition', 192, '∅')]
S32-PMC3103150	PMC3103150	3/2011	S32-PMC3103150	['clinical and anthropometric data:\ndetails regarding mode of Feeding of infant, supplementation of any Vitamin or Calcium to infant, mothers’ diet, Intake of Calcium and Vitamin D supplements during Pregnancy and after Delivery, education and profession, financial status of the family and usual duration and type of clothing worn during sunlight exposure for both infant and mother were recorded in a case record form.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 60, 'feeding'), ('CHEBI_33229', 'vitamin (role)', 102, 'vitamin'), ('CHEBI_22313', 'alkaline earth metal atom', 113, 'calcium'), ('GO_0007631', 'feeding behavior', 147, 'intake'), ('CHEBI_22313', 'alkaline earth metal atom', 157, 'calcium'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 198, 'pregnancy'), ('GO_0007567', 'parturition', 218, 'delivery')]
S9-PMC3107676	PMC3107676	4/2011	S9-PMC3107676	['supplemental Vitamin C, an Inhibitor Of Nitrosation, was not taken by 41.6% and 19.3% of Nitrosatable Drug users during the first and second months of Pregnancy, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin C'), ('CHEBI_52846', 'cycloalkane ring', 27, 'inhibitor of nitrosation'), ('CHEBI_7587', 'nitroalkane', 89, 'nitrosatable'), ('CHEBI_23888', 'drug', 102, 'drug'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy')]
S107-PMC3107676	PMC3107676	4/2011	S107-PMC3107676	['caption (table-wrap): table 3\n\nvitamin c supplementationaamong Nitrosatable Drug users during the first three months of Pregnancy, national Birth defects prevention study control women, 1997–2005number (%) who took Supplement with Vitamin C in the first month postconceptionnumber (%) who took Supplement with Vitamin C in the second month Postconceptionnumber (%) who took supplement with Vitamin C in the third month Postconceptionnitrosatable Drug takennoneless than dailydailynoneless than dailydailynoneless than dailydailyany652 (41.6)311 (19.8)604 (38.5)303 (19.3)299 (19.1)965 (61.6)193 (12.3)125 (8.0)1249 (79.7)secondary Amine334 (40.4)165 (20.0)327 (39.6)158 (19.1)149 (18.0)519 (62.8)89 (10.8)71 (8.6)666 (80.6)tertiary Amine333 (40.8)175 (21.4)308 (37.7)139 (17.0)176 (21.6)501 (61.4)98 (12.0)67 (8.2)651 (79.8)Amide205 (40.0)107 (20.9)200 (39.1)93 (18.2)97 (18.9)322 (62.9)58 (11.3)37 (7.2)417 (81.4)\nsupplementation from single, Prenatal, or multi-vitamin preparations.']	N/A	N/A	[('CHEBI_35705', 'immunosuppressive agent', 63, 'Nitrosatable Drug'), ('GO_0007565', 'female pregnancy', 120, 'Pregnancy'), ('GO_0007567', 'parturition', 140, 'Birth'), ('CHEBI_16158', 'steroid sulfate', 215, 'supplement'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin C'), ('CHEBI_16158', 'steroid sulfate', 294, 'supplement'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin C'), ('GO_0001110', 'promoter clearance from RNA polymerase III promoter', 340, 'postconceptionNumber'), ('CHEBI_27300', 'vitamin D', 390, 'vitamin C'), ('GO_0042711', 'maternal behavior', 419, 'postconceptionNitrosatable'), ('CHEBI_23888', 'drug', 446, 'drug'), ('CHEBI_82784', 'PVP38-Ag NP', 631, 'amine334'), ('CHEBI_83325', 'beta-carboline alkaloid', 732, 'amine333'), ('CHEBI_52661', 'Alexa Fluor 488', 824, 'Amide205'), ('GO_0007565', 'female pregnancy', 944, 'prenatal')]
S37-PMC3119798	PMC3119798	10/2010	S37-PMC3119798	['after the operation, patients received Prenatal Vitamins, Calcium supplements, Vitamin D, and Acid suppression medication.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 39, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 48, 'vitamins'), ('CHEBI_22313', 'alkaline earth metal atom', 58, 'calcium'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('CHEBI_37527', 'acid', 94, 'acid')]
S86-PMC3120197	PMC3120197	7/2011	S86-PMC3120197	['caption (table-wrap): table 2\n\nrrs and 95% cis of gdm according to quartiles of dietary Heme and nonheme Iron Intake, seattle and tacoma, wa, omega cohort studydietary iron variablesmediangdm ( n )energy adjustedadjusted*adjusted†incidence (%)rr (95% ci)rr (95% ci)rr (95% ci)dietary Heme iron (mg per day)\u2003quartile 1 (<0.48)0.3033 (4.1)1.00 (referent)1.00 (referent)1.00 (referent)\u2003quartile 2 (0.48–0.75)0.6136 (4.7)1.22 (0.76–1.96)1.17 (0.73–1.89)1.27 (0.77–2.09)\u2003quartile 3 (0.76–1.11)0.9336 (4.5)1.28 (0.79–2.08)1.20 (0.73–1.95)1.41 (0.81–2.44)\u2003quartile 4 (≥1.12)1.4353 (6.7)2.12 (1.31–3.43)1.57 (0.95–2.61)2.15 (1.09–4.27) \u2003p for trend0.0030.090.04\u2003quartile 1 (<0.48)0.3033 (4.1)1.00 (referent)1.00 (referent)1.00 (referent)\u2003upper decile (≥1.52)1.8525 (7.8)3.32 (1.70–6.47)2.26 (1.09–4.69)3.31 (1.02–10.72)dietary nonheme iron (mg per day)\u2003quartile 1 (<9.10)7.1650 (6.4)1.00 (referent)1.00 (referent)1.00 (referent)\u2003quartile 2 (9.10–12.16)10.6544 (5.6)0.83 (0.54–1.28)0.85 (0.54–1.33)0.83 (0.53–1.31)\u2003quartile 3 (12.17–15.97)13.8133 (4.2)0.60 (0.36–1.00)0.63 (0.37–1.08)0.62 (0.36–1.06)\u2003quartile 4 (≥12.98)19.6031 (3.9)0.54 (0.29–0.99)0.61 (0.32–1.17)0.61 (0.31–1.18) \u2003p for trend0.030.080.08\u2003quartile 1 (<9.10)7.1650 (6.4)1.00 (referent)1.00 (referent)1.00 (referent)\u2003upper decile (≥21.13)25.1911 (3.5)0.29 (0.10–0.84)0.34 (0.10–1.10)0.30 (0.09–0.99)\n*adjusted for daily energy intake, maternal age, race/ethnicity, parity, physical activity, Prepregnancy bmi, dietary fiber, and Vitamin C intake.']	N/A	N/A	[('CHEBI_30413', 'heme', 88, 'heme'), ('CHEBI_24870', 'ion', 105, 'iron'), ('GO_0007631', 'feeding behavior', 110, 'intake'), ('CHEBI_30413', 'heme', 284, 'heme'), ('GO_0007565', 'female pregnancy', 1449, 'prepregnancy'), ('CHEBI_27300', 'vitamin D', 1486, 'vitamin C')]
S87-PMC3120197	PMC3120197	7/2011	S87-PMC3120197	['†adjusted for daily energy intake; maternal age; race/ethnicity; parity; physical activity; Prepregnancy bmi; and dietary fiber, Vitamin C, saturated fat, Cholesterol, and red and processed meat Intake.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 92, 'prepregnancy'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin C'), ('CHEBI_16113', 'cholesterol', 155, 'cholesterol'), ('GO_0007631', 'feeding behavior', 195, 'intake')]
S96-PMC3120197	PMC3120197	7/2011	S96-PMC3120197	['caption (fig): figure 1\n\nrelationship between maternal dietary Heme iron Intake in early Pregnancy and risk of gdm (solid line) with 95% cis (dotted lines) after adjusting for daily energy intake; maternal age; race/ethnicity; parity; physical activity; Prepregnancy bmi; and dietary fiber, Vitamin C, Saturated Fat, Cholesterol, and red and processed meat intake.']	N/A	N/A	[('CHEBI_30413', 'heme', 63, 'heme'), ('GO_0007631', 'feeding behavior', 73, 'intake'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('GO_0007565', 'female pregnancy', 254, 'prepregnancy'), ('CHEBI_27300', 'vitamin D', 291, 'vitamin C'), ('CHEBI_26710', 'sodium chloride', 302, 'saturated fat'), ('CHEBI_16113', 'cholesterol', 317, 'cholesterol')]
S37-PMC3171895	PMC3171895	9/2011	S37-PMC3171895	['for this paper, we included data and relevant information obtained through a search of the pubmed database using free text and medical subject headings terms for all articles published in english from 1971 through 2011 which included the term “selenium,” “zinc,” “copper,” “manganese,” “Vitamin E and C,” and one of the following: “Pregnancy,” “Preeclampsia,” or “fetal growth restriction.” we further included published and unpublished data from our own laboratories and an “in-house” library of relevant publications.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 287, 'vitamin E'), ('PR_000004900', 'complement C3', 301, 'C'), ('GO_0007565', 'female pregnancy', 332, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 345, 'preeclampsia')]
S33-PMC3271033	PMC3271033	1/2012	S33-PMC3271033	['a brief questionnaire on Prenatal Vitamins, including name and frequency, and intake of Vitamin D rich Foods was completed.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 25, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 34, 'vitamins'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('CHEBI_33290', 'food', 103, 'foods')]
S78-PMC3271033	PMC3271033	1/2012	S78-PMC3271033	['none of the mothers reported taking additional Vitamin D supplements separate from their Prenatal Vitamins.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 98, 'vitamins')]
S80-PMC3271033	PMC3271033	1/2012	S80-PMC3271033	['average maternal intake of Vitamin D from Foods and Prenatal supplements was 439 ± 94 iu/day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33290', 'food', 42, 'foods'), ('GO_0007565', 'female pregnancy', 52, 'prenatal')]
S106-PMC3277098	PMC3277098	12/2011	S106-PMC3277098	['Pregnancy\nduring Pregnancy the foetus is exposed to Vitamin D through Cord Blood supply and the ability of 25(Oh)D and 24,25(Oh)d to cross the Placenta [23].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 17, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 70, 'cord'), ('UBERON_0000178', 'blood', 75, 'blood'), ('CHEBI_71657', 'versiconol acetate', 107, '25(OH)D'), ('CHEBI_51686', 'haematoxylin', 124, '(OH'), ('UBERON_0001987', 'placenta', 143, 'placenta')]
S127-PMC3277098	PMC3277098	12/2011	S127-PMC3277098	['there was no association between Vitamin D intake from diet or Supplements during Pregnancy, with the risk of eczema in infants at 12 months of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 63, 'supplements'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy')]
S66-PMC3296991	PMC3296991	2/2012	S66-PMC3296991	['none of the measured indices differed significantly by infant sex or by use of maternal Vitamin D supplements during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy')]
S84-PMC3296991	PMC3296991	2/2012	S84-PMC3296991	['none of the measured indices differed significantly in the maternal or Cord Blood of women who did or did not take daily Prenatal Vitamins containing 400 iu Vitamin D. the Food and nutrition board recommendation for Vitamin D intake by Pregnant women was raised in 2010 from 200 to 600 iu/day [22].']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 71, 'cord'), ('UBERON_0000178', 'blood', 76, 'blood'), ('GO_0007565', 'female pregnancy', 121, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 130, 'vitamins'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('CHEBI_33290', 'food', 172, 'Food'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('GO_0007565', 'female pregnancy', 236, 'pregnant')]
S189-PMC3338544	PMC3338544	4/2012	S189-PMC3338544	['Pregnant dams were checked every 12 h for pups and the Food of dams on the Vitamin D-deplete diet was replaced with control Food within 12 h of Birth.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_33290', 'food', 55, 'food'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_33290', 'food', 124, 'food'), ('GO_0007567', 'parturition', 144, 'birth')]
S2-PMC3347007	PMC3347007	4/2012	S2-PMC3347007	['in 68,447 danish Pregnant women the mean ± sd for Vitamin D intake was 9.23 ± 5.60 µg per day (diet: 3.56 ± 2.05 µg per day, supplements: 5.67 ± 5.20 µg per day).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 17, 'pregnant'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
S26-PMC3347007	PMC3347007	4/2012	S26-PMC3347007	['for instance in norway, 63% of Pregnant women consumed <10 µg per day of Vitamin D [17], in finland the prevalence was 85% [18], and 50% in the united states [19].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 31, 'pregnant'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
S60-PMC3347007	PMC3347007	4/2012	S60-PMC3347007	['these calculations led to the creation of a data set with information for all participants ( n = 68,447) on mean daily Vitamin D intake from supplements calculated from the ffq and mean daily Vitamin D intake from supplements per Gestational week from the interviews.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('GO_0007565', 'female pregnancy', 230, 'gestational')]
S68-PMC3347007	PMC3347007	4/2012	S68-PMC3347007	['univariate and multivariate logistic regression was employed to estimate the association between total Vitamin D intake and socio-demographic, Gestational, and Life-style characteristics.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'gestational'), ('UBERON_0000104', 'life cycle', 160, 'life')]
S78-PMC3347007	PMC3347007	4/2012	S78-PMC3347007	['44.4% had sufficient total Vitamin D intake.nutrients-04-00259-t001_table 1\n\ncaption (table-wrap): table 1\n\nintake of Vitamin D Supplements in the danish national Birth cohort during Gestational weeks 21–25 ( n = 68,447) *.daily Vitamin D dosen (%)0 µg22,214 (32.5)women who took Vitamin D supplements46,233 (67.5)>0 µg and ≤2.5 µg1020 (1.5)>2.5 µg and <5 µg2110 (3.1)≥5 µg and <7.5 µg16,710 (24.4)≥7.5 µg and <10 µg1114 (1.6)≥10 µg25,279 (36.9)\n* based on information from the Food frequency questionnaire.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 118, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 126, 'D'), ('CHEBI_33341', 'titanium atom', 128, 'supplements'), ('GO_0007567', 'parturition', 163, 'Birth'), ('GO_0007565', 'female pregnancy', 183, 'gestational'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_33290', 'food', 478, 'food')]
S80-PMC3347007	PMC3347007	4/2012	S80-PMC3347007	['the most common dose was 10 µg per day (31.5%) followed by 5 µg per day (22.2%) (data not shown).figure 2shows the proportion of women reporting use of Vitamin D supplements ≥10 µg per day per Gestational week based on the results from dnbc interview 2 and 3.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'gestational')]
S81-PMC3347007	PMC3347007	4/2012	S81-PMC3347007	['from Gestational week 7 onwards, more than 20% of the women reported use of Vitamin D supplements ≥10 µg per day with a maximum proportion of 31.7% in Gestational week 30.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'gestational')]
S84-PMC3347007	PMC3347007	4/2012	S84-PMC3347007	['from Gestational week 30, the proportion of women who reported sufficient use of Vitamin D supplements decreased.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
S101-PMC3347007	PMC3347007	4/2012	S101-PMC3347007	['before adjustment for relevant covariates, the or for sufficient total Vitamin D intake was significantly lower for partly Planned or non-planned Pregnancies than for Planned Pregnancies.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'planned'), ('GO_0007565', 'female pregnancy', 146, 'pregnancies'), ('GO_0007565', 'female pregnancy', 167, 'planned'), ('GO_0007565', 'female pregnancy', 175, 'pregnancies')]
S126-PMC3347007	PMC3347007	4/2012	S126-PMC3347007	['insufficient total Vitamin D intake (<10 µg per day) in Gestational weeks 21–25 ( n = 68,447) *.sufficient total Vitamin D intake ( n = 30,357)insufficient total Vitamin D intake ( n = 38,090) p -valuetotal energy (kj)10,042.6 (2439.8)9852.0 (2365.4)<0.0001†protein (% of energy)15.2 (2.4)15.0 (2.3)0.002†Carbohydrate (% of energy)54.5 (5.8)54.3 (5.9)0.1†fat (% of energy)29.8 (5.9)30.3 (6.0)0.03†Alcohol (% of energy)0.27 (0, 0.6)0.29 (0, 0.7)<0.0001‡dietary variables (g/mj)dairy products606.2 (359.7, 842.4)611.4 (366.1, 846.8)0.02‡fruit130.5 (67.5, 231.9)116.6 (65.2, 222.1)<0.0001‡vegetables113.2 (75.1, 168.2)102.7 (67.0, 152.8)<0.0001‡meat72.7 (31.1)72.9 (31.1)0.9†fish17.6 (9.3, 29.7)14.6 (7.9, 24.2)<0.0001‡poultry24.0 (13.2, 35.3)19.4 (11.2, 31.4)<0.0001‡cereals24.4 (5.5, 48.0)23.6 (5.2, 48.4)0.2‡potatoes115.9 (80.7, 165.8)120.1 (82.7, 173.0)<0.0001‡fats18.9 (11.1, 29.6)20.1 (11.5, 31.4)<0.0001‡\ndata are presented as mean (standard deviation) or median (25th percentile, 75th percentile).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'gestational'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('CHEBI_16646', 'carbohydrate', 305, 'Carbohydrate'), ('CHEBI_30879', 'alcohol', 397, 'Alcohol')]
S189-PMC3347007	PMC3347007	4/2012	S189-PMC3347007	['determinants of sufficient total Vitamin D intake were high maternal age, Giving Birth during fall or winter, nulliparity, and low number of daily cigarettes use during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007567', 'parturition', 74, 'giving birth'), ('GO_0007565', 'female pregnancy', 169, 'pregnancy')]
S114-PMC3347028	PMC3347028	3/2012	S114-PMC3347028	['[65], and the nichd Vitamin D supplementation trial [70,71] was the high incidence of Vitamin D deficiency during early Pregnancy in women with darker pigmentation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy')]
S159-PMC3347028	PMC3347028	3/2012	S159-PMC3347028	['during Pregnancy, supplementation with the current standard amount of Vitamin D in Prenatal Vitamins—400 iu (10 μg) Vitamin D/day—has minimal effect on circulating 25(Oh)D concentrations in the mother and her infant at term [6,124].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 92, 'vitamins'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 164, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 170, 'D')]
S198-PMC3347028	PMC3347028	3/2012	S198-PMC3347028	['preliminary analysis of the two concurrent Vitamin D Pregnancy nichd ( n = 350) and thrasher research fund ( n = 157) trials was undertaken to assess the health characteristics and outcomes of this larger, combined group using a common data dictionary [150].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy')]
S83-PMC3355895	PMC3355895	1/2011	S83-PMC3355895	['in this study around 31% of the mothers had insufficient and 18% had deficient circulating concentrations of 25(oh)-Vitamin D during late Pregnancy (11–20 and <11\u2009μg/l respectively).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007565', 'female pregnancy', 138, 'pregnancy')]
S35-PMC3366289	PMC3366289	7/2011	S35-PMC3366289	['at Delivery, all women received systematically Vitamin A (200,000\xa0iu) in the form of Retinyl Palmitate and Thiamine (7\xa0×\xa0100\xa0mg/week) was still provided for Postpartum women.']	N/A	N/A	[('GO_0007567', 'parturition', 3, 'delivery'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin A'), ('CHEBI_84054', 'resveratrol glucuronide sulfate 2', 85, 'retinyl palmitate'), ('CHEBI_26948', 'vitamin B1', 107, 'thiamine'), ('GO_0007565', 'female pregnancy', 157, 'postpartum')]
S108-PMC3376765	PMC3376765	6/2012	S108-PMC3376765	['in a trial in nepal [25], 4926 Pregnant women were allocated at random to five regimens: daily supplements of Fa, ifa, ifa with zinc, multiple Micronutrients, or Vitamin A alone (control).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 31, 'pregnant'), ('CHEBI_30751', 'formic acid', 110, 'FA'), ('CHEBI_33839', 'macromolecule', 143, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin A')]
S37-PMC3395583	PMC3395583	7/2012	S37-PMC3395583	"[""average predicted uvb exposure as well as Vitamin D status during the first, second and third Trimesters of Gestation were calculated for each month of Birth and tested for correlation with risk of id (monthly or) using the spearman's correlation coefficient.""]"	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0043033', 'isoamylase complex', 94, 'trimesters'), ('GO_0007565', 'female pregnancy', 108, 'gestation'), ('GO_0007567', 'parturition', 152, 'birth')]
S3-PMC3407995	PMC3407995	7/2012	S3-PMC3407995	['reports were selected if they included benefits and harms of maternal supplementation of Dha, Vitamin D, Folic Acid or Iodine supplementation during Pregnancy and/or Lactation.']	N/A	N/A	[('CHEBI_17874', 'dihydrozeatin', 89, 'DHA'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('CHEBI_30751', 'formic acid', 105, 'folic acid'), ('CHEBI_24859', 'iodine atom', 119, 'iodine'), ('GO_0007565', 'female pregnancy', 149, 'pregnancy'), ('GO_0007595', 'lactation', 166, 'lactation')]
S14-PMC3407995	PMC3407995	7/2012	S14-PMC3407995	['a systematic search was performed in medline for english-language articles published between january 2000 and february 2012 using broad search criteria including dha and Pregnancy , dha and Lactation , Docosahexaenoic Acid and Pregnancy , Docosahexaenoic Acid and Lactation , Vitamin D and Pregnancy , Vitamin D and Lactation , Folic Acid and Pregnancy , Folic Acid and Lactation , Iodine and Pregnancy and Iodine and Lactation .']	N/A	N/A	[('GO_0007565', 'female pregnancy', 170, 'pregnancy'), ('GO_0007595', 'lactation', 190, 'lactation'), ('CHEBI_36003', 'decenoic acid', 202, 'docosahexaenoic acid'), ('GO_0007565', 'female pregnancy', 227, 'pregnancy'), ('CHEBI_36003', 'decenoic acid', 239, 'docosahexaenoic acid'), ('GO_0007595', 'lactation', 264, 'lactation'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D'), ('GO_0007565', 'female pregnancy', 290, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 302, 'vitamin D'), ('GO_0007595', 'lactation', 316, 'lactation'), ('CHEBI_30751', 'formic acid', 328, 'folic acid'), ('GO_0007565', 'female pregnancy', 343, 'pregnancy'), ('CHEBI_30751', 'formic acid', 355, 'folic acid'), ('GO_0007595', 'lactation', 370, 'lactation'), ('CHEBI_24859', 'iodine atom', 382, 'iodine'), ('GO_0007565', 'female pregnancy', 393, 'pregnancy'), ('CHEBI_24859', 'iodine atom', 407, 'iodine'), ('GO_0007595', 'lactation', 418, 'lactation')]
S95-PMC3407995	PMC3407995	7/2012	S95-PMC3407995	['maintain Pregnancy—the circulating concentration of maternal active Vitamin D rises in the first trimester and doubles by the end of the third trimester [53].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 9, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
S267-PMC3407995	PMC3407995	7/2012	S267-PMC3407995	['intakes of Folate, iron, Vitamin D, Potassium, Iodine and Selenium were lower than uk recommendations during and after Pregnancy ( p< 0.05) [143].']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 11, 'folate'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_22314', 'alkali metal atom', 36, 'potassium'), ('CHEBI_24859', 'iodine atom', 47, 'iodine'), ('CHEBI_27568', 'selenium atom', 58, 'selenium'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy')]
S270-PMC3407995	PMC3407995	7/2012	S270-PMC3407995	['a cross-sectional study in iran included 147 Pregnant women whose Serum status of Vitamin D, a, and e were assessed at 5–9 months of Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 45, 'pregnant'), ('UBERON_0001977', 'blood serum', 66, 'serum'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy')]
S279-PMC3407995	PMC3407995	7/2012	S279-PMC3407995	['a cross-sectional study including 50 women in labour with a singleton term Pregnancy in pakistan measured Vitamin D status in maternal Blood before Delivery and Cord Blood at Delivery.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('UBERON_0000178', 'blood', 135, 'blood'), ('GO_0007567', 'parturition', 148, 'delivery'), ('UBERON_0002240', 'spinal cord', 161, 'cord'), ('UBERON_0000178', 'blood', 166, 'blood'), ('GO_0007567', 'parturition', 175, 'delivery')]
S285-PMC3407995	PMC3407995	7/2012	S285-PMC3407995	['bone health\ndoctors in leicester city, uk reported that a significant number of south asian mothers visiting their clinic had Vitamin D deficiency at the end of Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy')]
S308-PMC3407995	PMC3407995	7/2012	S308-PMC3407995	['maternal Vitamin D was measured at the 24th and 34th weeks of Pregnancy and at Delivery and infant Vitamin D was measured in Umbilical Blood at Birth and on the sixth day following Birth.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy'), ('GO_0007567', 'parturition', 79, 'delivery'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('UBERON_0007118', 'umbilicus', 125, 'umbilical'), ('UBERON_0000178', 'blood', 135, 'blood'), ('GO_0007567', 'parturition', 144, 'birth'), ('GO_0007567', 'parturition', 181, 'birth')]
S314-PMC3407995	PMC3407995	7/2012	S314-PMC3407995	['bone health\na prospective partially randomised study of Vitamin D supplementation during Pregnancy included indian subjects (known to be Vitamin D deficient) randomised in the second Trimester to receive either one oral dose of 1500 μg Vitamin D (group 1, n = 48) or two doses of 3000 μg Vitamin D each in the second and third Trimesters (group 2, n = 49) [151].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 183, 'trimester'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 288, 'vitamin D'), ('GO_0043033', 'isoamylase complex', 327, 'trimesters')]
S330-PMC3407995	PMC3407995	7/2012	S330-PMC3407995	['intakes of Folate, iron, Vitamin D, Potassium, Iodine and Selenium were lower than uk recommendations during and after Pregnancy ( p< 0.05) [143].']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 11, 'folate'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_22314', 'alkali metal atom', 36, 'potassium'), ('CHEBI_24859', 'iodine atom', 47, 'iodine'), ('CHEBI_27568', 'selenium atom', 58, 'selenium'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy')]
S29-PMC3424155	PMC3424155	8/2012	S29-PMC3424155	['the Vitamin D was added separately only to the sc diet, and the Vitamin Mixture added to both the sc and vitd- diets did not contain Vitamin D.table 1shows the nutritional components in each diet, including the dietary composition of Vitamin D. the recommended minimum dietary requirement of Pregnant Mice for Vitamin D, according to the ain93g, is 1,000.0 iu/kg of diet.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 64, 'vitamin'), ('CHEBI_60004', 'mixture', 72, 'mixture'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 234, 'vitamin D'), ('GO_0007565', 'female pregnancy', 292, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 301, 'mice'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin D')]
S10-PMC3427250	PMC3427250	8/2012	S10-PMC3427250	['the risk of severe Vitamin D deficiency (25-(Oh)D <10 ng/ml) decreased for women who reported Alcohol consumption during Pregnancy, decreased with more frequent use of sunscreen Lotion and increased for smokers and women who reported preference for shadow.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 41, '25-(OH)D'), ('CHEBI_30879', 'alcohol', 94, 'alcohol'), ('GO_0007565', 'female pregnancy', 121, 'pregnancy'), ('CHEBI_75903', 'arsenic(1-) sulfides', 178, 'lotion')]
S24-PMC3427250	PMC3427250	8/2012	S24-PMC3427250	['several modifications of Vitamin D Metabolism occur during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 25, 'vitamin D metabolism'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy')]
S61-PMC3427250	PMC3427250	8/2012	S61-PMC3427250	['for 1 hospital (n\u200a=\u200a23 women) certain questions (mainly nationality, ethnicity, education level) needed to be omitted from the questionnaire upon decision of the ethical committee of this particular hospital.10.1371/journal.pone.0043868.g001\n\ncaption (fig): figure 1\ngeographical distribution of the 55 hospitals visited in belgium and the number of Pregnant women (n\u200a=\u200a1311) investigated by site (national survey on Vitamin D status of Pregnant women belgium 2010–2011).10.1371/journal.pone.0043868.t001\n\ncaption (table-wrap): table 1\nnumber of Pregnant women by region, trimester and age (national survey on Vitamin D status among Pregnant women belgium, 2010–2011).regionsbrussels**flanders**walloniaage(years )1sttrimester3rdtrimester1sttrimester3rdtrimester1sttrimester3rdtrimester15–20721110211721–2534277751567326–304139108149765831–3534536975494536–4014142319132441–45231332total132138289307218219\n6 missing data for age.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 350, 'pregnant'), ('CHEBI_27300', 'vitamin D', 417, 'vitamin D'), ('GO_0007565', 'female pregnancy', 437, 'pregnant'), ('GO_0007565', 'female pregnancy', 546, 'pregnant'), ('CHEBI_27300', 'vitamin D', 610, 'vitamin D'), ('GO_0007565', 'female pregnancy', 633, 'pregnant')]
S75-PMC3427250	PMC3427250	8/2012	S75-PMC3427250	['of all women, 74.1% (95%ci\u200a=\u200a71.8–76.5%) were Vitamin D insufficient (25-(Oh)d concentration <30 ng/ml) and 44.6% (95%ci\u200a=\u200a41.9–47.3%) of the Pregnant women were Vitamin D deficient (25-(Oh)D concentration <20 ng/ml), while 12.1% (95%ci\u200a=\u200a10.3–13.8%) of the women were severely Vitamin D deficient (25-(Oh)D concentration <10 ng/ml).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_30254', 'sulfidocarbon(.1+)', 70, '25-(OH)'), ('GO_0007565', 'female pregnancy', 142, 'pregnant'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 183, '25-(OH)D'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 299, '25-(OH)D')]
S76-PMC3427250	PMC3427250	8/2012	S76-PMC3427250	['the percentage of women with Vitamin D insufficiency and deficiency was higher in the first than in the third Trimester of Pregnancy but the prevalence of severe Vitamin D deficiency was higher in the third trimester (table 3).10.1371/journal.pone.0043868.t003\n\ncaption (table-wrap): table 3\nSerum 25-(Oh)D concentration in Pregnant women (n\u200a=\u200a1311) (belgian national survey on Vitamin D status in Pregnant women, 2010–2011).all womenwalloniaflanders1sttrimester3rdtrimestern1300453633633665age28.5±5.127.9±5.528.8±4.728.3±5.128.8±5.1gestational weeks22.2±12.522.1±12.822.4±12.39.9±2.834.1±3.625-(oh)d(ng/ml)median21.220.922.320.422.7*iqr13.8–30.013.5–29.114.6–30.613.6–26.714.3–34.195% ci20.5–22.219.8–22.321.2–23.219.3–21.121.6–24.4% <10 ng/ml12.112.310.911.612.6% <20 ng/ml44.645.742.347.042.3% <30 ng/ml74.176.372.582.266.7\ndifferent from first Trimester Pregnant women, p<0.001.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 110, 'trimester'), ('GO_0007565', 'female pregnancy', 123, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('UBERON_0001977', 'blood serum', 292, 'Serum'), ('CHEBI_72657', '19,20-DiHDPA', 298, '25-(OH)D'), ('GO_0007565', 'female pregnancy', 324, 'pregnant'), ('CHEBI_27300', 'vitamin D', 378, 'vitamin D'), ('GO_0007565', 'female pregnancy', 398, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 849, 'trimester'), ('GO_0007565', 'female pregnancy', 859, 'pregnant')]
S78-PMC3427250	PMC3427250	8/2012	S78-PMC3427250	['women of other ethnic origins were Vitamin D deficient (25-(Oh)D concentration <20 ng/ml) all year round, except during summer for third trimester women (figure 2).10.1371/journal.pone.0043868.g002\n\ncaption (fig): figure 2\nSerum 25-(Oh)d concentrations over the different seasons, by Trimester of Pregnancy and ethnicity (national survey on Vitamin D status among Pregnant women in belgium, 2010–2011).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 56, '25-(OH)D'), ('UBERON_0001977', 'blood serum', 223, 'Serum'), ('CHEBI_30254', 'sulfidocarbon(.1+)', 229, '25-(OH)'), ('GO_0009294', 'DNA mediated transformation', 284, 'trimester'), ('GO_0007565', 'female pregnancy', 297, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 341, 'vitamin D'), ('GO_0007565', 'female pregnancy', 364, 'pregnant')]
S80-PMC3427250	PMC3427250	8/2012	S80-PMC3427250	['for 62.0% of them the multivitamin contained Vitamin D. in the first and third Trimester of Pregnancy the percentage of women taking a multivitamin containing vitamin d was 52.6% and 72.3% respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 79, 'trimester'), ('GO_0007565', 'female pregnancy', 92, 'pregnancy')]
S88-PMC3427250	PMC3427250	8/2012	S88-PMC3427250	['the risk of severe Vitamin D deficiency (25-(Oh)D <10 ng/ml) was significantly lower among third than first Trimester Pregnant women (table 5).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 41, '25-(OH)D'), ('GO_0009294', 'DNA mediated transformation', 108, 'trimester'), ('GO_0007565', 'female pregnancy', 118, 'pregnant')]
S89-PMC3427250	PMC3427250	8/2012	S89-PMC3427250	['in addition risk of severe Vitamin D deficiency increased for women who reported not taking Vitamin D containing multivitamins, who were of non caucasian origin and who reported smoking during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'pregnancy')]
S92-PMC3427250	PMC3427250	8/2012	S92-PMC3427250	['exposure to the sun during week and weekend days, and Consumption Of Milk and dairy Products were not associated with either severe or normal Vitamin D deficiency.10.1371/journal.pone.0043868.t005\n\ncaption (table-wrap): table 5\nrisk of severe Vitamin D deficiency during Pregnancy in belgium (25-(oh)d <10 ng/ml) (n\u200a=\u200a1121), results of multiple logistic regressions.n of subjectsn of severe deficient casesor[95% conf interval]p trimester of Pregnancy first trimester633741.000third trimester665841.7511.1282.7190.013 season winter470891.000spring384350.2830.1680.477<0.001summer930autumn351340.3240.1910.551<0.001 smoking yes219331.000no10781250.4630.2680.8010.006 Alcohol Consumption yes264131.000no10221432.3701.1624.8340.018 use of multivitamins containing Vitamin D no4891151.000yes809430.1210.0750.193<0.001 ethnicity caucasian, white955691.000asiatic3396.6562.41318.359<0.001african, black64132.6051.1515.8960.022african, north174638.1744.71214.177<0.001 frequency Fatty Fish Consumption never192181.000less than once a month188242.2051.0104.8160.0471–3 days a month498591.4810.7552.9040.2541 day per week291351.3910.6712.8850.3752–4 days a week or more frequent128221.5130.6593.4720.328 use of sunscreen Lotion yes, much of the time644361.000yes, sometimes281342.0871.1713.7220.013no368883.2631.9355.504<0.001 preference sun/shadow sun476531.000shadow497701.9831.2253.2100.005does not matter321351.2060.6912.1040.510\nor odds ratio.']	N/A	N/A	[('GO_0070817', 'P-TEFb-cap methyltransferase complex localization', 54, 'consumption of milk'), ('GO_0060208', 'proestrus', 84, 'products'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D'), ('GO_0007565', 'female pregnancy', 271, 'pregnancy'), ('GO_0007565', 'female pregnancy', 442, 'pregnancy'), ('CHEBI_30879', 'alcohol', 666, 'Alcohol'), ('GO_0007631', 'feeding behavior', 674, 'consumption'), ('CHEBI_27300', 'vitamin D', 761, 'vitamin D'), ('CHEBI_38677', 'famphur', 972, 'fatty fish'), ('GO_0007631', 'feeding behavior', 983, 'consumption'), ('CHEBI_75903', 'arsenic(1-) sulfides', 1212, 'lotion')]
S94-PMC3427250	PMC3427250	8/2012	S94-PMC3427250	['the prevalence of severe Vitamin D deficiency was 12% during the first trimester and was slightly higher, 13%, during the third Trimester of Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 128, 'trimester'), ('GO_0007565', 'female pregnancy', 141, 'pregnancy')]
S100-PMC3427250	PMC3427250	8/2012	S100-PMC3427250	['similarly as in our Pregnant women population, in the Adult population the risk of Vitamin D deficiency was higher in winter than in summer and increased with bmi[36],[37],[44],[45],[46].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 20, 'pregnant'), ('UBERON_0007023', 'adult organism', 54, 'adult'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
S104-PMC3427250	PMC3427250	8/2012	S104-PMC3427250	['in belgium, Pregnant women of different ethnic origins had substantially lower Vitamin D concentrations than caucasian women and were Vitamin D deficient all year long except during summer for third Trimester women.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 12, 'pregnant'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 199, 'trimester')]
S113-PMC3427250	PMC3427250	8/2012	S113-PMC3427250	['in belgium, Pregnant women who reported going on holidays to sunny climates had a lower risk of Vitamin D deficiency and women who reported using sunscreen Lotion had a lower risk of severe Vitamin D deficiency.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 12, 'pregnant'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('CHEBI_75903', 'arsenic(1-) sulfides', 156, 'lotion'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]
S199-PMC3465343	PMC3465343	10/2012	S199-PMC3465343	['then the Animals were Mated with normal males between 6 and 10 p.m. during Gestation, the vad group were Fed a modified ain-93g diet without any source of Vitamin A and the control group received an ain-93g diet sufficient in Vitamin A (4 Retinol equivalents (re)/g diet)[45].']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 9, 'animals'), ('GO_0007618', 'mating', 22, 'mated'), ('GO_0007565', 'female pregnancy', 75, 'gestation'), ('GO_0007631', 'feeding behavior', 105, 'fed'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 239, 'retinol')]
S14-PMC3470091	PMC3470091	9/2012	S14-PMC3470091	['during Pregnancy and Lactation outstanding changes occur in mother’s Vitamin D Metabolism.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('GO_0007595', 'lactation', 21, 'lactation'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007601', 'visual perception', 69, 'vitamin D'), ('GO_0008152', 'metabolic process', 79, 'metabolism')]
S25-PMC3472720	PMC3472720	8/2012	S25-PMC3472720	['f0female c57bl/6 Mice were Fed a Vitamin D-free diet before and during Pregnancy.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 17, 'mice'), ('GO_0007631', 'feeding behavior', 27, 'fed'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy')]
S27-PMC3472720	PMC3472720	8/2012	S27-PMC3472720	['a Vitamin D-containing diet was provided to all Animals, before, during and after Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 2, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 48, 'animals'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy')]
S68-PMC3472720	PMC3472720	8/2012	S68-PMC3472720	['being Born in the fall means that, during the third Trimester of Pregnancy, the fetus developed in a supposedly Vitamin D optimal environment.']	N/A	N/A	[('GO_0007567', 'parturition', 6, 'born'), ('GO_0009294', 'DNA mediated transformation', 52, 'trimester'), ('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
S126-PMC3485340	PMC3485340	10/2012	S126-PMC3485340	['closed circles (•) represent high and open circles (○) represent low Postnatal Vitamin C. at p10 and p27 there is a significant difference between Prenatal diet group by two-way anova, and by student’s t-test at p70.']	N/A	N/A	[('GO_0007567', 'parturition', 69, 'postnatal'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin C'), ('GO_0007565', 'female pregnancy', 147, 'prenatal')]
S127-PMC3488410	PMC3488410	10/2012	S127-PMC3488410	['Prenatal Vitamin D deficiency reduced Cell Proliferation in the subgranular zone.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0008283', 'cell proliferation', 38, 'cell proliferation')]
S34-PMC3501517	PMC3501517	11/2012	S34-PMC3501517	['when female breeder Mice were visibly Pregnant, they were either placed in Vitamin D sufficient or deficient housing.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 20, 'mice'), ('GO_0007565', 'female pregnancy', 38, 'pregnant'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
S5-PMC3513049	PMC3513049	2/2012	S5-PMC3513049	['household Pets were assessed during Pregnancy and Serum level of 25 (Oh)D (25-Hydroxyvitamin D) in Cord Blood was used as the measure of Vitamin D and a marker of maternal level.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 10, 'pets'), ('GO_0007565', 'female pregnancy', 36, 'pregnancy'), ('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_71657', 'versiconol acetate', 65, '25 (OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 75, '25-hydroxyvitamin D'), ('UBERON_0002240', 'spinal cord', 99, 'cord'), ('UBERON_0000178', 'blood', 104, 'blood'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
S44-PMC3515553	PMC3515553	12/2012	S44-PMC3515553	['assessment of maternal Vitamin B-12 dietary intake\nmaternal Vitamin B-12 intake was assessed in the whole cohort at 32 weeks of Pregnancy using a Food frequency questionnaire (ffq).']	N/A	N/A	[('PR_000017269', 'ventral anterior homeobox 2', 23, 'Vitamin B-12'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 60, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 128, 'pregnancy'), ('CHEBI_33290', 'food', 146, 'food')]
S38-PMC3521768	PMC3521768	12/2012	S38-PMC3521768	['Pregnant women were classified based on their Prenatal Serum zinc and Vitamin A statuses and followed until Birth.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0007565', 'female pregnancy', 46, 'prenatal'), ('UBERON_0001977', 'blood serum', 55, 'serum'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin A'), ('GO_0007567', 'parturition', 108, 'birth')]
S47-PMC3521768	PMC3521768	12/2012	S47-PMC3521768	['study subjects\nPregnant women whose zinc and Vitamin A statuses were determined at their second or third Trimester and who later gave singleton live-Births were eligible for the study.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 15, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin A'), ('GO_0009294', 'DNA mediated transformation', 105, 'trimester'), ('GO_0007567', 'parturition', 149, 'births')]
S136-PMC3521768	PMC3521768	12/2012	S136-PMC3521768	['maternal zinc and Vitamin A statuses and lbw\nstandard cutoff points were applied to define Prenatal zd (Serum zinc <7.6 µmol/l[29]) and vad (Serum Retinol <0.7 µmol/l[30]).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin A'), ('GO_0007565', 'female pregnancy', 91, 'prenatal'), ('UBERON_0001977', 'blood serum', 104, 'serum'), ('UBERON_0001977', 'blood serum', 141, 'serum'), ('CHEBI_26536', 'retinoic acid', 147, 'retinol')]
S137-PMC3521768	PMC3521768	12/2012	S137-PMC3521768	['using independent t-test analysis, statistically significant 82 g (95% ci: 9–150 g) and 76 g (95% ci: 6–145 g) decrease on Birthweight was observed in babies Born to women who had Prenatal Vitamin A and zinc deficiencies, respectively.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 123, 'birthweight'), ('GO_0007567', 'parturition', 158, 'born'), ('GO_0007565', 'female pregnancy', 180, 'prenatal'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin A')]
S208-PMC3521768	PMC3521768	12/2012	S208-PMC3521768	['Prenatal Vitamin A and zinc deficiencies occurring in the second or third trimesters were not associated with increased risk of lbw.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin A')]
S77-PMC3544621	PMC3544621	11/2012	S77-PMC3544621	['Prenatal Vitamin A improved infant Birth weight (wmd 89.78, 95% ci 84.73-94.83), but had no effect on stillbirth rate (rr 0.99, 95% ci 0.68-1.43) or ptd (rr 0.88, 95% ci 0.65-1.19).rumbold et al .']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin A'), ('GO_0007567', 'parturition', 35, 'birth')]
S4-PMC3616124	PMC3616124	4/2013	S4-PMC3616124	['this is a secondary analysis of a randomized controlled trial in which 10,154 low-risk women received daily Vitamin C and E, or placebo, from 9-16 weeks Gestation until Delivery.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 108, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 122, 'E'), ('GO_0007565', 'female pregnancy', 153, 'gestation'), ('GO_0007567', 'parturition', 169, 'delivery')]
S55-PMC3616124	PMC3616124	4/2013	S55-PMC3616124	['materials and methods\n\npopulation\nthis was a secondary analysis of a eunice kennedy shriver national institute of child health and Human development maternal-fetal medicine units network double-blind, multicenter rct (nct 00135707) in which 10,154 nulliparous, low risk women received daily doses of 400 iu of Vitamin E and 1000 mg of Vitamin C, or placebo, from 9-16 weeks Gestation until Delivery.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 131, 'Human'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 335, 'vitamin C'), ('GO_0007565', 'female pregnancy', 374, 'gestation'), ('GO_0007567', 'parturition', 390, 'delivery')]
S44-PMC3641012	PMC3641012	4/2013	S44-PMC3641012	['participants were advised to discontinue all other supplements containing Vitamin D, and were offered Prenatal iron and Folic Acid supplements (66\xa0mg elemental iron and 350 mcg/day Folic Acid per day), routine Antenatal monitoring, and obstetric care free of charge.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'prenatal'), ('CHEBI_30751', 'formic acid', 120, 'folic acid'), ('CHEBI_30751', 'formic acid', 181, 'folic acid'), ('GO_0007567', 'parturition', 210, 'antenatal')]
S48-PMC3641012	PMC3641012	4/2013	S48-PMC3641012	['Venous Blood specimens were collected at baseline and once between Gestational weeks 30 and 37 (the specific week was randomly varied among participants); these specimens were drawn immediately preceding the weekly Vitamin D dose administration; a third specimen was collected around the time of Delivery, irrespective of when the last Vitamin D dose was received.']	N/A	N/A	[('UBERON_0001638', 'vein', 0, 'Venous'), ('UBERON_0000178', 'blood', 7, 'blood'), ('GO_0007565', 'female pregnancy', 67, 'gestational'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('GO_0007567', 'parturition', 296, 'delivery'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]
S192-PMC3641012	PMC3641012	4/2013	S192-PMC3641012	['hypercalciuria, defined a priori as ca:cr\u2009>1.0\xa0mmol/mmol on 2 consecutive separate occasions, occurred in one participant in the Vitamin D group, at 29\xa0weeks Gestation on day 14 of follow-up.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('GO_0007565', 'female pregnancy', 158, 'gestation')]
S213-PMC3641012	PMC3641012	4/2013	S213-PMC3641012	['discussion\namong Pregnant women with relatively low average baseline Vitamin D status in dhaka, 3rd-Trimester Vitamin D3 supplementation (35,000\xa0iu/week) significantly raised maternal and neonatal (Cord Blood) Serum 25(Oh)D concentrations above the iom cut-off for sufficiency (50\xa0nmol/l) in virtually all participants without inducing hypercalcemia or other apparent short-term clinical adverse effects.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 17, 'pregnant'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 100, 'trimester'), ('CHEBI_33279', 'vitamin D5', 110, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 110, 'vitamin D3'), ('UBERON_0002240', 'spinal cord', 198, 'cord'), ('UBERON_0000178', 'blood', 203, 'blood'), ('UBERON_0001977', 'blood serum', 210, 'serum'), ('CHEBI_71657', 'versiconol acetate', 216, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 216, '25(OH ... D')]
S10-PMC3651971	PMC3651971	5/2013	S10-PMC3651971	['conclusions\nPreconceptional to Postpartum maternal Vitamin A supplementation, in an undernourished setting, does not improve Cognition or motor Development at ages 10–13\u2005years.']	N/A	N/A	[('GO_0019230', 'proprioception', 12, 'Preconceptional'), ('GO_0007565', 'female pregnancy', 31, 'postpartum'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin A'), ('GO_0050890', 'cognition', 125, 'cognition'), ('GO_0008289', 'lipid binding', 144, 'development')]
S12-PMC3651971	PMC3651971	5/2013	S12-PMC3651971	['the participants were Born to women who participated in a randomised, placebo-controlled Vitamin A supplementation trial before, during and after Pregnancy.']	N/A	N/A	[('GO_0007567', 'parturition', 22, 'born'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin A'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy')]
S36-PMC3651971	PMC3651971	5/2013	S36-PMC3651971	['the children studied were exposed in utero and Postnatally through Breast Milk Intake to a weekly supplemental supply of Vitamin A, calculated to meet maternal dietary recommendations during Pregnancy and Lactation,29or to placebo (serving as controls).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 47, 'postnatally'), ('UBERON_0001348', 'brown adipose tissue', 67, 'breast milk'), ('GO_0007631', 'feeding behavior', 79, 'intake'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin A'), ('GO_0007565', 'female pregnancy', 191, 'pregnancy'), ('GO_0007595', 'lactation', 205, 'lactation')]
S138-PMC3651971	PMC3651971	5/2013	S138-PMC3651971	['discussion\nin this rural, undernourished setting of southern nepal, we observed no effect of weekly maternal Vitamin A receipt before, during and after Pregnancy on Cognitive or Motor Skill development among 10-year-old to 13-year-old offspring.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 109, 'vitamin A'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy'), ('GO_0050890', 'cognition', 165, 'cognitive'), ('GO_0065007', 'biological regulation', 178, 'motor skill')]
S41-PMC3659910	PMC3659910	1/2013	S41-PMC3659910	['important changes occur in the maternal concentration of Vitamin D and in Calcium Metabolism to provide the calcium needed for fetal bone Mineral accretion during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0050817', 'coagulation', 74, 'calcium'), ('GO_0008152', 'metabolic process', 82, 'metabolism'), ('CHEBI_46662', 'mineral', 138, 'mineral'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy')]
S86-PMC3659910	PMC3659910	1/2013	S86-PMC3659910	['a study in Human subjects involved the administration of 100,000 iu Vitamin D per day (2.5 mg/day) throughout Pregnancy to hypoparathyroid women to maintain Serum calcium with no fatal outcome.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 11, 'human'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('UBERON_0001977', 'blood serum', 157, 'serum')]
S100-PMC3659910	PMC3659910	1/2013	S100-PMC3659910	['Pregnancy does not exacerbate hypocalcaemia and secondary hyperparathyroidism in People with pre-existing Vitamin D deficiency.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('NCBITaxon_10088', 'Mus <genus>', 81, 'people'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]
S108-PMC3659910	PMC3659910	1/2013	S108-PMC3659910	['in an uncontrolled trial, supplementation with a multivitamin/Mineral supplement and halibut Liver oil (containing 900 iu/d Vitamin D) provided at 20 wk Gestation reduced the odds of preeclampsia by 32% (95% ci, 11-47%).']	N/A	N/A	[('CHEBI_46662', 'mineral', 62, 'mineral'), ('UBERON_0002107', 'liver', 93, 'liver'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'gestation')]
S123-PMC3659910	PMC3659910	1/2013	S123-PMC3659910	['the cochrane library issued a review of Vitamin D supplementation during Pregnancy and identified 7 relevant studies.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy')]
S151-PMC3659910	PMC3659910	1/2013	S151-PMC3659910	['a study in Pregnant women in south india assessed maternal Vitamin D status by measuring Serum 25-Hydroxyvitamin D in stored Serum samples.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 11, 'pregnant'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('UBERON_0001977', 'blood serum', 89, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 95, '25-hydroxyvitamin D'), ('UBERON_0001977', 'blood serum', 125, 'serum')]
S156-PMC3659910	PMC3659910	1/2013	S156-PMC3659910	['the us preventive services task force does not comment for or against routine screening for Vitamin D deficiency in Pregnant women.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 116, 'pregnant')]
S35-PMC3668200	PMC3668200	5/2013	S35-PMC3668200	['when large amounts of Vitamin D (1,000 iu/day) are supplemented during the last trimester to achieve 25(Oh)D concentrations of 50 nmol/l in Pregnant woman, the Vitamin D concentration in the Cord Blood is consequently increased.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('GO_0007565', 'female pregnancy', 140, 'pregnant'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 191, 'cord'), ('UBERON_0000178', 'blood', 196, 'blood')]
S70-PMC3679329	PMC3679329	6/2013	S70-PMC3679329	['among Pregnant women, the proportion of women with an Intake of Vitamin C (from diet alone) below the ear was lower among Supplement users (44%) than among non-users (68%) ( p< 0.05).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 6, 'pregnant'), ('GO_0007631', 'feeding behavior', 54, 'intake'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin C'), ('CHEBI_16158', 'steroid sulfate', 122, 'supplement')]
S54-PMC3685533	PMC3685533	6/2013	S54-PMC3685533	['all mothers had used daily a standard Prenatal multivitamin containing 400 iu of Vitamin D (Vitamin D3), except for 4 mothers (2 times per day).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 38, 'prenatal'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 92, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 92, 'vitamin D3')]
S97-PMC3685533	PMC3685533	6/2013	S97-PMC3685533	['Gestational age not correlated with Cord Blood Vitamin D or neonatal Serum levels.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('UBERON_0002240', 'spinal cord', 36, 'cord'), ('UBERON_0000178', 'blood', 41, 'blood'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('UBERON_0001977', 'blood serum', 69, 'serum')]
S2-PMC3691177	PMC3691177	6/2013	S2-PMC3691177	['methods\nwe randomised 180 Pregnant women at 27 weeks Gestation to either no Vitamin D, 800 iu Ergocalciferol daily until Delivery or single oral bolus of 200,000 iu Cholecalciferol, in an ethnically stratified, randomised controlled trial.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('GO_0007565', 'female pregnancy', 53, 'gestation'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_4910', 'etomidate', 94, 'ergocalciferol'), ('GO_0007567', 'parturition', 121, 'delivery'), ('CHEBI_52550', 'theopalauamide', 165, 'cholecalciferol')]
S76-PMC3691177	PMC3691177	6/2013	S76-PMC3691177	['effect of Prenatal Vitamin D supplementation on parent reported wheezing, allergic disease and respiratory infections\nwe found no significant difference in the primary outcome of ‘wheeze ever’ between treatment groups (any Vitamin D vs. controltable 2, daily vs. controltable 3, bolus vs. controltable 4).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'Prenatal'), ('CHEBI_28384', 'vitamin K', 19, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 19, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 223, 'vitamin D')]
S85-PMC3691177	PMC3691177	6/2013	S85-PMC3691177	['model adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in Pregnancy, exclusive breast-feeding to four months, any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education and baseline concentration of 25(Oh)D in maternal Blood.10.1371/journal.pone.0066627.t004\n\ncaption (table-wrap): table 4\nclinical outcomes at age three years.controlbolus Vitamin drror p aor† p (%)(%)(95% ci)(95% ci)(95% ci)wheeze ever14/50 (28)15/52 (29)1.03 (0.56, 1.91)1.04 (0.44, 2.47)0.931.17 (0.44, 3.10)0.75recurrent wheezing7/50 (14)9/52 (17)1.24 (0.50 (3.07)1.29 (0.44, 3.77)0.651.91 (0.53, 6.75)0.31wheezing in the last year8/50 (16)9/52 (17)1.08 (0.45, 2.58)1.10 (0.39, 3.12)0.861.29 (0.40, 4.15)0.66wheeze with positive api7/50 (14)9/51 (18)1.26 (0.51, 3.12)1.32 (0.45, 3.86)0.622.01 (0.58, 6.99)0.27any Bronchodilator use4/49 (8)14/48 (29)3.57 (1.27, 10.09)4.63 (1.40, 15.34)0.008*5.43 (1.39, 21.20)0.02*eczema ever15/49 (31)15/48 (31)1.02 (0.56, 1.85)1.03 (0.44, 2.44)0.950.86 (0.32, 2.28)0.76eczema in the last year7/49 (14)9/48 (19)1.31 (0.53, 3.24)1.39 (0.47, 4.08)0.551.97 (0.47, 8.27)0.36atopy7/27 (26)7/32 (22)0.84 (0.34, 2.11)0.80 (0.24, 2.66)0.720.31 (0.05, 1.83)0.20allergic rhinitis7/49 (14)4/46 (9)0.61 (0.19, 1.94)0.57 (0.16, 2.10)0.400.91 (0.20, 4.11)0.90food allergy diagnosed3/49 (6)4/47 (9)1.36 (0.32, 5.78)1.43 (0.30, 6.75)0.651.31 (0.24, 7.18)0.76>4 urti/year7/50 (14)9/48 (19)1.34 (0.54, 3.31)1.42 (0.48, 4.17)0.531.72 (0.49, 6.04)0.39lrti ever11/50 (22)17/47 (36)1.64 (0.86, 3.14)2.01 (0.82, 4.92)0.122.87 (1.03, 8.03)0.05*primary health care recordrecurrent wheeze3/31 (10)6/34 (18)1.82 (0.50, 6.68)2.00 (0.46, 8.80)0.351.85 (0.36, 9.66)0.47eczema6/31 (19)5/34 (15)0.76 (0.26, 2.24)0.72 (0.20, 2.64)0.620.63 (0.11, 3.59)0.60food allergy2/31 (7)0/34 (0)0.0 (-, -) ----\nbolus Vitamin D versus control.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 314, '25(OH)D'), ('UBERON_0000178', 'blood', 334, 'blood'), ('CHEBI_33229', 'vitamin (role)', 455, 'Vitamin'), ('CHEBI_60874', 'phenylacetylglycine(1-)', 900, 'bronchodilator'), ('CHEBI_27300', 'vitamin D', 1893, 'vitamin D')]
S96-PMC3691177	PMC3691177	6/2013	S96-PMC3691177	['we found no significant difference between groups in baseline Respiratory resistance at 10 or 20 hz, resonant frequency, area under the reactance curve or percentage response of these parameters to bronchodilator, when data were analysed for the two forms of Prenatal Vitamin D supplementation combined (table s6 infile s1), or separately (figures 2and3).10.1371/journal.pone.0066627.g002\n\ncaption (fig): figure 2\nbaseline Respiratory resistance at 10 hz (r10, a), 20 hz (r20, b), resonant frequency (fres, c) and area under the reactance curve (ax, d) for control (n\u200a=\u200a13), daily (n\u200a=\u200a18), and bolus (n\u200a=\u200a20) Vitamin D groups at age three years.']	N/A	N/A	[('GO_0045333', 'cellular respiration', 62, 'respiratory'), ('UBERON_0001004', 'respiratory system', 62, 'respiratory'), ('GO_0007565', 'female pregnancy', 259, 'prenatal'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 423, 'respiratory'), ('CHEBI_27300', 'vitamin D', 610, 'vitamin D')]
S102-PMC3691177	PMC3691177	6/2013	S102-PMC3691177	['we found no significant difference between groups in these outcomes assessed at age 3, when analysed for the two forms of Prenatal Vitamin D supplementation combined (table s7 infile s1) or analysed separately (figure 4).10.1371/journal.pone.0066627.g004\n\ncaption (fig): figure 4\nmeasures of allergic inflammation at age three years.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 122, 'prenatal'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S122-PMC3691177	PMC3691177	6/2013	S122-PMC3691177	['fifth, supplementation with Vitamin D only started at 27 weeks of Gestation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'gestation')]
S66-PMC3702245	PMC3702245	6/2013	S66-PMC3702245	['these subjects with very low Vitamin D status were started on 800 iu/day of Vitamin D, increased to 1600 iu/day at 36 weeks’ Gestation if Serum 25(Oh)D was still low.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'gestation'), ('UBERON_0001977', 'blood serum', 138, 'serum'), ('CHEBI_71657', 'versiconol acetate', 144, '25(OH)D')]
S107-PMC3702339	PMC3702339	6/2013	S107-PMC3702339	['prevalence of Vitamin A deficiency among Pregnant women in rural sidama, southern ethiopia, february 2011\nabout 59 (8.4%) of the Blood samples were positive for crp (crp ≥5 mg/dl).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('GO_0007565', 'female pregnancy', 41, 'pregnant'), ('UBERON_0000178', 'blood', 129, 'blood')]
S200-PMC3702339	PMC3702339	6/2013	S200-PMC3702339	['distance from the nearby health facility, Prenatal nutrition education/counselling, and frequency of anc were not associated with Vitamin A status.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 42, 'prenatal'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin A')]
S80-PMC3708703	PMC3708703	6/2013	S80-PMC3708703	['Serum 25(Oh) Vitamin D concentration and Urinary Iodine concentration were measured at 32 wk Gestation.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_30778', 'gallic acid', 6, '25(OH)'), ('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('UBERON_0001088', 'urine', 41, 'urinary'), ('CHEBI_24859', 'iodine atom', 49, 'iodine'), ('GO_0007565', 'female pregnancy', 93, 'gestation')]
S111-PMC3708703	PMC3708703	6/2013	S111-PMC3708703	['five millilitres of maternal Venous Blood was collected for iron indices (Ferritin and Transferrin Receptor) and Serum Folate, Vitamin B12, and Vitamin D levels; maternal Urine was collected for Urinary Iodine concentration at 32 wk Gestation; and 1 ml of infant Venous Blood was collected for Serum ferritin.']	N/A	N/A	[('UBERON_0001638', 'vein', 29, 'venous'), ('UBERON_0000178', 'blood', 36, 'blood'), ('PR_000007309', 'fatty acid-binding protein, liver', 74, 'ferritin'), ('PR_000001679', 'trace amine-associated receptor 5', 87, 'transferrin receptor'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('CHEBI_30863', '5-azaorotic acid', 119, 'folate'), ('CHEBI_33279', 'vitamin D5', 127, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 127, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('UBERON_0001088', 'urine', 171, 'urine'), ('UBERON_0001088', 'urine', 195, 'urinary'), ('CHEBI_24859', 'iodine atom', 203, 'iodine'), ('GO_0007565', 'female pregnancy', 233, 'gestation'), ('UBERON_0001638', 'vein', 263, 'venous'), ('UBERON_0000178', 'blood', 270, 'blood'), ('UBERON_0001977', 'blood serum', 294, 'serum')]
S193-PMC3708703	PMC3708703	6/2013	S193-PMC3708703	['at 32 wk Gestation, the prevalence of other Micronutrient deficiencies was 92.5% for Iodine, 8.5% for B12, 2.4% for Folate, and 60.6% for Vitamin D insufficiency (table 5).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 9, 'gestation'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 44, 'micronutrient'), ('CHEBI_24859', 'iodine atom', 85, 'iodine'), ('CHEBI_27778', 'abequose', 102, 'B12'), ('CHEBI_30863', '5-azaorotic acid', 116, 'folate'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
S13-PMC3760821	PMC3760821	9/2013	S13-PMC3760821	['conclusion\nin t1dm Pregnancy, low Vitamin D levels persist throughout Gestation and post-Delivery.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 19, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'gestation'), ('GO_0007567', 'parturition', 89, 'delivery')]
S23-PMC3760821	PMC3760821	9/2013	S23-PMC3760821	['during Pregnancy, 25Ohd diffuses across the Placental barrier, meaning the Foetus relies entirely on the Vitamin D status of the mother[9].']	N/A	N/A	"[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 18, '25OHD'), ('UBERON_0001987', 'placenta', 44, 'placental'), ('UBERON_0000376', 'hindlimb stylopod', 75, 'foetus'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]"
S107-PMC3760821	PMC3760821	9/2013	S107-PMC3760821	['this information is presented to indicate the prevalence of Vitamin D deficiency (insufficiency) in control and t1dm women according to stage of Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy')]
S131-PMC3773449	PMC3773449	8/2013	S131-PMC3773449	['maternal low protein diet, Vitamin A deficiency and maternal iron deficiency, Uterine Arteries ligation, maternal Gestational administration of Glucocorticoids, or other Drugs (Antibiotics) lead in most cases to iugr and to a reduced Nephron number by an average of 20%–50%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin A'), ('UBERON_0001225', 'cortex of kidney', 78, 'uterine arteries'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('CHEBI_36597', 'phthalazine', 144, 'glucocorticoids'), ('CHEBI_23888', 'drug', 170, 'drugs'), ('CHEBI_33282', 'antibacterial agent', 177, 'antibiotics'), ('UBERON_0001285', 'nephron', 234, 'nephron')]
S52-PMC3873449	PMC3873449	12/2013	S52-PMC3873449	['the Vitamin supplements used were most commonly Pregnancy-specific multivitamins, containing relatively low doses of Vitamin D (between 5 and 12·5 μg/d).']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 4, 'vitamin'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]
S90-PMC3873449	PMC3873449	12/2013	S90-PMC3873449	['Serum 25(Oh)D levels and prevalence of Vitamin D deficiency or insufficiency in Pregnant women\nthe mean Serum 25(Oh)D concentration of women (n 125) was 28.4 ± 9.5; (range 15.1 - 57.1) nmol/l.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnant'), ('UBERON_0001977', 'blood serum', 104, 'serum'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D')]
S95-PMC3873449	PMC3873449	12/2013	S95-PMC3873449	['age, Gestational age, weight, height, pre-Pregnant bmi, income, duration of walking and duration of computer usage were not different between the two groups.10.1371/journal.pone.0085081.t002\n\ncaption (table-wrap): table 2\nmaternal characteristics of all subjects by Vitamin D group.descriptivewomen with 25(Oh)D<25 nmol/lwomen with 25(Oh)D≥25 nmol/lpnumber (n, %)56 (44.8)69 (55.2)___age (years, sd)28.1 (2.67)28.7 (3.02)p = 0.206gestational age (weeks, sd)17.0 (1.26)16.8 (1.11)p = 0.239height (cm, sd)161.9 (3.26)161.2 (4.03)p = 0.326weight (kg, sd)58.3 (8.37)57.6 (7.62)p = 0.616pre-Pregnant weight (kg, sd)53.4 (6.81)52.9 (6.65)p = 0.648pre-Pregnant bmi (kg/m2, sd)20.4 (2.49)20.3 (2.34)p = 0.902assoc.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 304, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 332, '25(OH)D'), ('GO_0007565', 'female pregnancy', 586, 'pregnant'), ('GO_0007565', 'female pregnancy', 645, 'pregnant')]
S175-PMC3873449	PMC3873449	12/2013	S175-PMC3873449	['in canada, the adequate intake for Vitamin D in Pregnancy is 5 μg/d [38], while in the uk the reference Nutrient intake is set at 10 μg/day [39].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('CHEBI_33284', 'nutrient', 104, 'nutrient')]
S190-PMC3873449	PMC3873449	12/2013	S190-PMC3873449	['in the present study, no women intended to use Vitamin D and only 46.4% of women reported taking Pregnancy-specific Multivitamin Supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_7025', 'mupirocin', 116, 'multivitamin'), ('CHEBI_33341', 'titanium atom', 129, 'supplements')]
S90-PMC3882256	PMC3882256	1/2014	S90-PMC3882256	['95% confidence intervals.10.1371/journal.pone.0084684.t002\n\ncaption (table-wrap): table 2\nsample characteristics by dietary iron intake as assessed by Food frequency questionnaire at 32 weeks Gestation (n\u200a=\u200a2958 for all, except where Cord ferritin data is used: n\u200a=\u200a795).dietary iron intake≥14.8 mg/day#(n\u200a=\u200a319)<14.8 mg/day (n\u200a=\u200a2,639)p value* dietary iron intake ## (mg/day) (m, sd ** ) 16.9 (1.9 )10.1 (2.5)– dietary Vitamin C intake ## (mg/day) (m, sd) 119.3 (35.6)81.8 (32.1)<0.001 age of mother (yrs) (m, sd) 30.0 (4.2)29.5 (4.2)0.02 pre-Pregnancy bmi (kg/m2) (m, sd) 21.7 (2.5)22.9 (3.6)<0.001 total energy Intake (kj) (m, sd) 10,100 (1,921)7,167 (1,645)<0.001 smoking in Pregnancy (%, 95% ci *** ) 10.7 (7.5, 14.6)15.0 (14.6, 14.4)0.001 caucasian (%, 95% ci) 98.1 (96.0, 99.3)99.0 (98.4, 99.3)0.2 university degree (%, 95% ci) 27.0 (22.2, 32.2)17.6 (16.2, 19.1)<0.001 vegetarian (%, 95% ci) 11.9 (8.3, 16.6)5.5 (4.6, 6.4)<0.001 primigravida (%, 95% ci) 48.0 (42.4, 53.6)51.0 (47.0, 50.9)0.8 early Pregnancy maternal anemia (<11 g/dl) (%, 95% ci) 6.6 (4.1, 9.9)4.1 (3.4, 4.9)0.04 report taking Iron supplements before 32 wks Gestation (%, 95% ci) 48.3 (42.7, 53.9)44.5 (42.6, 46.4)0.2 Cord Ferritin (µg/l) (m,sd) 151.9 (104.8) (n\u200a=\u200a−83)165.4 (123.6) (n\u200a=\u200a712)0.3 child systolic Blood pressure (mmhg) (m, sd) 103.9 (8.7)103.6 (8.8)0.5 child diastolic Blood pressure (mmhg) (m, sd) 60.3 (7.3)59.5 (7.8)0.08 child pulse wave velocity (m/s) (m, sd) 7.7 (1.3)7.5 (1.2)0.1 child flow mediated dilatation (%) (m, sd) 8.3 (3.5)8.0 (3.4)0.1 child body mass index (kg/m2) (m, sd) 17.9 (2.7)18.1 (3.0)0.2 child gender (male) (%, 95% ci) 55.2 (49.5, 60.7)50.3 (48.3, 52.2)0.1 Birthweight (g) (m, sd) 3,439 (486)3,450 (500)0.7 Gestational age (wks) (m, sd) 39.5 (1.6)39.6 (1.6)0.3\n#reference Nutrient intake (rni) for iron for women aged 19–50 years in the uk.']	N/A	N/A	[('CHEBI_33290', 'food', 151, 'food'), ('GO_0007565', 'female pregnancy', 192, 'gestation'), ('UBERON_0002240', 'spinal cord', 234, 'cord'), ('CHEBI_27300', 'vitamin D', 420, 'vitamin C'), ('PR_000004900', 'complement C3', 428, 'C'), ('GO_0007565', 'female pregnancy', 544, 'pregnancy'), ('GO_0007631', 'feeding behavior', 614, 'intake'), ('GO_0007565', 'female pregnancy', 679, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1005, 'pregnancy'), ('CHEBI_24870', 'ion', 1101, 'iron'), ('GO_0007565', 'female pregnancy', 1132, 'gestation'), ('UBERON_0000948', 'heart', 1192, 'Cord'), ('CHEBI_5018', 'ferreirin', 1197, 'ferritin'), ('UBERON_0000178', 'blood', 1285, 'blood'), ('UBERON_0000178', 'blood', 1357, 'blood'), ('GO_0007608', 'sensory perception of smell', 1671, 'Birthweight'), ('GO_0007565', 'female pregnancy', 1721, 'Gestational'), ('CHEBI_33284', 'nutrient', 1786, 'nutrient')]
S13-PMC3888066	PMC3888066	12/2012	S13-PMC3888066	['the frequency of defects was concentrated among babies Born to women who had Consumed high levels of Vitamin A before the seventh week of Gestation.']	N/A	N/A	[('GO_0007567', 'parturition', 55, 'born'), ('GO_0007631', 'feeding behavior', 77, 'consumed'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin A'), ('GO_0007565', 'female pregnancy', 138, 'gestation')]
S101-PMC3901983	PMC3901983	1/2013	S101-PMC3901983	['an additional benefit of Vitamin A supplementation in Pregnant women is increasing hemoglobin concentrations [20].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin A'), ('GO_0007565', 'female pregnancy', 54, 'pregnant')]
S64-PMC3991049	PMC3991049	11/2013	S64-PMC3991049	['in african-american women, Vitamin D deficiency occurred in 29.2% and insufficiency in 54.1%, compared with 5% and 42.1% of caucasian Pregnant women.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 134, 'pregnant')]
S73-PMC3991049	PMC3991049	11/2013	S73-PMC3991049	['the highest dose of Vitamin D studied during Pregnancy was given to 15 hypoparathyroid women who received 100,000 iu/day in order to maintain Serum calcium.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 45, 'pregnancy'), ('UBERON_0001977', 'blood serum', 142, 'serum')]
S75-PMC3991049	PMC3991049	11/2013	S75-PMC3991049	['routine supplementation of Pregnant mothers with 50,000 iu Vitamin D per week resulted in improvement of Vitamin D levels.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnant'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]
S125-PMC3994635	PMC3994635	8/2010	S125-PMC3994635	['significant group differences were observed at 13 wk Postpartum in Urinary Mineral outputs and Plasma concentrations of Vitamin D Metabolites, other calciotropic hormones, and bone turnover markers.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 53, 'postpartum'), ('UBERON_0001088', 'urine', 67, 'urinary'), ('CHEBI_46662', 'mineral', 75, 'mineral'), ('UBERON_0001969', 'blood plasma', 95, 'plasma'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_25212', 'metabolite', 130, 'metabolites')]
S28-PMC4072587	PMC4072587	6/2014	S28-PMC4072587	['our main exposure of interest was maternal Vitamin D concentration at 32 weeks Gestation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'gestation')]
S88-PMC4072587	PMC4072587	6/2014	S88-PMC4072587	['sixty percent (582/960) of women had Vitamin D concentrations less than 75 nmol/l in late Pregnancy.figure 2shows the distribution of Vitamin D concentration among Pregnant women at 32 weeks Gestation.10.1371/journal.pone.0099005.g002\n\ncaption (fig): figure 2\nmaternal 25(oh)-Vitamin D concentration (nmol/l) at 32 weeks Gestation.10.1371/journal.pone.0099005.t001\n\ncaption (table-wrap): table 1\nscreening, eligibility and enrolment, of trial participants.screened from commune lists2161 not Pregnant13Miscarried before enrollment42complicated Pregnancy/sickness12over eligible Gestational age (>16 weeks)628absent at enrollment time51migrated from province after screening31 eligible population1384 excluded at enrolmentwork commitments, could not commit to trial protocol90refused36 enrolled1258 10.1371/journal.pone.0099005.t002\n\ncaption (table-wrap): table 2\ndistribution of baseline maternal sociodemographic, anthropometric characteristics, and maternal Serum 25-Ohd concentration (nmol/l) at 32 weeks Gestation.maternal characteristicnumber (%)mean maternal Serum 25-Ohd concentration nmol/l [sd]overall960 (100)70.5 [22.2]maternal age at enrolment (years)<2037 (3.9)70.2 [21.4]20–24298 (31)72.3 [21.9]25–29400 (41.7)69.1 [21.5]30–34152 (15.8)69.5 [21.0]≥3573 (7.6)72.6 [29.4]maternal height≥145 cm930 (97.0)70.3 [22.2]<145 cm (short maternal stature)29 (3.0)75.8 [24.4]maternal body mass indexunderweight (<18.5 kg/m2)251 (26.2)70.7 [22.4]normal (18.5–25 kg/m2)655 (68.3)69.8 [21.4]overweight (>25 kg/m2)53 (5.5)77.4 [29.7]educational levelprimary school146 (15.2)73.0 [23.5]secondary school643 (67.0)70.9 [22.3]university/college171 (17.8)66.4 [20.2]occupationfarmer/housewife509 (53.0)74.1 [22.6]factory worker/trader324 (33.8)66.6 [22.1]government official/clerk127 (13.2)65.9 [18.4]gravidityprimigravida296 (30.8)67.7 [21.3]multigravida664 (69.2)71.7 [22.5]type of Supplement taken during Pregnancydaily ifa supplements327 (34.1)67.8 [21.5]twice weekly ifa supplements340 (35.4)68.0 [21.5]mmn supplements293 (30.5)76.3[23.8]\nifa\u200a=\u200airon Folic Acid, mmn\u200a=\u200amultiple Micronutrients, sd\u200a=\u200astandard deviation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 164, 'pregnant'), ('GO_0007565', 'female pregnancy', 191, 'gestation'), ('CHEBI_28384', 'vitamin K', 276, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 321, 'gestation'), ('GO_0016042', 'lipid catabolic process', 492, 'pregnant13Miscarried'), ('GO_0007565', 'female pregnancy', 544, 'pregnancy'), ('GO_0007565', 'female pregnancy', 578, 'gestational'), ('UBERON_0001977', 'blood serum', 960, 'serum'), ('CHEBI_72765', 'verruculogen', 966, '25-OHD'), ('GO_0007565', 'female pregnancy', 1008, 'gestation'), ('UBERON_0001977', 'blood serum', 1065, 'serum'), ('CHEBI_72765', 'verruculogen', 1071, '25-OHD'), ('CHEBI_16158', 'steroid sulfate', 1877, 'supplement'), ('GO_0007608', 'sensory perception of smell', 1901, 'pregnancyDaily'), ('CHEBI_30751', 'formic acid', 2048, 'folic acid'), ('CHEBI_33839', 'macromolecule', 2075, 'micronutrients')]
S92-PMC4072587	PMC4072587	6/2014	S92-PMC4072587	['(%)mean difference1,3or odds ratio2,3(95% ci)p valuemean difference1,4or odds ratio2,4(95% ci)p valuemean difference1,5or odds ratio2,5(95% ci)p valuebirth weight (g)3168.6 [392.3]−11.9 (−40.0 to 16.3)0.41−21.01(−51.2 to 9.3)0.17−18.9 (−49.0 to 11.3)0.22birth length (cm)49.1 [2.61]−0.05 (−0.34 to 0.24)0.73−0.081(−0.44 to 0.27)0.64−0.07 (−0.43 to 0.29)0.70head circumference (cm)32.7 [2.12]−0.27 (−0.49 to −0.03) 0.03 −0.381(−0.64 to −0.12) 0.01 −0.35 (−0.62 to −0.09) 0.01 low Birth weight (<2500 g)27 (2.8%)1.03 (0.67 to 1.59)0.891.112(0.77 to 1.61)0.571.15 (0.74 to 1.80)0.54gestational age (weeks)39.2 [1.87]0.07 (−0.06 to 0.20)0.310.08 (−0.09 to 0.25)0.380.07 (−0.10 to 0.24)0.42preterm Delivery (<37 weeks)103 (10.7%)0.78 (0.61 to 1.00)0.0540.602(0.57 to 1.05)0.090.77 (0.57 to 1.05)0.09small for Gestational age50 (5.3)1.24 (0.91 to 1.68)0.171.33 (0.94 to 1.87)0.111.37 (0.98 to 1.91)0.07\nvalues are estimated mean difference for each outcome associated with a 25 nmol/l increase in Vitamin D concentration (95% confidence interval).']	N/A	N/A	[('GO_0007567', 'parturition', 479, 'birth'), ('GO_0007567', 'parturition', 693, 'delivery'), ('GO_0007565', 'female pregnancy', 804, 'gestational'), ('CHEBI_27300', 'vitamin D', 991, 'vitamin D')]
S117-PMC4072587	PMC4072587	6/2014	S117-PMC4072587	['in this study, Vitamin D concentration was measured early, at 18 weeks Gestation, and receptive language was assessed using the peabody picture vocabulary test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'gestation')]
S567-PMC4113768	PMC4113768	7/2014	S567-PMC4113768	['results: 260 Pregnant women were randomised to placebo ( n = 87), lower dose ( n = 87) or higher dose ( n = 86) vitamin D. in comparison with placebo, Serum 25(Oh)D concentrations were higher during Pregnancy and infancy in both the lower and higher dose Vitamin D groups.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 13, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'D'), ('UBERON_0001977', 'blood serum', 151, 'serum'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 160, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 163, 'D'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
S831-PMC4113768	PMC4113768	7/2014	S831-PMC4113768	['results: Postnatal mothers: less than half the women surveyed were given information after Vitamin D supplementation during Pregnancy.']	N/A	N/A	[('GO_0007567', 'parturition', 9, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy')]
S833-PMC4113768	PMC4113768	7/2014	S833-PMC4113768	['no-one had been given information and advice about Vitamin D supplements whilst breastfeeding and only 20% breastfeeding mothers were planning to start Supplements (all as part of healthy start or Pregnancy multivitamin).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 152, 'supplements'), ('GO_0007565', 'female pregnancy', 197, 'pregnancy')]
S1029-PMC4113768	PMC4113768	7/2014	S1029-PMC4113768	['information on Birth outcomes and maternal health during Pregnancy, including bacterial and Viral infections and the use of Vitamin D supplementation was obtained from medical records, “maternity logbooks” filled in during visits to Prenatal care clinics, or through a retrospective structured questionnaire sent to the mother after Birth.']	N/A	N/A	[('GO_0007567', 'parturition', 15, 'birth'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('NCBITaxon_1', 'root', 92, 'viral'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 233, 'prenatal'), ('GO_0007567', 'parturition', 333, 'birth')]
S2596-PMC4113768	PMC4113768	7/2014	S2596-PMC4113768	['individuals Born in two years after milk fortification start were considered as exposed to Vitamin D fortification during Gestation; Individuals Born in two years before milk fortification end were considered as unexposed.']	N/A	N/A	[('GO_0007567', 'parturition', 12, 'born'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'gestation'), ('NCBITaxon_1', 'root', 133, 'individuals'), ('GO_0007567', 'parturition', 145, 'born')]
S2600-PMC4113768	PMC4113768	7/2014	S2600-PMC4113768	['results: there were no statistically significant differences in seasonality of month of Birth in t1d in Individuals exposed or unexposed to Vitamin D fortified milk during Gestation.']	N/A	N/A	[('GO_0007567', 'parturition', 88, 'birth'), ('NCBITaxon_1', 'root', 104, 'individuals'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007565', 'female pregnancy', 172, 'gestation')]
S3045-PMC4113768	PMC4113768	7/2014	S3045-PMC4113768	['among the 42% of women who took a Vitamin D-containing supplement at 15 weeks Gestation, 31 and 72% of the Cords were <30 and 50 nmol/l, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'gestation'), ('UBERON_0005297', 'testis sex cord', 107, 'cords')]
S3081-PMC4113768	PMC4113768	7/2014	S3081-PMC4113768	['methods: we randomised 180 Pregnant women at 27 weeks Gestation to either no Vitamin D, 800 iu Ergocalciferol daily until Delivery or single oral bolus of 200,000 iu Cholecalciferol, in an ethnically stratified, randomised controlled trial.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnant'), ('GO_0007565', 'female pregnancy', 54, 'gestation'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_4910', 'etomidate', 95, 'ergocalciferol'), ('GO_0007567', 'parturition', 122, 'delivery'), ('CHEBI_52550', 'theopalauamide', 166, 'cholecalciferol')]
S3341-PMC4113768	PMC4113768	7/2014	S3341-PMC4113768	['Vitamin D inadequate (Serum 25Ohd of 30~50 nmol/l) accounted for 35.9% of all Pregnant women, and only 24.0% of Pregnant women were Vitamin D sufficient.']	N/A	N/A	"[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 22, 'serum'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 28, '25OHD'), ('GO_0007565', 'female pregnancy', 78, 'pregnant'), ('GO_0007565', 'female pregnancy', 112, 'pregnant'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]"
S3342-PMC4113768	PMC4113768	7/2014	S3342-PMC4113768	['moreover, in the winter, most (58.7%) of Pregnant women were the deficiency of Vitamin D, and only 7.5% of the Pregnant women were adequate to Vitamin D. of the 32 newborns, all were deficient in Vitamin D. (2) maternal Vitamin D levels among different seasons were significant different (χ2= 326.15, p< 0.001), and the lowest level of Vitamin D was in the winter, and the highest was in the summer.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 41, 'pregnant'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'pregnant'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]
S3343-PMC4113768	PMC4113768	7/2014	S3343-PMC4113768	['(3) among different age groups of Pregnant women, Vitamin D levels had significant difference (χ2= 11.82, p = 0.003).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 34, 'pregnant'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
S3344-PMC4113768	PMC4113768	7/2014	S3344-PMC4113768	['the Vitamin D level in 30~35 age group of Pregnant women (median: 36.2 nmol/l, range: 13.8~108.7 nmol/l) was higher than that in the 25~30 age group (median: 35.9 nmol/l, range: 10.4~89.8 nmol/l) and the 18~25 age group (median: 33.3 nmol/l, range: 10.1~85.2 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnant')]
S121-PMC4169453	PMC4169453	9/2014	S121-PMC4169453	['the study visits: v0- the baseline visit, v3, v6 – the visits after 3 and 6 months of Vitamin D supplementation.10.1371/journal.pone.0107708.t001\n\ncaption (table-wrap): table 1\nsociodemographic and clinical characteristics of the mothers and infants at study enrollment based on vitamin d supplementation group.parameter400 iu/d group1200 iu/d group p -value between groups mathers n\u200a=\u200a67n\u200a=\u200a70age, years30 (27–33)30 (26–34)0.89baseline bmi, kg/m224.4 (22.1–27.3)23.8 (22.1–26.8)0.49bmi>30, n (%)8 (12%)5 (7%)0.34weight before Delivery, kg77.4 (69–86)74 (67–83)0.26season at Delivery, n (%)june–october25 (37%)22 (31%)0.47november–may42 (63%)48 (69%)education, n (%)>high school5 (8%)5 (7%)0.04high school27 (41%)15 (21%)college or more34 (52%)50 (71%)monthly income, n (%)<250 euro/capita16 (24%)16 (23%)0.59250–750 euro/capita32 (49%)37 (54%)>750 euro/capita18 (27%)16 (23%)Vitamin D during Pregnancy,n (%)46 (69%)50 (71%)0.73daily dose, iu/d400 (200–800)400 (200–800)0.70duration, months7 (6–9)7 (5–9)0.87 infants n\u200a=\u200a67n\u200a=\u200a70age at baseline visit, days18 (14–22)15 (13–20)0.09boys, n (%)29 (44%)27 (38%)0.48birth weight, g3500 (3200–3815)3480 (3280–3640)0.80birth length, cm55 (53–57)55 (53–56)0.25\ndata are presented as median and interquartile range (q1–q3) or number and (%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007567', 'parturition', 527, 'delivery'), ('GO_0007567', 'parturition', 575, 'delivery'), ('CHEBI_28384', 'vitamin K', 876, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 893, 'pregnancy')]
S3-PMC4188019	PMC4188019	1/2010	S3-PMC4188019	['method : from august 1 2009 until november 30 2009 we systematically determined 25-Hydroxy Vitamin D (25-Oh Vitamin D) in each Blood sample taken from Pregnant women visiting the Antenatal clinic.']	N/A	N/A	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 80, '25-hydroxy vitamin D'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 102, '25-OH'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('UBERON_0000178', 'blood', 127, 'blood'), ('GO_0007565', 'female pregnancy', 151, 'pregnant'), ('GO_0007567', 'parturition', 179, 'antenatal')]
S10-PMC4188019	PMC4188019	1/2010	S10-PMC4188019	['there was no effect of Gestational age, maternal age, gravidity, parity and intake of supplements on Vitamin D levels.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'gestational'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
S15-PMC4188019	PMC4188019	1/2010	S15-PMC4188019	['in the Liver, Vitamin D is hydroxylated to 25-Hydroxyvitamin D. subsequent hydroxylation in the Kidney forms the active Metabolite, 1,25-Oh vitamin D.\nin Pregnancy, there is a 2-fold higher concentration of 1,25-Oh Vitamin D in maternal Serum due to activity of Placental 1-α-hydroxylase (novakovic et al., 2009).']	N/A	N/A	[('UBERON_0002107', 'liver', 7, 'liver'), ('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 43, '25-hydroxyvitamin D'), ('UBERON_0002113', 'kidney', 96, 'kidney'), ('CHEBI_39382', 'flufenoxuron', 120, 'metabolite'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 134, '25-OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 148, 'D'), ('GO_0007565', 'female pregnancy', 154, 'pregnancy'), ('CHEBI_72639', '13-HODE', 207, '1,25-OH'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('UBERON_0001977', 'blood serum', 237, 'serum'), ('UBERON_0001987', 'placenta', 262, 'placental')]
S24-PMC4188019	PMC4188019	1/2010	S24-PMC4188019	['results of Vitamin D status in the Pregnant flemish population have never been published before.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007565', 'female pregnancy', 35, 'pregnant')]
S27-PMC4188019	PMC4188019	1/2010	S27-PMC4188019	['in each Blood sample that was taken from Pregnant women consulting the Antenatal clinic, we determined 25-Oh Vitamin D. the nurse taking the Blood samples put every patient in a category according to their sun exposure.']	N/A	N/A	[('UBERON_0000178', 'blood', 8, 'blood'), ('GO_0007565', 'female pregnancy', 41, 'pregnant'), ('GO_0007567', 'parturition', 71, 'antenatal'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 103, '25-OH'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('UBERON_0000178', 'blood', 141, 'blood')]
S48-PMC4188019	PMC4188019	1/2010	S48-PMC4188019	['there was no effect of age, gravidity, parity, Intake of Supplements nor Gestational age on the Vitamin D level.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 47, 'intake'), ('CHEBI_33341', 'titanium atom', 57, 'supplements'), ('GO_0007565', 'female pregnancy', 73, 'gestational'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
S68-PMC4188019	PMC4188019	1/2010	S68-PMC4188019	['we found no effect of maternal age, Gestational age, parity, gravidity and intake of supplements on the Vitamin D level.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 36, 'gestational'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
S22-PMC4224012	PMC4224012	11/2014	S22-PMC4224012	"[""gross domestic product is us$35·81 billion and per Person income is $1160 (at purchasing power parity), which places nepal 103rd in terms of wealth.22,23the Human Development index is 0·458, ranked 157th worldwide.23\nthe trial has been described previously.71200 women attending janakpur zonal hospital for Antenatal care were randomly allocated to receive either a multivitamin supplement (containing 800 μg Vitamin A, 10 mg Vitamin E, 5 μg Vitamin D, 1·4 mg vitamin b1, 1·4 mg Vitamin B2, 18 mg niacin, 1·9 mg Vitamin B6, 2·6 μg vitamin b12, 400 μg Folic Acid, 70 mg Vitamin C, 30 mg iron, 15 mg zinc, 2 mg copper, 65 μg Selenium, and 150 μg Iodine) or a control supplement of 60 mg Iron and 400 μg Folic Acid.6supplements were taken every day from 12 to 20 weeks' Gestation (average 15·9 weeks) until Delivery, and women were assessed every 2 weeks.""]"	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 51, 'person'), ('GO_0060976', 'coronary vasculature development', 157, 'Human Development'), ('NCBITaxon_10088', 'Mus <genus>', 157, 'Human'), ('GO_0007567', 'parturition', 307, 'antenatal'), ('CHEBI_27300', 'vitamin D', 409, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 417, 'A'), ('CHEBI_27300', 'vitamin D', 426, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 442, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 450, 'D'), ('CHEBI_33279', 'vitamin D5', 479, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 512, 'vitamin B6'), ('CHEBI_30751', 'formic acid', 551, 'folic acid'), ('CHEBI_27300', 'vitamin D', 569, 'vitamin C'), ('CHEBI_27568', 'selenium atom', 623, 'selenium'), ('CHEBI_24859', 'iodine atom', 644, 'iodine'), ('CHEBI_24870', 'ion', 685, 'iron'), ('CHEBI_30751', 'formic acid', 701, 'folic acid'), ('GO_0007565', 'female pregnancy', 767, 'gestation'), ('GO_0007567', 'parturition', 804, 'delivery')]
S88-PMC4231606	PMC4231606	10/2013	S88-PMC4231606	['there was no significant difference between the two groups with respect to premature Birth (p\u2009=\u20090.88), whether mothers took Vitamin D supplements during Pregnancy (p\u2009=\u20090.92), or Maternal milk intake during Pregnancy (p\u2009=\u20090.56) (data not shown).']	N/A	N/A	[('GO_0007567', 'parturition', 85, 'birth'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('GO_0007618', 'mating', 178, 'maternal'), ('GO_0007565', 'female pregnancy', 206, 'pregnancy')]
S15-PMC4256222	PMC4256222	12/2014	S15-PMC4256222	['during Pregnancy Vitamin D is transported from the mother to the fetus through the Placenta in the form of 25-Hydroxyvitamin D (25(Oh)D), and at Birth the concentration in Umbilical Cord Blood is around 80% of maternal Blood concentration[2].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('UBERON_0001987', 'placenta', 83, 'placenta'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 107, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 128, '25(OH)D'), ('GO_0007567', 'parturition', 145, 'birth'), ('UBERON_0002331', 'umbilical cord', 172, 'umbilical cord'), ('UBERON_0000178', 'blood', 187, 'blood'), ('UBERON_0000178', 'blood', 219, 'blood')]
S57-PMC4256222	PMC4256222	12/2014	S57-PMC4256222	['statistical methods\ncox proportional hazard model was used to investigate the association between total Vitamin D status in Pregnancy and first time bone fracture risk.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy')]
S66-PMC4256222	PMC4256222	12/2014	S66-PMC4256222	['based on accessibility and current knowledge about Vitamin D and fracture risk, the following variables were included as covariates: mother’s age (continuous), pre-Pregnancy body mass index (bmi) (continuous), smoking in Pregnancy (yes, no), parity (nulliparous, 1 child, 2+children) and sex (girl, boy).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 164, 'pregnancy'), ('GO_0007565', 'female pregnancy', 221, 'pregnancy')]
S69-PMC4256222	PMC4256222	12/2014	S69-PMC4256222	['results\nSerum samples were available from 88% of the women in the cohort, which in total provided 850 mother and child pairs with a maternal Vitamin D status from Gestation week 30.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 8, 'Serum'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'gestation')]
S71-PMC4256222	PMC4256222	12/2014	S71-PMC4256222	['the median (5–95 percentile) total Vitamin D status among the 850 Pregnant women was 76.2 (23.0–152.1) nmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnant')]
S88-PMC4256222	PMC4256222	12/2014	S88-PMC4256222	['adjustment for status of Vitamin D did not attenuate the association (hr\u200a=\u200a1.82, 95%ci: 1.12–2.97).10.1371/journal.pone.0114334.t002\n\ncaption (table-wrap): table 2\nthe association (hazard ratios and 95% confidence interval) between maternal Vitamin D status in Gestation week 30 and offspring bone fractures in childhood and adolescence among 850 mother and child pairs from the dafo88 cohort in aarhus city, denmark.crudeadjusted*ncaseshr (95% ci)hr (95% ci)all ages, 0–18 y<50 nmol/l)217781.13 (0.84–1.51)1.17 (0.87–1.57)50–75 nmol/l)199741.20 (0.89–1.62)1.19 (0.88–1.61)≥75–125 nmol/l)3211031.001.00>125 nmol/l)113391.09 (0.75–1.58)1.10 (0.76–1.59) p -valuea0.320.27childhood, 0–10 y<50 nmol/l)217391.04 (0.69–1.57)1.07 (0.70–1.62)50–75 nmol/l)199421.25 (0.84–1.87)1.26 (0.84–1.89)≥75–125 nmol/l)321551.001.00>125 nmol/l)113201.06 (0.64–1.78)1.09 (0.65–1.91) p -valuea0.590.53adolescence, 11–18 y<50 nmol/l)178391.23 (0.81–1.88)1.29 (0.84–1.99)50–75 nmol/l)157321.13 (0.72–1.77)1.11 (0.71–1.74)≥75–125 nmol/l)266481.001.00>125 nmol/l)93191.12 (0.66–1.91)1.13 (0.66–1.93) p -valuea0.370.35\n*adjusted for maternal age, pre-Pregnancy bmi, smoking, parity and sex.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('GO_0007565', 'female pregnancy', 261, 'gestation'), ('GO_0007565', 'female pregnancy', 1124, 'pregnancy')]
S89-PMC4256222	PMC4256222	12/2014	S89-PMC4256222	['continuous values of Vitamin D status in the cox regression model.10.1371/journal.pone.0114334.t003\n\ncaption (table-wrap): table 3\nthe association (hazard ratios and 95% confidence interval) between season in Gestation week 30 and offspring bone fractures in childhood and Adolescence among 850 mother and child pairs from the dafo88 cohort in aarhus city, denmark.adjusted*+ vitamin d¤ncaseshr (95% ci)hr (95% ci)all ages, 0–18 ymar/apr/may113351.06 (0.71–1.59)1.05 (0.69–1.59)jun/jul/aug247761.001.00sep/oct/nov3001101.26 (0.94–1.69)1.24 (0.90–1.71)dec/jan/feb190731.39 (1.01–1.92)1.36 (0.96–1.93)childhood, 0–10 ymar/apr/may113211.37 (0.79–2.37)1.42 (0.80–2.50)jun/jul/aug247341.001.00sep/oct/nov300581.45 (0.95–2.22)1.51 (0.95–2.40)dec/jan,/feb190431.75 (1.11–2.74)1.82 (1.12–2.97)adolescence, 11–18 ymar/apr/may92140.82 (0.44–1.50)0.77 (0.41–1.43)jun/jul/aug213421.001.00sep/oct/nov242521.10 (0.73–1.66)1.02 (0.65–1.59)dec/jan,/feb147301.08 (0.67–1.73)0.99 (0.60–1.65)\n*adjusted for maternal age, pre-Pregnancy bmi, smoking, parity and sex.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 209, 'gestation'), ('GO_0048848', 'neurohypophysis morphogenesis', 273, 'adolescence'), ('GO_0007565', 'female pregnancy', 1006, 'pregnancy')]
S90-PMC4256222	PMC4256222	12/2014	S90-PMC4256222	['adjusted for maternal age, pre-Pregnancy bmi, smoking, parity, sex and maternal Vitamin D status in Gestational week 30.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 31, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'gestational')]
S96-PMC4256222	PMC4256222	12/2014	S96-PMC4256222	['discussion\noverall, there was no significant association between maternal Vitamin D status in Gestation week 30 and offspring bone fractures from Birth until 18 years of age in the dafo88 cohort.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'gestation'), ('GO_0007567', 'parturition', 146, 'birth')]
S194-PMC4258799	PMC4258799	11/2014	S194-PMC4258799	['20% of those on therapy achieved Pregnancy Vitamin E\u2009+\u2009anti-estrogen (Clomiphene Citrate) prospective, placebo-controlled rctinfertile men with idiopathic oligozoospermia (n\u2009=\u200960)400\xa0mg Vitamin E +25\xa0mg Clomiphene Citrate x 6\xa0months (n\u2009=\u200930)placebo (n\u2009=\u200930)1.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 43, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 43, 'Vitamin E'), ('CHEBI_3755', 'clomipramine hydrochloride', 70, 'Clomiphene citrate'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin E'), ('CHEBI_3753', 'clomiphene citrate', 203, 'clomiphene citrate')]
S197-PMC4258799	PMC4258799	11/2014	S197-PMC4258799	['partners had higher incidence of Pregnancy Vitamin E\u2009+\u2009Selenium open, randomizedvolunteers and infertile men (n\u2009=\u200954)400\xa0mg Vitamin E +225\xa0μg Selenium x 3\xa0months (n\u2009=\u200928)4.5\xa0g Vitamin B x 3\xa0months (n\u2009=\u200926)1.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 43, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 43, 'Vitamin E'), ('CHEBI_27568', 'selenium atom', 55, 'selenium'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin E'), ('CHEBI_27568', 'selenium atom', 142, 'selenium'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin B'), ('PR_000000037', 'BMP receptor type-2', 184, 'B')]
S202-PMC4258799	PMC4258799	11/2014	S202-PMC4258799	['increased spontaneous Pregnancy rates (11%) Vitamin E\u2009+\u2009vitamin C double blind, placebo-controlled, rctmen (n\u2009=\u200931) with asthenozoospermia or moderate oligoasthenozoospermia1000\xa0mg Vitamin C +800\xa0mg Vitamin E x 8\xa0weeks (n\u2009=\u200915)placebo (n\u2009=\u200916)no improvement in Sperm parametersrolf et al.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 22, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 44, 'Vitamin E'), ('PR_000004900', 'complement C3', 64, 'C'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin C'), ('PR_000004900', 'complement C3', 189, 'C'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin E'), ('CL_0000019', 'sperm', 261, 'sperm')]
S207-PMC4258799	PMC4258799	11/2014	S207-PMC4258799	['marked improvement in Implantation and clinical Pregnancy rates in the 2ndicsi attempt vs 1stattempt vitamin c men with Sperm agglutination (>25%) (n\u2009=\u200930)200\xa0mg Vitamin C or 1000\xa0mg Vitamin Cplaceboimproved Sperm Motility, viability, morphology after 4\xa0weeks (more prominent improvement in 1000\xa0mg Vitamin C vs. 200\xa0mg Vitamin c)dawson et al.']	N/A	N/A	[('GO_0007566', 'embryo implantation', 22, 'implantation'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('CL_0000019', 'sperm', 120, 'sperm'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin C'), ('CHEBI_35447', 'biphenyl-4-yl group', 183, 'vitamin CPlaceboImproved'), ('CL_0000019', 'sperm', 208, 'sperm'), ('GO_0065007', 'biological regulation', 214, 'motility'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin C'), ('CHEBI_33229', 'vitamin (role)', 320, 'vitamin')]
S243-PMC4258799	PMC4258799	11/2014	S243-PMC4258799	['no significant increase in Implantation and Pregnancy rates vitamin c prospectivewomen undergoing ivf-et (n\u2009=\u200976)500\xa0mg Vitamin C/day (slow release) to women smokers (n\u2009=\u200919) and women non-smokers (n\u2009=\u200919)placebowomen non-smokers had higher Pregnancy rates than women smokerscrha et al.']	N/A	N/A	[('GO_0007566', 'embryo implantation', 27, 'implantation'), ('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin C'), ('GO_0007565', 'female pregnancy', 241, 'pregnancy')]
S314-PMC4258799	PMC4258799	11/2014	S314-PMC4258799	['in a large, placebo-controlled, double blind rct, Vitamin C supplementation for a period of 14\xa0days starting on the day of follicle aspiration in women undergoing ivf-et showed no improvement in clinical Pregnancy or Implantation rates [125].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin C'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy'), ('GO_0007566', 'embryo implantation', 217, 'implantation')]
S3-PMC4263713	PMC4263713	12/2014	S3-PMC4263713	['Vitamin A-deficient Pregnant Rats or their offspring were administered a low-dose of Vitamin A daily for 7 days starting on Gestational day 14 or Postnatal day 1, day 14 or day 28.']	N/A	N/A	[('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin A'), ('GO_0007565', 'female pregnancy', 20, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 29, 'rats'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin A'), ('GO_0007565', 'female pregnancy', 124, 'gestational'), ('GO_0007567', 'parturition', 146, 'postnatal')]
S7-PMC4263713	PMC4263713	12/2014	S7-PMC4263713	['additionally, Vitamin A supplementation during late Gestation increased the numbers of Cd8+Intestinal Intraepithelial lymphocytes and decreased the numbers of B Lymphocytes in the Mesenteric Lymph Nodes.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('GO_0007565', 'female pregnancy', 52, 'gestation'), ('PR_000005170', 'CD37 molecule', 87, 'CD8'), ('UBERON_0000160', 'intestine', 91, 'intestinal'), ('UBERON_0004821', 'pulmonary alveolus epithelium', 102, 'intraepithelial'), ('CL_0000236', 'B cell', 159, 'B lymphocytes'), ('UBERON_0002509', 'mesenteric lymph node', 180, 'mesenteric lymph nodes')]
S205-PMC4263713	PMC4263713	12/2014	S205-PMC4263713	['in the current study, Pregnant vad Rats or their vad offspring received a low-dose of Vitamin A daily for 7 days[19].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 22, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 35, 'rats'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin A')]
S49-PMC4289064	PMC4289064	1/2015	S49-PMC4289064	['this comparison was made for five age categories (children 1 to less than 4 years, children 4 to less than 9 years, women 19 to less than 51 years who were not Pregnant or Lactating, Lactating women 19 to less than 51 years, and Pregnant women 19 to less than 51 years) in each of four countries (bangladesh, mozambique, uganda, and zambia) across five Nutrients (Vitamin A, Calcium, Folate, iron, zinc).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 160, 'pregnant'), ('GO_0007594', 'puparial adhesion', 172, 'lactating'), ('GO_0007594', 'puparial adhesion', 183, 'lactating'), ('GO_0007565', 'female pregnancy', 229, 'pregnant'), ('CHEBI_33284', 'nutrient', 353, 'nutrients'), ('CHEBI_27300', 'vitamin D', 364, 'vitamin A'), ('CHEBI_22313', 'alkaline earth metal atom', 375, 'calcium'), ('CHEBI_30863', '5-azaorotic acid', 384, 'folate')]
S190-PMC4289064	PMC4289064	1/2015	S190-PMC4289064	['supporting information\n\ncaption (supplementary-material): s1 fig\n\naverage proportion of dietary intake of Vitamin A from different sources for women 19 to 50 years old (including Pregnant and Lactating women).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 106, 'vitamin A'), ('GO_0007565', 'female pregnancy', 179, 'pregnant'), ('GO_0007594', 'puparial adhesion', 192, 'lactating')]
S2-PMC4329404	PMC4329404	10/2014	S2-PMC4329404	['methods\nin utero and early-Life Vitamin D deficiency was achieved using a Vitamin D-deficient diet for female Mice during the third Trimester of Pregnancy and Lactation.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 27, 'life'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 110, 'mice'), ('GO_0009294', 'DNA mediated transformation', 132, 'trimester'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('GO_0007595', 'lactation', 159, 'lactation')]
S34-PMC4329404	PMC4329404	10/2014	S34-PMC4329404	['female balb/c Mice were Mated and, from day-16 Gestation, were either Fed a Vitamin D-deficient Chow (special diets services, uk) or remained on a regular diet throughout Pregnancy and Lactation.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 14, 'mice'), ('GO_0007618', 'mating', 24, 'mated'), ('GO_0007565', 'female pregnancy', 47, 'gestation'), ('GO_0007631', 'feeding behavior', 70, 'fed'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_33290', 'food', 96, 'chow'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy'), ('GO_0007595', 'lactation', 185, 'lactation')]
S42-PMC4329404	PMC4329404	10/2014	S42-PMC4329404	['Pregnant female balb/c Mice were Fed a Vitamin D-deficient diet from day-16 Gestation or remained on a normal Chow diet.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0007631', 'feeding behavior', 33, 'fed'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'gestation'), ('CHEBI_33290', 'food', 110, 'chow')]
S68-PMC4329404	PMC4329404	10/2014	S68-PMC4329404	['results\n\nVitamin D insufficiency skews towards a Pulmonary th2 phenotype and reduces Il-10+T Regulatory Cells in Pregnant females\nPregnant female balb/c Mice received a Vitamin D-deficient diet from day-16 Gestation and throughout Lactation for a total of 4\xa0weeks to induce Vitamin D insufficiency (fig.1a) (29).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('UBERON_0002048', 'lung', 49, 'pulmonary'), ('PR_000001470', 'interleukin-28B', 85, 'IL-10'), ('CL_0000902', 'induced T-regulatory cell', 91, 'T regulatory cells'), ('GO_0065007', 'biological regulation', 93, 'regulatory'), ('GO_0007565', 'female pregnancy', 113, 'pregnant'), ('GO_0007565', 'female pregnancy', 130, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 153, 'mice'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 206, 'gestation'), ('GO_0007595', 'lactation', 231, 'lactation'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D')]
S79-PMC4329404	PMC4329404	10/2014	S79-PMC4329404	['Pregnant female balb/c Mice were either Fed a Vitamin D-deficient diet from day-16 Gestation or remained on a normal Chow diet.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0007631', 'feeding behavior', 40, 'fed'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'gestation'), ('CHEBI_33290', 'food', 117, 'chow')]
S94-PMC4329404	PMC4329404	10/2014	S94-PMC4329404	['Pregnant female balb/c Mice were Fed a Vitamin D-deficient diet from day-16 Gestation or remained on a normal Chow diet.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0007631', 'feeding behavior', 33, 'fed'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'gestation'), ('CHEBI_33290', 'food', 110, 'chow')]
S106-PMC4329404	PMC4329404	10/2014	S106-PMC4329404	['Pregnant female balb/c Mice were Fed a Vitamin D-deficient diet from day-16 Gestation or remained on a normal Chow diet.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0007631', 'feeding behavior', 33, 'fed'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'gestation'), ('CHEBI_33290', 'food', 110, 'chow')]
S124-PMC4329404	PMC4329404	10/2014	S124-PMC4329404	['Pregnant female balb/c Mice were Fed a Vitamin D-deficient diet from day-16 Gestation or remained on a normal Chow diet.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0007631', 'feeding behavior', 33, 'fed'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'gestation'), ('CHEBI_33290', 'food', 110, 'chow')]
S20-PMC4329745	PMC4329745	10/2014	S20-PMC4329745	['exclusion criteria included chronic illness, history of cancer, Pregnancy or Lactation, malabsorption syndrome or gastric disorders, Metabolic bone disease, Renal or Hepatic failure, recent history of therapeutic Vitamin D consumption or osteoporosis treatment.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007595', 'lactation', 77, 'lactation'), ('GO_0008152', 'metabolic process', 133, 'metabolic'), ('UBERON_0002113', 'kidney', 157, 'renal'), ('UBERON_0002107', 'liver', 166, 'hepatic'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D')]
S204-PMC4377879	PMC4377879	3/2015	S204-PMC4377879	['supplementation with multivitamins (Vitamin B Complex, Vitamin C and Vitamin E) also significantly decreases the risk of adverse Pregnancy outcomes among hiv-infected women [76].']	N/A	N/A	[('CHEBI_75427', 'deuterated fatty acid', 36, 'vitamin B complex'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin E'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]
S67-PMC4377888	PMC4377888	3/2015	S67-PMC4377888	['[54] report a 20% reduction in Nephron number in Adult Rats Born to mothers that were Fed a Vitamin A deficient diet during 3 weeks prior to Pregnancy, throughout Pregnancy up until day 21 of Gestation.']	N/A	N/A	[('UBERON_0001285', 'nephron', 31, 'nephron'), ('UBERON_0007023', 'adult organism', 49, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 55, 'rats'), ('GO_0007567', 'parturition', 60, 'born'), ('GO_0007631', 'feeding behavior', 86, 'fed'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin A'), ('GO_0007565', 'female pregnancy', 141, 'pregnancy'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy'), ('GO_0007565', 'female pregnancy', 192, 'gestation')]
S12-PMC4380518	PMC4380518	9/2014	S12-PMC4380518	['this substudy includes women enrolled from brigham and women’s hospital, a high-risk tertiary Perinatal center in boston, ma who had complete exposure (pnv use) and outcome data (Vitamin D status at two time points during Pregnancy).']	N/A	N/A	[('GO_0036268', 'swimming', 94, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 94, 'perinatal'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D'), ('GO_0007565', 'female pregnancy', 222, 'pregnancy')]
S131-PMC4383575	PMC4383575	1/2015	S131-PMC4383575	['caption (table-wrap): table 3\n\ndietary predictors in adjusted associations with bulky dna adduct levels.predictor n mra(95% ci) p -valuemeat donenessnormal2521.00 (reference)well-done980.93 (0.77, 1.13)0.47processed meat (per 1 g/day)low1491.00 (reference)middle1581.15 (0.97, 1.37)0.11high1371.15 (0.94, 1.40)0.17dietary supplementssome3921.00 (reference)none481.03 (0.78, 1.36)0.82dairy products (per 1 g/day)4541.00 (1.00, 1.00)0.06low1421.00 (reference)middle1531.10 (0.92, 1.32)0.31high1591.21 (1.00, 1.46)0.05fruits with Vitamin C (per 1 g/day)4531.00 (1.00, 1.00)0.06low1471.00 (reference)middle1570.88 (0.74, 1.04)0.13high1490.83 (0.70, 0.99)0.04healthy dietary score (0–7 no units)4550.93 (0.88, 0.98)0.008low1061.00 (reference)middle2460.85 (0.71, 1.01)0.06high1030.78 (0.63, 0.96)0.02mean ratios (mrs) (95% cis) represent the proportional differences in bulky dna adduct levels ( n /108nucleotides) associated with a 1-unit increase in continuous variables, and for the categorical variables the mr and 95% cis are relative to the referent group.aadjusted for country, Maternal smoking (no, yes), and Prepregnancy bmi (kg/m2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 527, 'vitamin C'), ('GO_0007618', 'mating', 1080, 'maternal'), ('GO_0007565', 'female pregnancy', 1112, 'prepregnancy')]
S73-PMC4392531	PMC4392531	3/2015	S73-PMC4392531	['in Pregnant women who consumed less than 65 mg of Vitamin C per day, this percentage during the second Trimester and increased risk of these complications was 70%.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 3, 'pregnant'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin C'), ('GO_0009294', 'DNA mediated transformation', 103, 'trimester')]
S5-PMC4405493	PMC4405493	4/2015	S5-PMC4405493	['competitive enzymatic Vitamin D assays were performed on banked Plasma specimens and Pregnancy outcomes were collected after Delivery.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 30, 'D'), ('UBERON_0001969', 'blood plasma', 64, 'plasma'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('GO_0007567', 'parturition', 125, 'delivery')]
S6-PMC4405493	PMC4405493	4/2015	S6-PMC4405493	['logistic regression was performed on patients stratified by Plasma Vitamin D concentration and the following combined clinical outcomes: Preeclampsia, Preterm Delivery, Intrauterine growth restriction, Gestational diabetes, and Spontaneous Abortion.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 60, 'plasma'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 137, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 151, 'preterm'), ('GO_0007567', 'parturition', 159, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 169, 'intrauterine'), ('GO_0007565', 'female pregnancy', 202, 'gestational'), ('GO_0035042', 'fertilization, exchange of chromosomal proteins', 228, 'spontaneous abortion')]
S11-PMC4405493	PMC4405493	4/2015	S11-PMC4405493	['there was no association between Vitamin D deficiency and composite adverse Pregnancy outcomes with an adjusted odds ratio of 1.01 ( p value 0.738, 95% confidence intervals 0.961-1.057).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy')]
S45-PMC4405493	PMC4405493	4/2015	S45-PMC4405493	['Plasma preparation and Vitamin D elisa\nmaternal Blood was collected by venipuncture in vacutainer edta-containing tubes at 5 to 12 weeks Gestational age and the date of the Blood draw was recorded.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0000178', 'blood', 48, 'blood'), ('GO_0007565', 'female pregnancy', 137, 'gestational'), ('UBERON_0000178', 'blood', 173, 'blood')]
S92-PMC4405493	PMC4405493	4/2015	S92-PMC4405493	['the mean Serum 25-Oh Vitamin D concentration for our study population was 27.6 ng/ml (range 13–71.6 ng/ml).10.1371/journal.pone.0123763.t001\n\ncaption (table-wrap): table 1\nfrequency of clinical outcomes compared to national and global epidemiology.Pregnancy outcome n (% of 235 total)comorbiditiespredicted population us (%)frequencies global (%)madigan 2014 (%) none 176 (75%)-------- Preeclampsia 19 (8%)5 Preterm Deliveries3–10% [22,24–26]2–17% [20,23]3% spontaneous Preterm Delivery 10 (4%)2 iugr, 1 Gdm11.3% [27]9.6% [28]9% iugr 9 (4%)--8.6% [29]3–7% [30]0.6% gdm 5 (2%)--4.6–9.2% [33]4.1–27.5% [36]4% spontaneous Abortion 16 (7%)--8–20% [37,38]6%\niugr, Intrauterine growth restriction; gdm, Gestational diabetes mellitus.10.1371/journal.pone.0123763.t002\n\ncaption (table-wrap): table 2\ndemographics of the study population by Vitamin D classification.totalvitamin D sufficient (>30 ng/ml)Vitamin D insufficient (21–29 ng/ml)Vitamin D deficient (<20 ng/ml)p value**n = 235 (%)n = 70 (30%)n = 141 (60%)n = 24 (10%) age (years) *24.3 ± 4.424.5 ± 4.224.6 ± 4.522.5 ± 3.70.08 Gestational age at analysis (days) *62.2 ± 29.761.8 ± 13.762.2 ± 36.963.0 ± 11.20.99 n (% of 235)n (% of 70)n (% of 141)n (% of 24)p value ** race 0.03 caucasian 183 (77.9)57 (81.4)114 (80.9)12 (50) african american 16 (6.8)3 (4.3)10 (7.1)3 (12.5) asian 6 (2.6)1 (1.4)3 (2.1)2 (8.3) other 30 (12.8)9 (12.9)14 (9.9)7 (29.2) body mass index 0.36 <25 111 (47.2)39 (55.7)62 (44)10 (41.7) 25–30 82 (34.9)21 (30.0)50 (35.5)11 (45.8) >30 42 (17.9)10 (14.3)29 (20.5)3 (12.5) season 0.22 winter 89 (37.9)22 (31.4)61 (43.3)6 (25.0) spring 45 (19.1)16 (22.9)25 (17.7)4 (16.6) summer 53 (22.6)20 (28.6)26 (18.4)7 (29.2) fall 48 (20.4)12 (17.1)29 (20.6)7 (29.2) mode of delivery 0.41 Vaginal 155 (66.0)47 (67.1)95 (67.4)13 (54.2) cesarean section 63 (26.8)18 (25.7)36 (25.5)9 (37.5) iufd or sab 17 (7.2)5 (7.1)10 (7.1)2 (8.3) duty status 0.12 active duty 83 (35.3)22 (31.4)48 (34.0)13 (54.2) dependent 152 (64.6)48 (68.6)93 (66.0)11 (45.8) tobacco use 0.67 yes 15 (6.4)3 (4.3)10 (7.1)2 (8.3) no 220 (93.6)67 (95.7)131 (92.9)22 (91.7)\n*expressed in mean ± standard deviation\n**, p value calculated by analysis of variance for continuous variables and chi-square analysis for categorical variables\niufd, Intrauterine fetal demise; sab, spontaneous Abortion.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 15, '25-OH'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 248, 'Pregnancy'), ('GO_0007128', 'meiotic prophase I', 386, 'Preeclampsia'), ('GO_0007565', 'female pregnancy', 408, 'preterm'), ('GO_0007567', 'parturition', 416, 'deliveries3'), ('GO_0007565', 'female pregnancy', 470, 'preterm'), ('GO_0007567', 'parturition', 478, 'delivery'), ('PR_000007939', 'glial fibrillary acidic protein', 504, 'GDM11'), ('GO_0007569', 'cell aging', 619, 'abortion'), ('UBERON_0022293', 'reproductive gland secretion', 659, 'intrauterine'), ('GO_0007565', 'female pregnancy', 697, 'gestational'), ('CHEBI_27300', 'vitamin D', 832, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 870, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 870, 'D'), ('CHEBI_28384', 'vitamin K', 894, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 930, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 930, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1077, 'Gestational'), ('UBERON_0000970', 'eye', 1748, 'Vaginal'), ('UBERON_0022293', 'reproductive gland secretion', 2266, 'intrauterine'), ('GO_0007569', 'cell aging', 2310, 'abortion')]
S102-PMC4405493	PMC4405493	4/2015	S102-PMC4405493	['preeclampsia was sub-stratified into severe, early onset preeclampsia and mild, late-onset preeclampsia.10.1371/journal.pone.0123763.t003\n\ncaption (table-wrap): table 3\nPlasma Vitamin D concentrations in women according to clinical outcome.n (% of 235 total)median Vitamin D concentration in ng/ml (range) no complications 176 (75)27.4 (13.0–71.6) all complications 59 (25)26.5 (13.2–42.3) Preeclampsia 19 (8)26.5 (16.1–35.9) severe, early onset 5 (2)27.1 (18.0–33.8) mild, late onset 14 (6)27.7 (16.1–35.9) spontaneous Preterm Delivery 10 (4)28.4 (19.9–42.3) iugr 9 (4)27.0 (16.6–38.8) gdm 5 (2)22.2 (20.5–31.9) spontaneous abortion 16 (7)25.1 (13.2–38.8)\niugr, Intrauterine growth restriction; gdm, Gestational diabetes mellitus.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 169, 'Plasma'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 265, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 273, 'D'), ('GO_0007128', 'meiotic prophase I', 390, 'Preeclampsia'), ('GO_0007128', 'meiotic prophase I', 520, 'Preterm'), ('GO_0007567', 'parturition', 528, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 663, 'intrauterine'), ('GO_0007565', 'female pregnancy', 701, 'gestational')]
S106-PMC4405493	PMC4405493	4/2015	S106-PMC4405493	['there was no association between Vitamin D deficiency in the first trimester and adverse Pregnancy outcomes with an adjusted odds ratio of 1.01 ( p value 0.738, 95% ci 0.947–1.164).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy')]
S108-PMC4405493	PMC4405493	4/2015	S108-PMC4405493	['there was no association between first Trimester Vitamin D levels and subsequent development of combined complications, or complications sub-stratified into preeclampsia, Gestational diabetes, Preterm Delivery, Intrauterine growth restriction (iugr), or spontaneous Abortion when each outcome was evaluated individually (table 5).']	N/A	N/A	[('GO_0009294', 'DNA mediated transformation', 39, 'trimester'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 171, 'gestational'), ('GO_0007565', 'female pregnancy', 193, 'preterm'), ('GO_0007567', 'parturition', 201, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 211, 'intrauterine'), ('GO_0007569', 'cell aging', 266, 'abortion')]
S110-PMC4405493	PMC4405493	4/2015	S110-PMC4405493	['there was no association between first Trimester Vitamin D levels and subsequent development of composite adverse Pregnancy complications (including Preeclampsia [severe, early onset or mild, late onset], Gestational diabetes, Preterm Delivery, growth restriction, or spontaneous Abortion (combined outcomes; p > 0.05 intable 5).']	N/A	N/A	[('GO_0009294', 'DNA mediated transformation', 39, 'trimester'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 149, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 205, 'gestational'), ('GO_0007565', 'female pregnancy', 227, 'preterm'), ('GO_0007567', 'parturition', 235, 'delivery'), ('GO_0007569', 'cell aging', 280, 'abortion')]
S101-PMC4427001	PMC4427001	4/2015	S101-PMC4427001	['nearly 50% of Pregnant women were Vitamin D deficient in september while it was 82% in december.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 14, 'pregnant'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
S110-PMC4427001	PMC4427001	4/2015	S110-PMC4427001	['given the high overall prevalence of Vitamin D deficiency, we did not find any statistically significant difference in 25(Oh)D levels between woman with gdm diagnosed by who criteria and controls during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 121, '('), ('PR_000013502', 'parvalbumin alpha', 124, ')D'), ('GO_0007565', 'female pregnancy', 203, 'pregnancy')]
S112-PMC4427001	PMC4427001	4/2015	S112-PMC4427001	['[25] reported higher prevalence of severe Vitamin D deficiency (≤12.5\u2009nmol/l) in gdm than in normoglycaemic Pregnancies in 741 iranian women.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'pregnancies')]
S382-PMC4448820	PMC4448820	5/2015	S382-PMC4448820	['like Vitamin A, the Generation and Degradation Of the Bioactive Form Of Vitamin D is under tight Control.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 13, 'A'), ('GO_0007565', 'female pregnancy', 20, 'generation ...'), ('GO_0051625', 'epinephrine uptake', 35, 'degradation of ... form of vitamin D'), ('CHEBI_51870', 'boryl group', 54, 'bioactive'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0065007', 'biological regulation', 97, 'control')]
S110-PMC4452099	PMC4452099	6/2015	S110-PMC4452099	['supporting information\n\ncaption (supplementary-material): s1 table\nslopes (95% ci) for linear increase in t1d incidence for Individuals Born during various periods of Gestational exposure to Vitamin D fortification by age at t1d diagnosis.']	N/A	N/A	[('NCBITaxon_1', 'root', 124, 'individuals'), ('GO_0007567', 'parturition', 136, 'born'), ('GO_0007565', 'female pregnancy', 167, 'gestational'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]
S5-PMC4466139	PMC4466139	6/2015	S5-PMC4466139	['maternal country of origin, skin phototype, Vitamin D dietary intake and supplementation during Pregnancy were recorded.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]
S34-PMC4466139	PMC4466139	6/2015	S34-PMC4466139	['data on maternal Vitamin D supplementation during the whole Pregnancy and during the last month of Pregnancy, including doses, duration and type of integration were collected.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('GO_0007565', 'female pregnancy', 99, 'pregnancy')]
S77-PMC4466139	PMC4466139	6/2015	S77-PMC4466139	['data on Vitamin D supplementation and dietary intake in Pregnancy are reported intable 3.10.1371/journal.pone.0129586.t003\n\ncaption (table-wrap): table 3\nmaternal Vitamin D supplementation and dietary intake during Pregnancy in italian and migrants.supplementationall (533)italian (342)migrant (191)p value n (%) 283/486 (58.2%)213 (68.9%)70 (39.5%)<0.0001 last month n (%) 255/483 (52.8%)193 (62.9%)62 (35.2%)<0.0001 duration of supplementation (days) 185.7±75.14191.8±74.6167.6±74.40.01 Vitamin D intake from supplementation (iu/die) 398±52400.47\xa0±61.19394.37±44.360.01 diet questionnaires analyzed n (%) 450/533 (84.4%)298 (66.2%)152 (33.8%)- Vitamin D intake from diet (iu/die) 136±68128±64152±680.0003\ndata are expressed as frequencies or as mean±sd and number (%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 489, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 646, 'Vitamin D')]
S144-PMC4476607	PMC4476607	1/2015	S144-PMC4476607	['in Rodent models of fasd, Pregnant females given Nutrients high in antioxidant properties (e.g., Vitamin C, Vitamin E, Omega-3 Fatty Acids) during the time they also are given Alcohol, Give Birth to offspring with reduced oxidative stress and cell loss, and fewer behavioral impairments (brocardo et al.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 3, 'rodent'), ('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('CHEBI_33284', 'nutrient', 49, 'nutrients'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin E'), ('CHEBI_75862', 'alpha-D-rhamnofuranose', 119, 'omega-3 fatty acids'), ('CHEBI_30879', 'alcohol', 176, 'alcohol'), ('GO_0007631', 'feeding behavior', 185, 'give'), ('GO_0007567', 'parturition', 190, 'birth')]
S0-PMC4499946	PMC4499946	7/2015	S0-PMC4499946	['maternal Vitamin D supplementation during Pregnancy and Lactation to promote infant growth in dhaka, bangladesh (mdig trial): study protocol for a randomized controlled trial\n\nabstract\n\nbackground\nVitamin d Regulates bone Mineral Metabolism and Skeletal Development.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('GO_0007595', 'lactation', 56, 'lactation'), ('CHEBI_33229', 'vitamin (role)', 197, 'Vitamin'), ('GO_0065007', 'biological regulation', 207, 'regulates'), ('CHEBI_46662', 'mineral', 222, 'mineral'), ('GO_0008152', 'metabolic process', 230, 'metabolism'), ('GO_0001501', 'skeletal system development', 245, 'skeletal development'), ('UBERON_0004288', 'skeleton', 245, 'skeletal')]
S3-PMC4499946	PMC4499946	7/2015	S3-PMC4499946	['methods/design\nthe maternal Vitamin D for infant growth study is a randomized, placebo-controlled, dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation in dhaka, bangladesh.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 28, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy'), ('GO_0007595', 'lactation', 177, 'lactation')]
S43-PMC4499946	PMC4499946	7/2015	S43-PMC4499946	['methods/design\nthe maternal Vitamin D for infant Growth (mdig) trial is randomized, placebo-controlled, dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation to improve infant linear growth in dhaka, bangladesh (clinicaltrials.gov identifier nct01924013).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 28, 'Vitamin D'), ('GO_0006099', 'tricarboxylic acid cycle', 49, 'Growth'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('GO_0007595', 'lactation', 182, 'lactation')]
S107-PMC4499946	PMC4499946	7/2015	S107-PMC4499946	['the Vitamin E content of each tablet is 2.8 mg/wk (about 0.4 mg/day), which is far below recommended dietary allowances for Pregnancy (15 mg/day) and Lactation (19 mg/day)\n\ncaption (table-wrap): table 2\n\nVitamin D3Content of custom-made trial tablets, based on postproduction coated tablet content analysis by high-performance liquid chromatographyalabel claimcholecalciferol content (% label claim)batch 1b(november 2013)batch 2 (april 2014)batch 3 (june 2014)4200 iu106 %103 %101 %16,800 iu105 %101 %102 %28,000 iu102 %101 %99 %\namodified united states pharmacopeia method, as reported by the manufacturer (toronto institute of Pharmaceutical technology, toronto, on, canada).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin E'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('GO_0007595', 'lactation', 150, 'lactation'), ('CHEBI_33229', 'vitamin (role)', 204, 'Vitamin'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 204, 'Vitamin D3content'), ('CHEBI_52217', 'pharmaceutical', 630, 'Pharmaceutical')]
S126-PMC4499946	PMC4499946	7/2015	S126-PMC4499946	['visit schedule\nfollowing enrollment and randomization of Pregnant women at 17–24 weeks of Gestation, weekly supplementation (Vitamin D or placebo) occurs throughout the Prenatal period and during the first 6 months Postpartum.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('GO_0007565', 'female pregnancy', 90, 'gestation'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'prenatal'), ('GO_0007565', 'female pregnancy', 215, 'postpartum')]
S144-PMC4499946	PMC4499946	7/2015	S144-PMC4499946	['dietary intake of Vitamin D, Calcium, Phosphorus, and phytates are assessed among participants (mothers) at enrollment and 6 months Postpartum using a customized, focused Food frequency questionnaire.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 29, 'calcium'), ('CHEBI_35885', 'secondary phosphine', 38, 'phosphorus'), ('GO_0007565', 'female pregnancy', 132, 'postpartum'), ('CHEBI_33290', 'food', 171, 'food')]
S270-PMC4499946	PMC4499946	7/2015	S270-PMC4499946	['in previous Prenatal Vitamin D supplementation trials in dhaka, we used regular monitoring of maternal Urinary Ca:cr ratio as a screening measure for Vitamin D toxicity [16,40].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 12, 'prenatal'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0001088', 'urine', 103, 'urinary'), ('CHEBI_32588', 'potassium chloride', 111, 'Ca'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
S150-PMC4555116	PMC4555116	7/2015	S150-PMC4555116	['the ffq provided a similar estimate of dietary Intake between pre-Pregnant and non-Pregnant groups for energy, Macronutrients, and key Micronutrients Long-Chain Omega-3 Fatty Acids, Folate, Vitamin B6, Vitamin B12, Vitamin D and iron.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 47, 'intake'), ('GO_0007565', 'female pregnancy', 66, 'pregnant'), ('GO_0007565', 'female pregnancy', 83, 'pregnant'), ('CHEBI_33839', 'macromolecule', 111, 'macronutrients'), ('CHEBI_33839', 'macromolecule', 135, 'micronutrients'), ('CHEBI_27610', 'cyclohexa-2,5-diene-1-carbonyl-CoA', 150, 'long-chain omega'), ('CHEBI_35366', 'fatty acid', 169, 'fatty acids'), ('CHEBI_30863', '5-azaorotic acid', 182, 'folate'), ('CHEBI_33237', 'vitamin D4', 190, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 202, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D')]
S75-PMC4598849	PMC4598849	10/2015	S75-PMC4598849	['second, 25(Oh)D levels at Birth cannot represent the Vitamin D status in early Pregnancy.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 8, '25(OH)D'), ('GO_0007567', 'parturition', 26, 'birth'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy')]
S18-PMC4617437	PMC4617437	9/2015	S18-PMC4617437	['Food Consumption was assessed with a semi-quantitative Food frequency questionnaire (ffq), referring to the last Gestational quarter, with 29 Food items and obtained by simplifying a 80-item ffq, validated by sichieri and everhart.28to this simplification, we performed a secondary analysis of the database employed in the elaboration of the original ffq, using stepwise regression to explain 95.0% of variance for the following Nutrients: energy, Carbohydrates, Lipids, saturated Fatty Acids, monounsaturated and polyunsaturated fats, Cholesterol, Calcium and Vitamin C.c\nthe Birth weight information came from medical records.']	N/A	N/A	[('CHEBI_33290', 'food', 0, 'Food'), ('GO_0007631', 'feeding behavior', 0, 'Food consumption'), ('CHEBI_33290', 'food', 55, 'food'), ('GO_0007565', 'female pregnancy', 113, 'gestational'), ('CHEBI_33290', 'food', 142, 'food'), ('CHEBI_33284', 'nutrient', 429, 'nutrients'), ('CHEBI_16646', 'carbohydrate', 448, 'carbohydrates'), ('CHEBI_18059', 'lipid', 463, 'lipids'), ('CHEBI_35366', 'fatty acid', 481, 'fatty acids'), ('CHEBI_16113', 'cholesterol', 536, 'cholesterol'), ('CHEBI_22313', 'alkaline earth metal atom', 549, 'calcium'), ('CHEBI_27300', 'vitamin D', 561, 'vitamin C'), ('PR_000004900', 'complement C3', 569, 'C'), ('GO_0007567', 'parturition', 577, 'birth')]
S29-PMC4632418	PMC4632418	10/2015	S29-PMC4632418	['the following keywords were used in the search: “Vitamin D” or “Cholecalciferol” or “25-Hydroxyvitamin D” or “25(Oh)d” in combination with “Gestational diabetes”.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 64, 'cholecalciferol'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 85, '25-hydroxyvitamin D'), ('CHEBI_30778', 'gallic acid', 110, '25(OH)'), ('GO_0007565', 'female pregnancy', 140, 'gestational')]
S63-PMC4632418	PMC4632418	10/2015	S63-PMC4632418	['seven different criteria were used to diagnose gdm and five assay techniques were used to measure Serum 25(Oh)D level.nutrients-07-05398-t001_table 1\n\ncaption (table-wrap): table 1\n\ncharacteristics of observational studies included in this meta-analysis.author and yearlocationstudy typeparticipants( n )gdm( n )gdm criteria *assay methodmean 25(Oh)D nmol/l (sd)prevalencesignificantadjustments**gdmngtmaghbooli (2008) [22]irancross-sectional57952c&cria16.5(10.4)22.9(18.3)70.60%yesa, bclifton-bligh (2008) [23]australiacross-sectional30781adpslc–ms48.6(24.9)55.3(23.3)48%yesa, b, czhang (2008) [24]usnested-case-control17157adaelisa60.4(21.22)75.13(24.21)19.80%yesa, b, c, dfarrant (2009) [16]indiacross-sectional55939c&cria49.3(31.2)46.4(30.9)66%noa, b, e, fsoheilykhah (2010) [25]irancase-control16554c&celisa24.01(20.62)32.2(35.74)78.40%yesnrbaker (2012) [15]usnested-case-control18060nddglc–ms97.0(29.0)86.0(22.0)7.20%yesa, b, e, hmakgoba (2011) [26]ukcase-control24890wholc–ms47.2(26.7)47.6 (26.7)58.80%noa, b, c, d, e, gparlea (2012) [27]canadanested-case-control337118nddgclia56.3(19.4)62.0(21.6)nryesh, ifernandez-alonso (2012) [28]spaincross-sectional46636adaeclianrnr23.40%nrnrparildar (2013) [29]turkeycase-control12244iadpsgclia48.67(23.21)57.16(24.96)43.40%nonrwang (2012) [30]chinanested-case-control400200adaelisa22.4(10.7)25.9(12.3)96.25%yesa, d, jburris (2012) [31]uscross-sectional115568adaclianrnr33.10%nra, b, c, e, h, k, l, m, n, o, p, tperez-ferre (2012) [32]spaincross-sectional26649adaclianrnr59.02%nra, c, d, gzuhur (2013) [33]turkeycross-sectional402234iadpsgeclia30.8(16.3)36.0(16.2)84.30%yesa, b, d, gbener (2013) [34]qatariprospective cohort1873260whorianrnr48.40%nrnrlacroix (2014) [35]canadacross-sectional65554iadpsglc–ms57.5(17.2)63.5(18.9)26.70%yesa, c, d, e, g, r, s, t, umcmanus (2014) [36]canadacase-control7336cdaria77.3(24.3)93.2(19.2)6.85%yesa, bpark (2014) [37]koreaprospective cohort52323c&ceclia49.4(19.4)48(24.8)88.90%noa, b, e, h, g, varnold (2015) [38]usnested-case-control652135adalc–ms59.7(23.5)66.6(22)25.61%yesa, b, c, d, epleskacova (2015) [39]czechcase-control7647whoeiasa28(3.76)31.85(4.62)94.7%nob\nnote: nr, not reported; prevalence: prevalence of Vitamin D deficiency; significant: significant difference in Serum 25(Oh)d between Gestational diabetes mellitus (gdm) & normal Glucose tolerance (ngt).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 98, 'serum'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 104, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 343, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 2203, 'vitamin D'), ('UBERON_0001977', 'blood serum', 2264, 'serum'), ('CHEBI_30778', 'gallic acid', 2270, '25(OH)'), ('GO_0007565', 'female pregnancy', 2286, 'gestational'), ('CHEBI_17234', 'glucose', 2331, 'glucose')]
S66-PMC4632418	PMC4632418	10/2015	S66-PMC4632418	['**, adjustments a: age; b: body mass index (bmi); c: ethnicity; d: family history of type 2 diabetes mellitus (t2dm); e: season; f: socio-economic status; g: previous history of gdm; h: Gestational age; i: maternal weight; j: Triglyceride (Tg); k: education; l: marital status; m: smoking; n: Pregnancy weight gain; o: physical activity; p: dietary intake of fish and calcium; q: trimester; r: Vitamin D lifestyle score; s: Parathyroid hormone (pth); t: parity; u: waist circumference; v: Vitamin D intake.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 186, 'gestational'), ('CHEBI_17855', 'triglyceride', 226, 'triglyceride'), ('CHEBI_17855', 'triglyceride', 240, 'TG'), ('GO_0007565', 'female pregnancy', 293, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 394, 'vitamin D'), ('UBERON_0001132', 'parathyroid gland', 424, 'parathyroid'), ('CHEBI_27300', 'vitamin D', 489, 'vitamin D')]
S79-PMC4632418	PMC4632418	10/2015	S79-PMC4632418	['caption (fig): figure 2\n\nmeta-analysis of the association between Vitamin D deficiency and risk of Gestational diabetes mellitus (gdm).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 99, 'gestational')]
S47-PMC4645901	PMC4645901	8/2014	S47-PMC4645901	['at the time of the study, Pregnancy supplementation products that could be purchased over the counter in the uk provided either 200 or 400 units of Vitamin D daily.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 26, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]
S13-PMC4661480	PMC4661480	10/2015	S13-PMC4661480	['medications taken during Pregnancy included Amoxicillin-clavulanate, Acetaminophen with codeine, Vitamin D, and Prenatal Vitamins.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 25, 'pregnancy'), ('CHEBI_2676', 'amoxicillin', 44, 'amoxicillin'), ('CHEBI_15343', 'acetaldehyde', 69, 'acetaminophen'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 121, 'vitamins')]
S42-PMC4684854	PMC4684854	12/2015	S42-PMC4684854	['terms searched included Gestational Vitamin D, Pregnancy and Vitamin D, fetus and Vitamin D, nutrition in Pregnancy, as well as pediatric health and Vitamin D. relevant references found in these publications were also searched in order to glean pertinent information.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 24, 'gestational'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D')]
S27-PMC4689556	PMC4689556	12/2015	S27-PMC4689556	['methods\n\nstudy setting and subjects\nthis was a follow up study of the offspring of 180 women who took part in an ethnically stratified, parallel group, randomised controlled trial of Vitamin D supplementation in Pregnancy at st mary’s hospital london, a university-affiliated hospital Antenatal clinic, between april and november 2007.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 183, 'vitamin D'), ('GO_0007565', 'female pregnancy', 212, 'pregnancy'), ('GO_0007567', 'parturition', 285, 'antenatal'), ('UBERON_0001760', 'frontal sinus', 285, 'antenatal')]
S110-PMC4689556	PMC4689556	12/2015	S110-PMC4689556	['effect of Prenatal Vitamin D supplementation on healthcare utilisation\nthere was no significant difference in the primary outcome measure, total unscheduled healthcare utilisation, between treatment groups (fig 2).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'prenatal'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
S112-PMC4689556	PMC4689556	12/2015	S112-PMC4689556	['for bolus Vitamin D supplementation versus controls the mean difference was -0.46 (95%ci-0.97, 0.06); adjusted mean difference -0.34 (95%ci -0.90, 0.22).10.1371/journal.pone.0145303.g002\n\ncaption (fig): fig 2\neffect of Prenatal Vitamin D randomisation on total healthcare utilisation in the first three years of Life.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007565', 'female pregnancy', 219, 'prenatal'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('UBERON_0000104', 'life cycle', 312, 'life')]
S128-PMC4689556	PMC4689556	12/2015	S128-PMC4689556	['effect of Prenatal Vitamin D supplementation on need for prescription Medications\nprescribing data were also dichotomized according to whether any prescription was made in the first three years of Life.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'prenatal'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_25441', 'mycothiols', 70, 'medications'), ('UBERON_0000104', 'life cycle', 197, 'life')]
S135-PMC4689556	PMC4689556	12/2015	S135-PMC4689556	['association between Prenatal or Postnatal Vitamin D level and healthcare utilisation\nof the 99 offspring with complete e-hr data, Cord levels of 25(Oh)D were available for 79, and 25(Oh)D levels at age three years for 65.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 20, 'prenatal'), ('GO_0007567', 'parturition', 32, 'postnatal'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 130, 'cord'), ('CHEBI_71657', 'versiconol acetate', 145, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 180, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 180, '25('), ('PR_000006444', 'diacylglycerol kinase delta', 186, 'D')]
S87-PMC4690051	PMC4690051	12/2015	S87-PMC4690051	['median dietary intake of Vitamin D during the second trimester for the whole cohort was 177 iu (range 13.3–772).nutrients-07-05499-t001_table 1\n\ncaption (table-wrap): table 1\n\ncharacteristics of the mothers at enrollment and the children at 2-year assessment (cv2; n = 1020).n %insurance\u2003other insurance48947.9\u2003medicaid, medicare53152.1education\u2003hs diploma or lower56755.6\u2003college or higher degree45344.4marital status\u2003cohabitation60158.9\u2003single41941.1pre-Pregnancy bmi, kg/m2\u2003underweight454.4\u2003normal39738.9\u2003overweight24023.5\u2003obese33833.1alcohol use, yes868.4tobacco use, yes858.3total Pregnancies1\u2003130930.3\u20032–559458.2\u2003>511711.5gestational 25(Oh)D\u2003<20 ng/dl42541.7\u200320.00–29.99 ng/dl44043.1\u2003≥30 ng/dl15515.2 meansd Weeks Of Gestation38.91.725(Oh)D, ng/dl22.38.5maternal age, years26.65.5maternal total iq96.216.4birth weight, z -score0.050.95birth length, z -score0.531.28head circumference, z -score−0.031.34child age at cv2 assessment, months25.01.5cognitive scaled score29.62.6receptive language scaled score29.52.9expressive language scaled score29.92.7\n1includes current Pregnancy and previously completed term and pre-term Pregnancies;2as assessed at 2-year exam (cv2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 456, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 586, 'Pregnancies1'), ('CHEBI_71657', 'versiconol acetate', 640, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 646, 'D'), ('GO_0016055', 'Wnt signaling pathway', 714, 'Weeks of Gestation38'), ('CHEBI_33010', 'chromide(1-)', 741, '(OH)D'), ('GO_0007565', 'female pregnancy', 1075, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1128, 'pregnancies')]
S100-PMC4690051	PMC4690051	12/2015	S100-PMC4690051	['dietary intake of Vitamin D was not associated with scaled scores or mid-Gestational 25(Oh)D levels.nutrients-07-05499-t002_table 2\n\ncaption (table-wrap): table 2\n\nscaled developmental scores by selective characteristics ( n = 1020).Cognitivereceptive languageexpressive languagemeansd p1meansd p1meansd p1race<0.0001<0.0001<0.0001\u2003african-american8.82.28.62.39.32.3\u2003european-american11.02.711.13.111.03.1insurance<0.0001<0.0001<0.0001\u2003other insurance10.42.810.53.110.73.0\u2003medicaid, medicare8.82.18.62.39.22.2education<0.0001<0.0001<0.0001\u2003hs diploma or lower8.92.18.72.49.32.2\u2003college or higher degree10.42.810.53.110.73.0marital status<0.0001<0.0001<0.0001\u2003cohabitation10.12.710.13.010.32.9\u2003single8.82.28.62.39.32.3pre-Pregnancy bmi, kg/m20.00010.00010.0001\u2003under weight9.72.29.92.99.92.6\u2003normal9.92.79.93.110.42.9\u2003overweight9.52.39.42.710.02.6\u2003obese9.22.69.02.79.42.4alcohol use0.00240.0020.007\u2003no9.52.59.42.89.82.6\u2003yes10.33.010.73.610.63.1tobacco use<0.0006<0.0006<0.0006\u2003no9.62.69.62.910.02.7\u2003yes8.72.08.52.78.82.6total Pregnancies0.00060.0290.0028\u2003110.02.99.83.010.32.7\u20032–59.52.49.52.99.82.8\u2003>58.82.28.82.39.42.2gestational diabetes0.100.220.14\u2003missing8.32.19.72.59.71.2\u2003no9.52.69.52.99.92.7\u2003yes10.02.69.93.010.32.9pre-eclampsia0.0670.0230.19\u2003missing9.02.29.62.59.81.6\u2003no9.62.69.62.910.02.7\u2003yes9.12.28.82.49.52.6delivery0.00210.1020.024\u2003pre-term8.82.28.92.99.32.8\u2003full term9.62.69.52.910.02.7gestational 25(oh)d<0.0001<0.0001<0.0001\u2003<20 ng/dl9.12.48.92.59.42.4\u200320.00–29.99 ng/dl9.82.89.73.010.22.9\u2003≥30 ng/dl10.12.410.53.210.42.6\n1p -value for comparison among the subgroups ( i.e.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 85, '25 ... OH ... D'), ('GO_0050802', 'circadian sleep/wake cycle, sleep', 233, 'CognitiveReceptive'), ('GO_0007565', 'female pregnancy', 721, 'Pregnancy'), ('GO_0006412', 'translation', 1025, 'Pregnancies0'), ('CHEBI_37972', 'phosphorus-32 atom', 1410, '25')]
S115-PMC4690051	PMC4690051	12/2015	S115-PMC4690051	['Expression of Vitamin D Receptors (vdr) in Mammalian Brain occurs as early as day 12 of Gestation, then increases throughout Pregnancy [40].']	N/A	N/A	[('GO_0010467', 'gene expression', 0, 'Expression'), ('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('PR_000002025', 'T-cell surface glycoprotein CD1a', 22, 'D receptors'), ('NCBITaxon_40674', 'Mammalia', 43, 'mammalian'), ('UBERON_0000955', 'brain', 53, 'brain'), ('GO_0007565', 'female pregnancy', 88, 'gestation'), ('GO_0007565', 'female pregnancy', 125, 'pregnancy')]
S86-PMC4719746	PMC4719746	1/2016	S86-PMC4719746	['caption (table-wrap): table 2\n\ndescriptive Vitamin D at inclusion (Gestational week 15) and at Gestational week 28.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'gestational'), ('GO_0007565', 'female pregnancy', 95, 'gestational')]
S88-PMC4719746	PMC4719746	1/2016	S88-PMC4719746	['1\n\nproportions of participants with levels of 25(Oh)D 12-\u2009<\u200925\xa0nmol/l and <12\xa0nmol/l at Gestational week 15 and 28\nin early Pregnancy, the values of 25(Oh)D differed between the ethnic groups and remained significant after adjustment for age, parity, season, education and intake of Vitamin D supplements (table\xa03).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 46, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 46, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 88, 'gestational'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 149, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 149, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D')]
S93-PMC4719746	PMC4719746	1/2016	S93-PMC4719746	['caption (table-wrap): table 3\n\nlinear regression analysis with Vitamin D [25(Oh)D] at inclusion and Gestational week 28 as dependant variablesat inclusionat Gestational week 28univariate analysismultiple analysisunivariate analysismultiple analysisn\u2009=\u2009735, r2adj.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 74, '25(OH)D'), ('GO_0007565', 'female pregnancy', 100, 'gestational'), ('GO_0007565', 'female pregnancy', 157, 'gestational')]
S98-PMC4719746	PMC4719746	1/2016	S98-PMC4719746	['mean 25(Oh)D values were −17 (95 % ci: −23, −11), −10 (−16, −2.9) and −12 (−20, −3.1) nmol/l lower in south asians, middle easterners and sub-saharan africans compared with western europeans after adjustments for Gestational week at inclusion, age, parity, season, education and Vitamin D supplements (table\xa03).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 5, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 5, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 213, 'gestational'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin D')]
S43-PMC4729160	PMC4729160	1/2016	S43-PMC4729160	['the questionnaires included questions regarding the Pregnant such as:age; Gestational age; parity; whether use the Vitamin A supplements; Pregnant women drinkers defined as pregnant women who drink Alcohol during the past 12\xa0months; education levels of the Pregnant ; whether received college or university education; annual income of the Pregnant women rmb(yuan) was divided into four levels: <10,000,10,000–20,000,20,000–30,000, >\u2009=\u200930,000; smoking habit was divided into three categories: non-smoker without passive smoking, non-smoker with passive smoking,smokers.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 52, 'pregnant'), ('GO_0007565', 'female pregnancy', 74, 'gestational'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin A'), ('GO_0007565', 'female pregnancy', 138, 'pregnant'), ('CHEBI_30879', 'alcohol', 198, 'alcohol'), ('GO_0007565', 'female pregnancy', 257, 'pregnant'), ('GO_0007565', 'female pregnancy', 339, 'pregnant')]
S73-PMC4729160	PMC4729160	1/2016	S73-PMC4729160	['Pregnant women with Vitamin A supplements compared with without Vitamin A supplements was significant difference ( f \u2009=\u20098.67, p \u2009=\u20090.00).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin A')]
S2-PMC4770602	PMC4770602	1/2016	S2-PMC4770602	['materials and methods:\nin this randomized controlled trial, in 2012, 140 nulliparous Pregnant women in two groups received supplementation with 600 iu/day of Vitamin D or supplementation free of Vitamin D at 16 week Gestation until the Delivery.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 85, 'pregnant'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'gestation'), ('GO_0007567', 'parturition', 236, 'delivery')]
S28-PMC4770602	PMC4770602	1/2016	S28-PMC4770602	['Pregnant women at less than 16 week Gestation from outpatient clinics at “shahid beheshti” hospital were eligible if they did not have any sign of Vitamin D deficiency, did not using Aspirin and had no diagnosis of chronic hypertension, Gestational diabetes, Renal disease or systemic lupus erythematus.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0007565', 'female pregnancy', 36, 'gestation'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_2904', 'atenolol', 183, 'aspirin'), ('GO_0007565', 'female pregnancy', 237, 'gestational'), ('UBERON_0002113', 'kidney', 259, 'renal')]
S32-PMC4770602	PMC4770602	1/2016	S32-PMC4770602	['case group included 70 Pregnant women who received supplementation with 600 iu daily of Vitamin D at 16 week Gestation until Labor, also, in control group, 70 Pregnant women received daily supplementation free of Vitamin D and followed through Pregnancy to Labor process.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'pregnant'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'gestation'), ('GO_0007612', 'learning', 125, 'labor'), ('GO_0007565', 'female pregnancy', 159, 'pregnant'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('GO_0007565', 'female pregnancy', 244, 'pregnancy'), ('GO_0007612', 'learning', 257, 'labor')]
S99-PMC4785305	PMC4785305	3/2016	S99-PMC4785305	['Pregnant women will be randomised early in their second Trimester to one of two Vitamin D doses as discussed above.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0009294', 'DNA mediated transformation', 56, 'trimester'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S121-PMC4785305	PMC4785305	3/2016	S121-PMC4785305	['this computation takes into consideration that all groups will be taking additional 200\u2005iu Vitamin D daily from their Prenatal Vitamin Pills, thus increasing the final Vitamin D intake approximately to 900\u2005iu/day in the low-dose group and 3050\u2005iu/day in the high-dose group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 118, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 127, 'vitamin'), ('CHEBI_35710', 'pinane', 135, 'pills'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D')]
S42-PMC4811441	PMC4811441	3/2016	S42-PMC4811441	['during these periods, chosen to capture the seasonality of Vitamin D status, all Pregnant women registering at the Antenatal Care within the study areas were eligible for inclusion.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnant'), ('GO_0007608', 'sensory perception of smell', 115, 'antenatal care')]
S0-PMC4829940	PMC4829940	5/2016	S0-PMC4829940	['25-Hydroxyvitamin D in Pregnancy and Genome wide Cord Blood Dna Methylation in two Pregnancy cohorts (moba and alspac)\n\nabstract:author-highlightshighlights\n\nPregnancy Vitamin D and Cord Blood Dna Methylation compared in 1416 infants.']	N/A	N/A	"[('CHEBI_27844', ""2',3'-cyclic AMP"", 0, '25-Hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 23, 'pregnancy'), ('SO_0001026', 'genome', 37, 'genome'), ('UBERON_0002240', 'spinal cord', 49, 'cord'), ('UBERON_0000178', 'blood', 54, 'blood'), ('GO_0006306', 'DNA methylation', 60, 'DNA methylation'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('GO_0007565', 'female pregnancy', 158, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 182, 'cord'), ('UBERON_0000178', 'blood', 187, 'blood'), ('GO_0006306', 'DNA methylation', 193, 'DNA methylation')]"
S234-PMC4856298	PMC4856298	5/2016	S234-PMC4856298	"['/ none of the study participants that were given the advice to contact an official facility, followed up on this advice.jivitaa2012 study design: cross-sectional / purpose of study: post-analysis of utilization for a pilot study nested within a rct / research methods: data collection / location: bangladesh / health care setting: rural (19 unions of gaidbandha and rangpur districts) / target population: Pregnant women and newborns / size: 500 and >16,000 Births emergency medical response system : labor notification system to ensure the presence of nurses at Birth to collect Placentas and Cord Blood / communication and support : mobile birth notification allowing newborns to be reached for the provision of a Vitamin A dose direct two-way communication337/611 of the total number of ""near miss"" events used a mobile phone.']"	N/A	N/A	[('GO_0007565', 'female pregnancy', 406, 'Pregnant'), ('GO_0007567', 'parturition', 458, 'births'), ('GO_0007567', 'parturition', 563, 'birth'), ('UBERON_0001987', 'placenta', 580, 'placentas'), ('UBERON_0009472', 'axilla', 594, 'cord blood'), ('CHEBI_27300', 'vitamin D', 716, 'vitamin A')]
S2-PMC4859539	PMC4859539	5/2016	S2-PMC4859539	['Blood samples were obtained during yearly visits from 133 children, ages 2–7, whose mothers had participated in a Pregnancy Vitamin D supplementation rct.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
S17-PMC4859539	PMC4859539	5/2016	S17-PMC4859539	['offspring of mothers enrolled in an nichd Pregnancy Vitamin D supplementation trial (results of which were previously published [21,22]) were seen in follow-up from ages 2–7 years during a three-year study period.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D')]
S20-PMC4859539	PMC4859539	5/2016	S20-PMC4859539	['materials and methods\n\nsubjects\nthe offspring of mothers who had participated in an nichd, irb-approved Vitamin D supplementation study during Pregnancy (hr#10727; ctrc protocol #670; n = 350) were invited back for yearly follow-up beginning at 2 years of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]
S52-PMC4859539	PMC4859539	5/2016	S52-PMC4859539	['results\n\ncohort\nwhile 194 children had participated in the follow-up study (55% of the original cohort participating in the Vitamin D Pregnancy study), 133 (38%) had a Blood sample obtained at the time of the study visit and thus, were able to have Cathelicidin measured.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy'), ('UBERON_0000178', 'blood', 168, 'blood'), ('CHEBI_3364', 'Canthiumine', 249, 'cathelicidin')]
S57-PMC4859539	PMC4859539	5/2016	S57-PMC4859539	"[""of infections in the last year [median (range)]1.0 (0.0–5.0)child’s daily Vitamin D intake at time of visit (iu/day)1205.3 ± 109.8 (17.1–512.5)child's 25(Oh)D at time of visit (ng/ml)127.2 ± 9.4 (8.3–61.5)child's Vitamin D status at time of visit\xa0\xa0\xa0\xa0\xa0sufficient (≥20 ng/ml) [n (%)]106 (79.7)\xa0\xa0\xa0\xa0deficient (<20 ng/ml) [n (%)]27 (20.3)total circulating 25(Oh)D (ng/ml) at Birth122.8 ± 9.8 (3.6–47.8)maternal 25(Oh)D (ng/ml) within 1 month prior to Delivery139.2 ± 15.0 (10.0–78.6)maternal 25(Oh)D area under curve, Pregnancy visits 3–71153.1 ± 44.6 (50.1–251.4)\n1mean±std (range)\n\nstudy outcomes\nthe median Cathelicidin concentration for the entire cohort was 28.1 ng/ml, ranging from 5.6 to 3368.6 ng/ml.""]"	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 154, 'OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 157, 'D'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 351, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 351, '25 ... OH ... D'), ('GO_0042750', 'hibernation', 370, 'birth122'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 406, '25(OH)D'), ('GO_0030324', 'lung development', 446, 'delivery139'), ('CHEBI_71657', 'versiconol acetate', 487, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 487, '25(OH)D'), ('GO_0007565', 'female pregnancy', 513, 'pregnancy'), ('CHEBI_3364', 'Canthiumine', 605, 'cathelicidin')]
S9-PMC4861121	PMC4861121	5/2016	S9-PMC4861121	['adherence to all seven Food pyramid guidelines was less than 1% overall, and less than 1% of participants met all four Micronutrient guidelines on Vitamin D, Folate, calcium and iron Intake around the time of Pregnancy.']	N/A	N/A	[('CHEBI_33290', 'food', 23, 'food'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 119, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 158, 'folate'), ('GO_0007631', 'feeding behavior', 183, 'intake'), ('GO_0007565', 'female pregnancy', 209, 'pregnancy')]
S17-PMC4908484	PMC4908484	6/2016	S17-PMC4908484	['Gestational Vitamin D deficiency induces long‐lasting alterations in the Brain structure, including changes in volume, Cell Proliferation and reduced Expression of Nerve growth factors, glia‐Derived Neurotrophic Factor, and Neurotrophins 3 and 4 (eyles et\xa0al.2003; tetich et\xa0al.2004; cui et\xa0al.2007).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('UBERON_0000955', 'brain', 73, 'brain'), ('GO_0008283', 'cell proliferation', 119, 'cell proliferation'), ('GO_0010467', 'gene expression', 150, 'expression'), ('UBERON_0001021', 'nerve', 164, 'nerve'), ('PR_000006860', 'transcription factor E4F1', 191, 'derived neurotrophic factor'), ('PR_000011459', 'neurotrophin-3', 224, 'neurotrophins 3'), ('PR_000017527', 'YEATS domain-containing protein 4', 244, '4')]
S19-PMC4910255	PMC4910255	6/2016	S19-PMC4910255	['for example, 38\xa0% of Pregnant women have iron deficiency leading to anaemia [5] and 15\xa0% have Vitamin A deficiency causing night blindness and increasing the risk of infection [6,7].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 21, 'pregnant'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin A')]
S93-PMC4910255	PMC4910255	6/2016	S93-PMC4910255	['[25]individual873 children Born in the trial were subsequently randomised to receive Postnatal multiple Micronutrients or Iron and Vitamin A supplements69\xa0days until Birthiron 60\xa0mg; no supplements on sundaysvit a, Thiamine, riboflavin, niacin, vit b6, Folic Acid, vit b12, vit c, vit d3, vit e, iron, magnesium, zinc; no supplements taken on sundays24.1birthweight in mmn, 2981\xa0g; birthweight in control, 2977\xa0gsga in mmn, 10.1\xa0%; sga in control, 11.8\xa0% Gestation in mmn, 39.5\xa0weeks; Gestation in control, 39.6\xa0weeksnepal janakpurosrin et al.']	N/A	N/A	[('GO_0007567', 'parturition', 27, 'born'), ('GO_0007567', 'parturition', 85, 'postnatal'), ('CHEBI_33839', 'macromolecule', 104, 'micronutrients'), ('CHEBI_24870', 'ion', 122, 'iron'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin A'), ('GO_0007567', 'parturition', 166, 'birthIron'), ('CHEBI_26948', 'vitamin B1', 215, 'thiamine'), ('CHEBI_30751', 'formic acid', 253, 'folic acid'), ('GO_0006266', 'DNA ligation', 455, 'Gestation'), ('GO_0007565', 'female pregnancy', 485, 'gestation')]
S57-PMC4930210	PMC4930210	7/2016	S57-PMC4930210	['no participants took a separate Vitamin D supplement through a prescription, although a Prenatal supplement would have been recommended by their physician.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'prenatal')]
S88-PMC4930210	PMC4930210	7/2016	S88-PMC4930210	['the median (iqr) overall reported Intake of Vitamin D (iu) from the combined (24-hour Recall + siq) was 568 (404) for the first trimester, 600 (472) for the second trimester, and 634 (516) for the third trimester (table 3).10.1371/journal.pone.0157262.t003\n\ncaption (table-wrap): table 3\ndistribution of reported dietary Vitamin D intake (iu/day) in the first, second, and third trimesters of Pregnancy in a longitudinal cohort of Pregnant women and their infants in alberta, canada.trimesternmean ± sdmin to maxmedian (25thto 75th) first trimester supplement intake398451 ± 5300 to 4250320 (200 to 400)dietary intakes113185 ± 1465 to 840165 (71 to 264)overall intakesa112704 ± 55432 to 4482568 (407 to 810) second trimester supplement intake537590 ± 6900 to 8400400 (250 to 544)dietary intakes528218 ± 1730 to 1350175 (98 to 298)overall intakesa526812 ± 72238 to 9209600 (449 to 921) third trimester supplement intake493634 ± 6800 to 5427400 (250 to 689)dietary intakes471236 ± 1930 to 1633192 (105 to 321)overall Intakesa469872 ± 69528 to 3790634 (469 to 985)\naoverall intakes: supplements + diet; the repeated measures anova showed no significant difference in log transformed mean Vitamin D intake from diet (24 hour recall) (p = 0.13), but a significant difference in log transformed mean intake from Supplement across all trimesters (p<0.001), resulting in a significant difference in total Vitamin D intake across all trimesters (p = 0.004).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 34, 'intake'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0060033', 'anatomical structure regression', 86, 'recall'), ('CHEBI_28384', 'vitamin K', 321, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 393, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 431, 'Pregnant'), ('GO_0042332', 'gravitaxis', 1015, 'intakesa469872'), ('CHEBI_27300', 'vitamin D', 1185, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 1306, 'supplement'), ('CHEBI_27300', 'vitamin D', 1397, 'vitamin D')]
S93-PMC4930210	PMC4930210	7/2016	S93-PMC4930210	['fifty-four percent of Pregnant women reported taking 600 and higher iu/day of Vitamin D through their diet and supplements in the second Trimester of Pregnancy; maternal characteristics were not different between those who reported taking <600 iu/day Vitamin D vs .']	N/A	N/A	[('GO_0007565', 'female pregnancy', 22, 'pregnant'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 137, 'trimester'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D')]
S2-PMC4934634	PMC4934634	11/2015	S2-PMC4934634	['rates of Vitamin D deficiency during Pregnancy remain high worldwide.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 37, 'pregnancy')]
S95-PMC4934634	PMC4934634	11/2015	S95-PMC4934634	['the current rda for Vitamin D is 600 iu/day for both non-Pregnant females of Reproductive age and Pregnant/Lactating females according to iom recommendations (table 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('GO_0000003', 'reproduction', 77, 'reproductive'), ('GO_0007565', 'female pregnancy', 98, 'pregnant'), ('GO_0007594', 'puparial adhesion', 107, 'lactating')]
S107-PMC4934634	PMC4934634	11/2015	S107-PMC4934634	['these changes induced by Vitamin D would dampen the Adaptive Immune System while optimizing the innate Immune’s function to kill pathogens aiding the maternal body to protect against microbial insults and establish an environment of fetal tolerance.healthcare-03-01097-t002_table 2\n\ncaption (table-wrap): table 2\n\nVitamin D recommended intakes.ageiomendocrine societyaustralian nhmrc **whordauldaily requirementulaiulrni0–6 months400 iu (10 μg) *1000 iu (25 μg)400–1000 iu2000 iu (50 μg)200 iu (5 μg)1000 iu (25 μg)200 iu (5 μg)7–12 months400 iu (10 μg) *1500 iu (38 μg)400–1000 iu2000 iu (50 μg)200 iu (5 μg)1000 iu (25 μg)200 iu (5 μg)1–3 years600 iu (15 μg)2500 iu (63μg)600–1000 iu4000 iu (100 μg)200 iu (5 μg)3200 iu (80 μg)200 iu (5 μg)4–8 years600 iu (15 μg)3000 iu (75 μg)600–1000 iu4000 iu (100 μg)200 iu (5 μg)3200 iu (80 μg)200 iu (5 μg)Pregnancy/lactation14–18 years600 iu (15 μg)4000 iu (100 μg)600–1000 iu4000 iu (100 μg)200–400 iu3200 iu (80 μg)200 iu (5 μg)19–50 years600 iu (15 μg)4000 iu (100 μg)1500–2000 iu10,000 iu (250 μg)200–400 iu3200 iu (80 μg)200 iu (5 μg)\n* adequate intake (ai); ** national health and medical research council.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0019825', 'oxygen binding', 52, 'adaptive immune'), ('UBERON_0002405', 'immune system', 61, 'immune system'), ('UBERON_0002405', 'immune system', 103, 'immune'), ('CHEBI_28384', 'vitamin K', 314, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 848, 'Pregnancy')]
S148-PMC4934634	PMC4934634	11/2015	S148-PMC4934634	['when the culture media was supplemented with Vitamin D in hypoxic conditions (used to stimulate the production and secretion of pro-inflammatory cytokines), Placental Tissue from preeclamptic Pregnancies Secreted significantly lower concentrations of hypoxia-induced Antiangiogenic factor, Sflt-1, and had diminished il-6 production compared to Preeclamptic Placentas cultured without vitamin D supplementation [57].']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001987', 'placenta', 157, 'placental'), ('UBERON_0000479', 'tissue', 167, 'tissue'), ('GO_0007565', 'female pregnancy', 192, 'pregnancies'), ('GO_0046903', 'secretion', 204, 'secreted'), ('CHEBI_76219', 'fluorogen', 267, 'antiangiogenic'), ('PR_000014793', 'inactive tyrosine-protein kinase PRAG1', 290, 'sFlt-1'), ('PR_000017511', ""5'-3' exoribonuclease 1"", 320, '6'), ('GO_0007565', 'female pregnancy', 345, 'preeclamptic'), ('UBERON_0001987', 'placenta', 358, 'placentas'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 393, 'D')]"
S193-PMC4934634	PMC4934634	11/2015	S193-PMC4934634	['women were asked to avoid use of Vitamin D supplements and were randomized at 27 weeks Gestation to receive 800 iu/day Vitamin D2Until Delivery, a single oral bolus of 200,000 iu Vitamin D3, or no intervention [75].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'gestation'), ('CHEBI_72701', '2-oxopimelate(2-)', 119, 'vitamin D2until'), ('GO_0007567', 'parturition', 135, 'delivery'), ('CHEBI_33279', 'vitamin D5', 179, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 179, 'vitamin D3')]
S243-PMC4934634	PMC4934634	11/2015	S243-PMC4934634	[', supplemented a cohort of Vitamin D deficient women with varying doses of Vitamin D3: 4000 iu/day, 2000 iu/day, or 400 iu/day starting at 12–16 weeks of Gestation to Delivery [87].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 75, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 75, 'vitamin D3'), ('GO_0007565', 'female pregnancy', 154, 'gestation'), ('GO_0007567', 'parturition', 167, 'delivery')]
S78-PMC4944244	PMC4944244	7/2016	S78-PMC4944244	['the selected independent variables ( p<0.25) were age, ethnicity, education level, household income per month, household number, weeks of Pregnancy, number of children/parity, fitzpatrick classification, Melanin index, sun protection score, Vitamin D intake from Food (iu/day), Vitamin D intake from Food and supplement (iu/day), and the level of Vitamin D in Foods and supplements (iu/day).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 138, 'pregnancy'), ('CHEBI_25179', 'melanins', 204, 'melanin'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('CHEBI_33290', 'food', 263, 'food'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D'), ('CHEBI_33290', 'food', 300, 'food'), ('CHEBI_27300', 'vitamin D', 347, 'vitamin D'), ('CHEBI_33290', 'food', 360, 'foods')]
S83-PMC4944244	PMC4944244	7/2016	S83-PMC4944244	['caption (table-wrap): table 3\n\ncombination of descriptive and simple logistic regression analysis to show the relationship between risk factors and hypovitaminosis d ( n \u2009=\u2009396)variableserum 25(Oh)D <50\xa0nmol/l n\u2009(%) mean\u2009±\u2009sd median (iqr)Serum 25(Oh)D ≥50\xa0nmol/l n\u2009(%) mean\u2009±\u2009sd median (iqr)crude or (95 % ci) p valueage(year)c27.91\u2009±\u20093.9529.47\u2009±\u20095.070.91(0.84, 0.99)0.026ethnic groupscmalay296 (96.40)11 (3.60)22.42(9.63, 52.21)<0.001chinese24 (54.50)20 (45.5)1.00indian32 (91.40)3 (8.60)8.89(2.36, 33.40)0.001others6 (60.00)4 (40.00)1.25(0.31, 5.06)0.754education levelcprimary11 (68.80)5 (31.20)1.00secondary136 (91.30)13 (8.70)4.75(1.43, 15.80)0.011tertiary211 (91.30)20 (8.70)4.80(1.52, 15.18)0.008working statusworking275 (91.40)26 (8.60)1.000.252not working83 (87.40)12 (12.60)0.65(0.32, 1.35)household income per monthc3500 (2800,5000)3750 (2500,5250)1.00(1.00, 1.00)0.060household Membersc3 (2,4)3 (2,5)0.90(0.75, 1.07)0.225weeks of Pregnancy at first Antenatal visitc10.0 (8.0,12.0)11.5 (8.0,12.0)0.89(0.77,1.02)0.100parityc0 (0,1)1 (0,1)0.79(0.61, 1.03)0.083last child Birth≤ 2\xa0years111 (89.50)13 (10.50)0.86(0.43,1.75)0.686>2 yearsa247 (90.80)25 (9.20)1.00breastfeedingyes36 (87.80)5 (12.20)0.74(0.27,2.01)0.552nob322 (90.70)33 (9.30)1.00bmi before Pregnant (kg/m2)22.76 (20.00,26.25)22.15 (19.75,26.58)1.02(0.96,1.09)0.499weight at first Antenatal visit (Kg)57.85 (49.30,68.54)57.03 (51.49,65.61)1.01(0.98,1.03)0.569fitzpatrick classificationcskin type i-ii83 (80.60)20 (19.40)1.00skin type iii163 (94.20)10 (5.80)3.93(1.76,8.77)0.001skin type iv-vi112 (93.30)8 (6.70)3.37(1.42,8.03)0.006melanin indices (using mexameter)(0-999.000)306.17 (254.17,373.67)242.83 (181.08, 354.00)1.01(1.00,1.01)0.006sun protection score(0-8)c5 (4,5)3.5 (1,5)1.77(1.42,2.21)<0.001total of respondents exposed to sunlight (10\xa0am-2\xa0pm)yes201 (90.10)22 (9.90)1.00no157 (90.80)16 (9.20)1.07(0.55,2.11)0.836the length of time exposed to sunlight (minutes in week)35 (0,150)55 (0,210)1.00(1.00,1.00)0.570intake of Vitamin D from Food (iu/day)c197.51 (122.70,332.05)263.81 (142.90,460.55)1.00(1.00,1.00)0.042intake of Vitamin D from Food and supplements (iu/day)215.080 (132.93,361.98)302.135 (147.89,515.74)1.00(1.00,1.00)0.064the level of Vitamin D in Foods and supplements (iu/day)<200\xa0iu/day165 (92.70)13 (7.30)1.64(0.82,3.32)0.165≥200\xa0iu/day193 (88.50)25 (11.50)1.00\nor odds ratio, ci confidence interval\np values have been derived from wald tests\narespondents with last child Birth more than 2\xa0years and respondents who did not have previous child (primid)\nbrespondents who did not Breastfeed during Pregnancy and those who did not have children.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 191, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 194, 'OH ... D'), ('UBERON_0001977', 'blood serum', 238, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 244, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 247, 'OH ... D'), ('PR_000010433', 'makorin-3', 890, 'membersc3'), ('GO_0007565', 'female pregnancy', 942, 'pregnancy'), ('GO_0007567', 'parturition', 961, 'antenatal'), ('GO_0007567', 'parturition', 1080, 'birth'), ('GO_0007565', 'female pregnancy', 1261, 'pregnant'), ('GO_0007567', 'parturition', 1351, 'antenatal'), ('UBERON_0001465', 'knee', 1368, 'kg'), ('CHEBI_27300', 'vitamin D', 2001, 'vitamin D'), ('CHEBI_33290', 'food', 2016, 'food'), ('CHEBI_27300', 'vitamin D', 2104, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 2112, 'D'), ('CHEBI_33290', 'food', 2119, 'food'), ('CHEBI_27300', 'vitamin D', 2227, 'vitamin D'), ('CHEBI_33290', 'food', 2240, 'foods'), ('GO_0007567', 'parturition', 2468, 'birth'), ('GO_0007596', 'blood coagulation', 2574, 'breastfeed'), ('GO_0007565', 'female pregnancy', 2592, 'pregnancy')]
S102-PMC4944244	PMC4944244	7/2016	S102-PMC4944244	['[21] reported that the prevalence of Vitamin D deficiency (Serum 25(Oh)D <25\xa0nmol/l) among Pregnant women in tehran was 70.6\xa0% and the prevalence of severe Vitamin D deficiency (Serum 25(Oh)D <12.5\xa0nmol/l) was 28.8\xa0%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('UBERON_0001977', 'blood serum', 59, 'serum'), ('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 65, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 91, 'pregnant'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('UBERON_0001977', 'blood serum', 178, 'serum'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 184, '25(OH ... D')]
S117-PMC4944244	PMC4944244	7/2016	S117-PMC4944244	['predictors of low Vitamin D among the third trimester Pregnant women were they did not take Milk that has been fortified with Vitamin D (or 11:42; 95\xa0% ci: 3.12–41.86), did not take Antenatal Vitamin Supplements (or 9.70; 95\xa0% ci: 2.28–41.19) and had low Vitamin D level in the first trimester (or 10.58; 95\xa0% ci: 2.89–38.80).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnant'), ('UBERON_0001913', 'milk', 92, 'milk'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007567', 'parturition', 182, 'antenatal'), ('CHEBI_33229', 'vitamin (role)', 192, 'vitamin'), ('CHEBI_33341', 'titanium atom', 200, 'supplements'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
S176-PMC4944244	PMC4944244	7/2016	S176-PMC4944244	['high-income families provided better outdoor activities for school teenagers, better Antenatal care facilities for Pregnant women, consumed balanced diet and could afford Vitamin D supplements for their older People.']	N/A	N/A	[('GO_0007567', 'parturition', 85, 'antenatal'), ('GO_0007565', 'female pregnancy', 115, 'pregnant'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 209, 'people')]
S215-PMC4944244	PMC4944244	7/2016	S215-PMC4944244	['meanwhile, the institute of medicine [40] reported that the recommended dietary allowance (rda) of Vitamin D for Pregnant mothers is 600\xa0iu/day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]
S75-PMC4969253	PMC4969253	8/2016	S75-PMC4969253	['mild maternal Vitamin A deficiency in Pregnant Rats resulted in changes in the composition of the Extracellular Matrix of the Lung in Adult offspring; these Mice showed increased collagen and decreased elastin deposition in the Lungs.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('GO_0007565', 'female pregnancy', 38, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 47, 'rats'), ('GO_0031012', 'extracellular matrix', 98, 'extracellular matrix'), ('UBERON_0002048', 'lung', 126, 'lung'), ('UBERON_0007023', 'adult organism', 134, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 157, 'mice'), ('UBERON_0002048', 'lung', 228, 'lungs')]
S10-PMC4971719	PMC4971719	8/2016	S10-PMC4971719	['for every one unit increase in Vitamin D in early Pregnancy, the average decrease in the mean bdi score was .14 units.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy')]
S56-PMC4971719	PMC4971719	8/2016	S56-PMC4971719	['all participating women were taking Prenatal Vitamins, which typically contain approximately 400\xa0iu Vitamin D [39].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 36, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 45, 'vitamins'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
S88-PMC4971719	PMC4971719	8/2016	S88-PMC4971719	['using a generalized linear models (ancova) approach we entered winter and Vitamin D at visit 1 into the model as predictors of the Bdi score at visit 1 (study entry), at 34–36 weeks Gestation and at 6–8 weeks Postpartum.']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('PR_000004717', ""transcription factor TFIIIB component B''"", 131, 'BDI'), ('GO_0007565', 'female pregnancy', 182, 'gestation'), ('GO_0007565', 'female pregnancy', 209, 'postpartum')]"
S89-PMC4971719	PMC4971719	8/2016	S89-PMC4971719	['we used repeated measures anova to fit the Vitamin D level at baseline and in late Pregnancy to the square root of the Bdi score at visits 1, 2, 3, and 5, adjusting for “winter”, baseline bdi, baseline Vitamin D and most recent Vitamin D. we transformed the bdi by its square root to correct for skewed (non-normal) distribution.']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('PR_000004717', ""transcription factor TFIIIB component B''"", 119, 'BDI'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D')]"
S135-PMC4971719	PMC4971719	8/2016	S135-PMC4971719	['when evaluating “low Vitamin D” as a categorical variable, there was no association seen between Vitamin D level at 12–20 weeks and Bdi score at that time ( p \u2009=\u20090.11) or with Postpartum bdi score ( p \u2009=\u20090.97).']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('PR_000004717', ""transcription factor TFIIIB component B''"", 132, 'BDI'), ('GO_0007565', 'female pregnancy', 176, 'postpartum')]"
S139-PMC4971719	PMC4971719	8/2016	S139-PMC4971719	['there was no association between low Vitamin D and Postpartum bdi scores in the regression analysis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'postpartum')]
S147-PMC4971719	PMC4971719	8/2016	S147-PMC4971719	['low Vitamin D levels (at any time point) were not significantly associated with higher Postpartum depression symptom scores.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'postpartum')]
S36-PMC4973215	PMC4973215	8/2016	S36-PMC4973215	['results\nof the 506 non-hispanic white and black infants, 438 with available data on Vitamin D status, bmi at Delivery, Prenatal Vitamin use and pre-eclampsia/Pregnancy-induced hypertension (pih) history were included in final analyses.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007567', 'parturition', 109, 'delivery'), ('GO_0007565', 'female pregnancy', 119, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 128, 'vitamin'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy')]
S44-PMC4973215	PMC4973215	8/2016	S44-PMC4973215	['after adjusting for medicaid status, bmi at Delivery and Prenatal vitamin use, black infants had a 3.6 greater odds (95% confidence interval (ci): 2.4, 5.6) of having Vitamin D deficiency compared with white infants (table 2).']	N/A	N/A	[('GO_0007567', 'parturition', 44, 'delivery'), ('GO_0007565', 'female pregnancy', 57, 'prenatal'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
S96-PMC4979151	PMC4979151	8/2016	S96-PMC4979151	['Prenatal Vitamin D supplementation and T and B Cell Activation pathways\nwithin each intervention group, comparisons were made between Genes from unstimulated and Stimulated Lymphocytes.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CL_0000909', 'CD8-positive, alpha-beta memory T cell', 39, 'T ...'), ('GO_0050909', 'sensory perception of taste', 39, 'T ...'), ('CL_0000236', 'B cell', 45, 'B cell'), ('GO_0042113', 'B cell activation', 45, 'B cell activation'), ('SO_0000704', 'gene', 134, 'genes'), ('CL_0002651', 'endothelial cell of venous sinus of spleen', 162, 'stimulated'), ('CL_0000542', 'lymphocyte', 173, 'lymphocytes')]
S124-PMC4979151	PMC4979151	8/2016	S124-PMC4979151	['active Vitamin D can inhibit in vitro Proliferation and Differentiation Of B Cells into Plasma Cells as well as Antibody Production [23,24].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('GO_0007565', 'female pregnancy', 38, 'proliferation ...'), ('GO_0030154', 'cell differentiation', 56, 'differentiation of ... cells ... cells'), ('CL_0000236', 'B cell', 75, 'B cells'), ('CL_0000786', 'plasma cell', 88, 'plasma cells'), ('GO_0002376', 'immune system process', 112, 'antibody production'), ('GO_0042571', 'immunoglobulin complex, circulating', 112, 'antibody')]
S42-PMC4982007	PMC4982007	8/2016	S42-PMC4982007	['eligibility criteria, search strategy and identification of literature\nour exposure of interest was maternal nutritional status during Pregnancy: bmi, height and weight; status or intake of selected single Micronutrients (Vitamins D, b1, b6, b12 and Folate) and iron and dietary intake of Macronutrients (Carbohydrate, protein and fat).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 135, 'pregnancy'), ('CHEBI_33839', 'macromolecule', 206, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 222, 'vitamins D'), ('CHEBI_30863', '5-azaorotic acid', 250, 'folate'), ('CHEBI_33839', 'macromolecule', 289, 'macronutrients'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 305, 'carbohydrate')]
S47-PMC4982007	PMC4982007	8/2016	S47-PMC4982007	['caption (table-wrap): table 1\n\nlist of mesh terms and the text word terms used for exposure and outcomeexposure: maternal nutritional status during Pregnancyoutcome: childhood and adolescent Cognitive functionmesh termstext word termsmesh termstext word terms“exp body weight/or exp body mass index/or exp anthropometry/or exp body size/or exp Skinfold thickness/or exp nutrition assessment/or exp nutritional status/or exp mothers/or exp Pregnancy/or exp malnutrition/or exp diet vegetarian/or exp haemoglobin/or Pregnancy complications/or exp anemia/or exp Folic Acid/or exp Folic Acid deficiency/or exp Vitamin B12 deficiency/or exp ferritin/or exp iron, dietary/or exp Cholecalciferol/or exp Pyridoxine/or exp Vitamin B Complex/or exp riboflavin/or exp Thiamine/or exp Vitamin D/”“maternal nutrition or maternal anthropometry or Pregnancy nutrition or Antenatal nutrition or intrauterine nutrition or Gestational nutrition or maternal undernutrition or Prenatal nutrition or maternal bmi or maternal Micronutrients or vegan mothers or vegetarian mothers or Macrobiotic mothers or maternal Folate or maternal Folic Acid or maternal Vitamin B12 or maternal cobalamin or maternal Vitamin D or 25 Hydoxy Vitamin D or maternal Cholecaliciferol or maternal haemoglobin or maternal iron or maternal b Vitamins or maternal vitamin b1 or maternal vitamin b6 or maternal Vitamin B9 or maternal b Vitamins or maternal anaemia or maternal diet”“exp child/or exp Child Development/or exp adolescent/or exp neurobehavioral manifestations/or exp child, preschool/or exp Cognition, physiology/or exp attention/or exp Memory, Long-Term/or exp Memory, short-term/or exp Memory/or exp intelligence tests/or exp psycho motor performance/or exp child psychology/or exp Decision Making/or exp psychometrics/or exp intelligence/or exp mental competence/or exp Cognition/or exp motor skills/or exp Language Development/or exp Learning/or exp Verbal Learning/or exp Problem Solving/or exp perception/or exp Thinking/or exp executive function/or exp function/or exp Human development/or exp adolescent development/or exp speech/or exp mental Processes/Cognitive function or intelligence or iq or executive function or Psychomotor Development or cognitive performance or Cognition or educational attainment or Cognitive ability or Cognitive deficits or intellectual ability or Learning or Memory or Language Development.']	N/A	N/A	[('GO_0006606', 'protein import into nucleus', 148, 'pregnancyOutcome'), ('GO_0050890', 'cognition', 191, 'cognitive'), ('UBERON_0009007', 'superficial inguinal lymph node', 344, 'skinfold'), ('GO_0007565', 'female pregnancy', 439, 'pregnancy'), ('GO_0007565', 'female pregnancy', 514, 'pregnancy'), ('CHEBI_30751', 'formic acid', 559, 'folic acid'), ('CHEBI_30751', 'formic acid', 577, 'folic acid'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 606, 'vitamin b12'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 606, 'vitamin b12'), ('CHEBI_52550', 'theopalauamide', 673, 'cholecalciferol'), ('CHEBI_16410', 'pyridoxamine', 696, 'pyridoxine'), ('CHEBI_49976', 'zinc dichloride', 714, 'vitamin b'), ('GO_0032991', 'protein-containing complex', 724, 'complex'), ('CHEBI_26948', 'vitamin B1', 757, 'thiamine'), ('CHEBI_27300', 'vitamin D', 773, 'vitamin D'), ('GO_0007565', 'female pregnancy', 833, 'pregnancy'), ('GO_0007567', 'parturition', 856, 'antenatal'), ('GO_0007565', 'female pregnancy', 905, 'gestational'), ('GO_0007565', 'female pregnancy', 957, 'prenatal'), ('CHEBI_33839', 'macromolecule', 1004, 'micronutrients'), ('CHEBI_64709', 'organic acid', 1061, 'macrobiotic'), ('CHEBI_30863', '5-azaorotic acid', 1093, 'folate'), ('CHEBI_30751', 'formic acid', 1112, 'folic acid'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 1135, 'vitamin b12'), ('PR_000004677', 'breast cancer anti-estrogen resistance protein 3', 1143, 'b12'), ('CHEBI_27300', 'vitamin D', 1181, 'vitamin D'), ('CHEBI_45557', 'sec-butyl group', 1194, '25 hydoxy'), ('CHEBI_27300', 'vitamin D', 1204, 'vitamin D'), ('CHEBI_17937', 'L-rhamnono-1,4-lactone', 1226, 'cholecaliciferol'), ('CHEBI_33277', 'gamma-tocotrienol', 1298, 'vitamins'), ('CHEBI_33229', 'vitamin (role)', 1365, 'vitamin'), ('PR_000017209', 'utrophin', 1365, 'vitamin b9'), ('CHEBI_33277', 'gamma-tocotrienol', 1390, 'vitamins'), ('GO_0001410', 'chlamydospore formation', 1454, 'child development'), ('GO_0050890', 'cognition', 1559, 'cognition'), ('GO_0007613', 'memory', 1605, 'memory'), ('GO_0007616', 'long-term memory', 1613, 'long-term'), ('GO_0007613', 'memory', 1630, 'memory'), ('GO_0007613', 'memory', 1656, 'memory'), ('GO_0016045', 'detection of bacterium', 1752, 'decision making'), ('GO_0050890', 'cognition', 1841, 'cognition'), ('GO_0060132', 'prolactin secreting cell development', 1878, 'language development'), ('GO_0007612', 'learning', 1906, 'learning'), ('GO_0008355', 'olfactory learning', 1922, 'verbal learning'), ('GO_0008283', 'cell proliferation', 1945, 'problem solving'), ('GO_0007596', 'blood coagulation', 1986, 'thinking'), ('NCBITaxon_9606', 'Homo sapiens', 2044, 'human'), ('GO_0007565', 'female pregnancy', 2120, 'processes'), ('GO_0050890', 'cognition', 2130, 'Cognitive'), ('GO_0030324', 'lung development', 2196, 'psychomotor development'), ('GO_0050890', 'cognition', 2248, 'cognition'), ('GO_0050890', 'cognition', 2287, 'cognitive'), ('GO_0050890', 'cognition', 2308, 'cognitive'), ('GO_0007612', 'learning', 2354, 'learning'), ('GO_0007613', 'memory', 2366, 'memory'), ('GO_0060132', 'prolactin secreting cell development', 2376, 'language development')]
S311-PMC4990268	PMC4990268	8/2016	S311-PMC4990268	['the trial in bangladesh included 59,666 Pregnancies randomized to Vitamin A (7,000 μg), Β-Carotene (42 mg), or placebo from the first Trimester through 12 weeks post-Partum[107].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 40, 'pregnancies'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 88, 'β-carotene'), ('GO_0009294', 'DNA mediated transformation', 134, 'trimester'), ('GO_0007567', 'parturition', 166, 'partum')]
S312-PMC4990268	PMC4990268	8/2016	S312-PMC4990268	['this population had evidence of significant Vitamin A deficiency, with night blindness rates during Pregnancy approaching 10%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin A'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy')]
S428-PMC4990268	PMC4990268	8/2016	S428-PMC4990268	['antenatal Vitamin A///// when given to night-blind Pregnant women, infant mortality is ↓d Postnatal Vitamin A 10% or greater ↓ in infant mortality to 6 months of age in areas with endemic Vitamin A deficiency [119,121,123]Iodine ↓ Cognitive disability; universal coverage could prevent ~18m cases of Cognitive impairment/ year [129]balanced protein-energy supplementation up to ~30%↓?, rct evidence underpowered [132,135]up to ~40%↓ in populations with significant malnutrition [132,135]/ up to 30%↓ in populations with significant malnutrition [133,135]expected knock-on effects on stuntingeffectiveness estimate assumes 100% coverage.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin A'), ('GO_0007565', 'female pregnancy', 51, 'pregnant'), ('GO_0007567', 'parturition', 90, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin A'), ('CHEBI_31719', 'ipriflavone', 222, 'Iodine'), ('CHEBI_24870', 'ion', 229, '↓'), ('GO_0050890', 'cognition', 231, 'cognitive'), ('GO_0050890', 'cognition', 300, 'cognitive')]
S14-PMC4992225	PMC4992225	8/2016	S14-PMC4992225	['while, the Vitamin D group had greater reduction in depression scores than the control group at 38–40 weeks of Gestation ( p \u2009=\u20090.01) also, at 4 and 8 weeks after Birth ( p \u2009<\u20090.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'gestation'), ('GO_0007567', 'parturition', 163, 'birth')]
S110-PMC4992225	PMC4992225	8/2016	S110-PMC4992225	['in the strata, each eligible Pregnant woman was assigned in the control or the Vitamin D groups using block randomization strategy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 29, 'pregnant'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
S199-PMC4992225	PMC4992225	8/2016	S199-PMC4992225	['in their study used a dosage of 14,000\xa0iu Vitamin D supplement per week, equal to 2000\xa0iu per day, started at 27–30 weeks of Gestation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'gestation')]
S202-PMC4992225	PMC4992225	8/2016	S202-PMC4992225	['gave 2000\xa0iu of Vitamin D per day to non-Pregnant women in form of oral drops for 105\xa0days.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnant')]
S233-PMC4992225	PMC4992225	8/2016	S233-PMC4992225	['unplanned Pregnancy was more frequent in the Vitamin D group than the control group.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D')]
S9-PMC4997567	PMC4997567	8/2016	S9-PMC4997567	['raising the standard of living, level of education, housings, and dietary supplementation of Vitamin D to the Pregnant women and infants are the Solution.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnant'), ('CHEBI_75958', 'solution', 145, 'solution')]
S25-PMC4997567	PMC4997567	8/2016	S25-PMC4997567	['maternal questionnaire\nthe mothers of all children were inquired about the number of Pregnancies, the intervals between Pregnancies, maternal nutrition, and Calcium and Vitamin D supplementation during Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 85, 'pregnancies'), ('GO_0007565', 'female pregnancy', 120, 'pregnancies'), ('CHEBI_22313', 'alkaline earth metal atom', 157, 'calcium'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy')]
S70-PMC5014971	PMC5014971	8/2016	S70-PMC5014971	['more than half of the respondents indicated that they never (32.7%) or rarely (23.8%) screen their Pregnant patients for Vitamin D; about one in four always (12.9%) or often (12.9%) screen.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 99, 'pregnant'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
S84-PMC5014971	PMC5014971	8/2016	S84-PMC5014971	['the most common answer for Vitamin D supplementation dose given to a Pregnant woman with no sign of Vitamin D insufficiency was 1,000\u2009iu/day (41.6%), followed by 400\u2009iu/day (22.8%) and 600\u2009iu/day (20.8%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
S21-PMC5051327	PMC5051327	9/2016	S21-PMC5051327	['furthermore, we compared the rate of Birth asphyxia in women with Vitamin D deficiency and non-deficiency in early Pregnancy.']	N/A	N/A	[('GO_0007567', 'parturition', 37, 'birth'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy')]
S29-PMC5051327	PMC5051327	9/2016	S29-PMC5051327	['Vitamin D analysis\nVenous Serum samples were collected at enrolment between february 1994 and june 1995 at a mean of 12\u2005weeks of Gestation, centrifuged and stored at −80°c until analysis of 25-Oh Vitamin D. 25-Oh Vitamin D levels were measured in nmol/l.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin'), ('UBERON_0001638', 'vein', 19, 'Venous'), ('UBERON_0001977', 'blood serum', 26, 'serum'), ('GO_0007565', 'female pregnancy', 129, 'gestation'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 190, '25-OH'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 207, '25-OH'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D')]
S48-PMC5051327	PMC5051327	9/2016	S48-PMC5051327	['the proportion of Pregnant women with Vitamin D deficiency (<50\u2005nmol/l) in the whole population was 70% during winter/spring season (december–may) and 36% during summer season.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 18, 'pregnant'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
S49-PMC5051327	PMC5051327	9/2016	S49-PMC5051327	['caption (table-wrap): table\xa02\n\ncharacteristics in relation to maternal Vitamin D levels in the whole study group25-Oh Vitamin D<50\u2005nmol/l≥ 50\u2005nmol/lsignificance of difference (p)Vitamin D deficiencynot deficiencyn=95n=78 maternal characteristics \u2003age (years)29.15.330.24.40.1\u2003height (cm)163.25.9166.37.10.02\u2003body mass index (kg/m2)23.74.122.93.60.2\u2003nulliparous (n)4244.2%4355.1%0.2\u2003smoker (n)1818.9%1721.8%0.6 mode of Delivery \u2003vaginal spontaneous (n)5254.7%4659.0%0.6\u2003vaginal assisted (n)33.2%79.0%0.2\u2003caesarean section (n)4042.1%2532.1%0.2\u2003cs due to suspected fetal distress (n)3334.7%2025.6%0.2 neonatal outcome \u2003Gestational age (days)273.019.1278.914.60.02\u2003Preterm Delivery (n)1313.7%45.1%0.06\u2003Birth weight (g)3323.58193447.56780.3\u2003sga (n)1111.6%56.4%0.2\u20035\u2005min apgar score <7 (n)66.3%22.6%0.3\u2003Umbilical Artery ph7.200.097.230.070.1\u2003Umbilical Vein ph7.280.097.300.080.4\u2003Umbilical Cord ph ≤7.152021.1%810.3%0.06\u2003Birth asphyxia2324.2%911.5%0.03\nmean and sd or number and percentages are given.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_86030', 'O-(hydroxyhexadecanoyl)carnitine', 114, '-OH'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 178, 'Vitamin D'), ('GO_0007567', 'parturition', 418, 'delivery'), ('GO_0007565', 'female pregnancy', 616, 'Gestational'), ('GO_0007128', 'meiotic prophase I', 661, 'Preterm'), ('GO_0007567', 'parturition', 669, 'delivery'), ('GO_0007567', 'parturition', 698, 'Birth'), ('UBERON_0001310', 'umbilical artery', 797, 'Umbilical artery'), ('UBERON_0002066', 'umbilical vein', 836, 'Umbilical vein'), ('UBERON_0002331', 'umbilical cord', 873, 'Umbilical cord'), ('GO_0007567', 'parturition', 914, 'Birth')]
S30-PMC5054480	PMC5054480	9/2016	S30-PMC5054480	['the patient was taking Prenatal Vitamins daily, Vitamin D tablets (1000 iu), and Calcium Carbonate tablets as needed.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 32, 'vitamins'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_3311', 'calcium carbonate', 81, 'calcium carbonate')]
S34-PMC5062906	PMC5062906	10/2016	S34-PMC5062906	['among females 12–44\xa0years of age, 28\xa0% of Pregnant/Lactating females and 37\xa0% of non-Pregnant/non-Lactating females are at risk of Vitamin D inadequacy [15].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('GO_0007594', 'puparial adhesion', 51, 'lactating'), ('GO_0007565', 'female pregnancy', 85, 'pregnant'), ('GO_0007594', 'puparial adhesion', 98, 'lactating'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S33-PMC5064894	PMC5064894	10/2016	S33-PMC5064894	['in this study, Pregnant women in london, england were randomized at 27\xa0weeks Gestation to receive either no Vitamin D, 800\xa0iu Ergocalciferol daily until Delivery, or a single bolus of 200,000\xa0iu Cholecalciferol.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 15, 'pregnant'), ('GO_0007565', 'female pregnancy', 77, 'gestation'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('CHEBI_4910', 'etomidate', 126, 'ergocalciferol'), ('GO_0007567', 'parturition', 153, 'delivery'), ('CHEBI_52550', 'theopalauamide', 195, 'cholecalciferol')]
S46-PMC5064894	PMC5064894	10/2016	S46-PMC5064894	['methods\n\ndesign\nthe mdig trial is a randomized placebo-controlled dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation to improve infant linear growth in dhaka, bangladesh.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('GO_0007595', 'lactation', 144, 'lactation')]
S62-PMC5064894	PMC5064894	10/2016	S62-PMC5064894	['three intervention groups are receiving weekly Prenatal Vitamin D supplementation of 4200\xa0iu/week, 16,800\xa0iu/week, or 28,000\xa0iu/week respectively given as a single weekly dose beginning in the 2ndtrimester of Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 47, 'prenatal'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 209, 'pregnancy')]
S193-PMC5084016	PMC5084016	10/2016	S193-PMC5084016	['Folic Acid, iron, zinc, Calcium, Vitamin C, and Vitamin D (in addition to energy and protein), are the main Micronutrients for which the requirement physiologically increases during Pregnancy and Lactation.']	N/A	N/A	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('CHEBI_22313', 'alkaline earth metal atom', 24, 'calcium'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_33839', 'macromolecule', 108, 'micronutrients'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('GO_0007595', 'lactation', 196, 'lactation')]
S15-PMC5084041	PMC5084041	10/2016	S15-PMC5084041	['one of these areas of interest is Vitamin D status during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy')]
S16-PMC5084041	PMC5084041	10/2016	S16-PMC5084041	['the Pregnant woman’s Vitamin D status determines the Vitamin D status of her newborn infant [1].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 4, 'pregnant'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
S34-PMC5084041	PMC5084041	10/2016	S34-PMC5084041	['determinants of Vitamin D deficiency in the first trimester of Pregnancy and of changes in Vitamin D status during Pregnancy were identified.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy')]
S76-PMC5084041	PMC5084041	10/2016	S76-PMC5084041	['also, 25(Oh)D at t1 and tobacco use at t1 were considered as confounders in the regression analysis of season-corrected change in 25(Oh)D.\ncontinuous variables were bmi (kg/m2), Gestational weight gain, dietary Vitamin D intake and age.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 133, 'OH)D'), ('GO_0007565', 'female pregnancy', 178, 'gestational'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D')]
S3-PMC5118763	PMC5118763	12/2016	S3-PMC5118763	['Plasma concentrations of Vitamin B-12, Folate, ferritin, and zinc were analyzed before the start of Micronutrient supplementation (week 14) and at week 30 of Pregnancy in 641 randomly selected women.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 25, 'vitamin B-12'), ('CHEBI_30863', '5-azaorotic acid', 39, 'folate'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 100, 'micronutrient'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy')]
S6-PMC5118763	PMC5118763	12/2016	S6-PMC5118763	['results: at week 30 of Pregnancy, women in the mmn group had higher geometric mean concentrations of Vitamin B-12 than women in the fe60f group (119 compared with 101 pmol/l, respectively); no other differences in effectiveness of Micronutrient and Food regimens were observed.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 101, 'vitamin B-12'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 231, 'micronutrient'), ('CHEBI_33290', 'food', 249, 'food')]
S91-PMC5118763	PMC5118763	12/2016	S91-PMC5118763	['the mean Plasma Vitamin B-12 concentration was significantly higher among women in the mmn regimen at week 30 of Pregnancy, but no other significant differences were observed in Plasma concentrations of Folate, ferritin, and zinc between the different Micronutrient supplementation regimens (table 2).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 9, 'plasma'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 16, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 178, 'plasma'), ('CHEBI_30863', '5-azaorotic acid', 203, 'folate'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 252, 'micronutrient')]
S102-PMC5118763	PMC5118763	12/2016	S102-PMC5118763	['caption (fig): figure 2\n\nlowess curves of associations between total numbers of capsules Consumed from week 14 to 30 of Pregnancy and maternal Plasma concentrations of Vitamin B-12 (a), Folate (b), ferritin (c), and zinc (d) at week 30 of Pregnancy, by Micronutrient supplementation type.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 89, 'consumed'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 143, 'plasma'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin B'), ('CHEBI_30863', '5-azaorotic acid', 186, 'folate'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 253, 'micronutrient')]
S109-PMC5118763	PMC5118763	12/2016	S109-PMC5118763	['caption (table-wrap): table 3\n\nPlasma Vitamin B-12 concentrations at week 30 of Pregnancy by tertile of capsule Intake and Micronutrient supplementation type in a selected sample of rural bangladeshi women participating in the minimat trial1micronutrient typelowest tertile (6–65 capsules)middle tertile (66–99 capsules)highest tertile (100–157 capsules)fe30f \u2003n 605465\u2003mean,2pmol/l103 (88, 120)120 (87, 141)101 (87, 119)\u2003unadjusted mean difference3reference0.15 (−0.08, 0.38)−0.01 (−0.23, 0.21)\u2003adjusted mean difference4reference0.23 (−0.01, 0.47)0.02 (−0.22, 0.25)fe60f \u2003n 676561\u2003mean,2pmol/l94 (81, 109)112 (96, 130)98 (85, 116)\u2003unadjusted mean difference3reference0.17 (−0.04, 0.39)0.05 (−0.17, 0.26)\u2003adjusted mean difference4reference0.18 (−0.04, 0.40)−0.00 (−0.23, 0.22)mmn \u2003n 526967\u2003mean,2pmol/l103 (87, 119)124 (108, 143)128 (111, 147)\u2003unadjusted mean difference3reference0.19 (−0.01, 0.40)0.22 (0.02, 0.43)*\u2003adjusted mean difference4reference0.16 (−0.05, 0.38)0.15 (−0.07, 0.37)\ndata were analyzed by using general linear models.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 31, 'Plasma'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 38, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('GO_0007631', 'feeding behavior', 112, 'intake'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 123, 'micronutrient')]
S157-PMC5118763	PMC5118763	12/2016	S157-PMC5118763	['at week 30 of Pregnancy, Plasma Vitamin B-12 concentrations were significantly higher among the women in the mmn group.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 14, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 25, 'plasma'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 32, 'vitamin B-12')]
S49-PMC5119728	PMC5119728	11/2016	S49-PMC5119728	['christian, 2010 [43]rct, 676 children followed to age of 7 to 9 years.Pregnant women were randomly allocatedto receive daily Iron/Folic Acid (400 ug), Iron/Folic Acid/zinc, or multiple Micronutrients containing these plus 11 other Micronutrients, or placebo (Vitamin A only) groups from early Pregnancy to 3 months Postpartum.beneficial.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 70, 'Pregnant'), ('CHEBI_24870', 'ion', 125, 'iron'), ('CHEBI_30751', 'formic acid', 130, 'folic acid'), ('CHEBI_24870', 'ion', 151, 'iron'), ('CHEBI_30751', 'formic acid', 156, 'folic acid'), ('CHEBI_33839', 'macromolecule', 185, 'micronutrients'), ('CHEBI_33839', 'macromolecule', 231, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 259, 'vitamin A'), ('GO_0007565', 'female pregnancy', 293, 'pregnancy'), ('GO_0007565', 'female pregnancy', 315, 'postpartum')]
S59-PMC5146866	PMC5146866	12/2016	S59-PMC5146866	['as shown in table\xa01, mothers of infants with deficient and insufficient level of Vitamin D in cb were younger and had a greater number of Pregnancies as compared to mothers of infants with sufficient level of [25(Oh)D].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 138, 'pregnancies'), ('CHEBI_71657', 'versiconol acetate', 210, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 210, '25(OH ... D')]
S63-PMC5146866	PMC5146866	12/2016	S63-PMC5146866	['caption (table-wrap): table 1\n\nmaternal demographics and clinical characteristics with respect to cb Vitamin D statusparametricvitamin D status p valuedeficiency n \u2009=\u200995insufficiency n \u2009=\u200979sufficiency n \u2009=\u200991age (years)30.6+/−5.7(29.4–31.8)29.9+/−5.1(28.8–31.1)32.6+/−5.3(31.5–33.8)<0.01medicaid/uninsured16.0%(9.9–24.7)8.8%(4.3–16.9)6.7%(3.1–13.6)0.09weight at Birth (pounds)175+/−41(167–183)172+/−34(165–180)174+/−39(166–182)0.89multiple Gestation1.1%(0.002–0.06)1.3%(0.002–0.07)3.3%(0.11–0.09)0.47nulliparity (%)27.7%(19.6–37.4)38.8%(28.8–49.7)36.3%(27.1–46.5)0.26first gravidity (%)21.3%(9.1–23.5)26.3%(14.7–32.8)31.9%(6.9–20.4)0.56gravidity (number)3.4+/−2.4(2.9–3.9)2.8+/−1.9(2.3–3.2)2.4+/−1.3(2.1–2.6)<0.01gestational age38.9+/−1.3(38.6–39.1)39.2+/−1.2(38.9–39.5)39.0+/−1.3(38.7–39.3)0.15winter season Deliveries14.9%(9.1–23.5)22.5%(14.7–32.8)12.1%(6.9–20.4)0.17cesarean section32.9%(24.3–42.9)35.0%(25.5–45.9)41.8%(32.2–52.1)0.44vitamins supplementation66.0%(60.3–78.5)77.5%(67.2–85.3)67.0%(56.9–75.8)0.20iron supplementation8.5%(4.4–15.9)3.8%(1.3–10.5)2.2%(0.6–7.7)0.15thyroid medications9.6%(5.1–17.2)8.8%(4.3–16.9)8.8%(4.5–16.4)0.98substance abuse (smoking/alcohol/Drugs)3.2%(1.1–8.9)5.0%(2.0–12.2)6.6%(3.1–13.6)0.56morbidities during Pregnancy21.3%(14.2–30.6)26.3%(17.9–36.8)23.1%(15.6–32.7)0.74diabetes10.6%(5.9–18.5)12.5%(6.9–21.5)7.7%(3.8–15.1)0.57\ndata presented as mean or proportion (%) with 95% confidence interval\n\ncaption (fig): fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 135, 'D'), ('GO_0007567', 'parturition', 363, 'birth'), ('GO_0007565', 'female pregnancy', 441, 'gestation1'), ('GO_0060179', 'male mating behavior', 810, 'deliveries14'), ('CHEBI_23888', 'drug', 1177, 'drugs'), ('GO_0007565', 'female pregnancy', 1247, 'pregnancy21')]
S75-PMC5146866	PMC5146866	12/2016	S75-PMC5146866	['cb Vitamin D status: deficiency ( n \u2009=\u200995), insufficiency ( n \u2009=\u200979), sufficient ( n \u2009=\u200991)\n\nneonatal characteristics and cb Vitamin D status\namong the 265 infants in this study, 6.4% were Born at Gestational age between 37 and 34\xa0weeks and 1.9% from multiple Gestations.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007567', 'parturition', 189, 'born'), ('GO_0007565', 'female pregnancy', 197, 'gestational'), ('GO_0007565', 'female pregnancy', 260, 'gestations')]
S2-PMC5155676	PMC5155676	12/2016	S2-PMC5155676	['design:\nwithin-randomization-group analysis of participants in the maternal Vitamin D osteoporosis study trial of Vitamin D supplementation in Pregnancy.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 76, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]
S9-PMC5155676	PMC5155676	12/2016	S9-PMC5155676	['results:\n25(Oh)D at 34 weeks of Gestation was higher in the women randomized to Vitamin D (mean [sd], 67.7 [21.3] nmol/l) compared with placebo (43.1 [22.5] nmol/l; p< .001).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('GO_0007565', 'female pregnancy', 32, 'gestation'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
S25-PMC5155676	PMC5155676	12/2016	S25-PMC5155676	['materials and methods\n\nthe maternal Vitamin D osteoporosis study (mavidos)\nthe mavidos study is a multicenter, double-blind, randomized, placebo-controlled trial of Vitamin D supplementation in Pregnancy.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 36, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007565', 'female pregnancy', 194, 'pregnancy')]
S37-PMC5155676	PMC5155676	12/2016	S37-PMC5155676	['all participants received standard Antenatal care and could continue self-administration of dietary supplements containing up to 400 iu/d Vitamin D.\n\nmaternal assessments during Pregnancy\nbefore commencing the study Medication, and again at 34 weeks of Gestation, the women attended the research center for a detailed assessment of diet (including supplement use), lifestyle (smoking, physical activity participation, employment), and health (past medical history, current medication use) using interviewer-led questionnaires.']	N/A	N/A	[('GO_0007567', 'parturition', 35, 'antenatal'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('CHEBI_60211', 'compound Z', 216, 'medication'), ('GO_0007565', 'female pregnancy', 253, 'gestation')]
S58-PMC5155676	PMC5155676	12/2016	S58-PMC5155676	['finally, in sensitivity analysis, we excluded women who reported having taken any additional Vitamin D-containing Supplements within 90 days of the late Pregnancy Blood sampling.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 114, 'supplements'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('UBERON_0000178', 'blood', 163, 'blood')]
S68-PMC5155676	PMC5155676	12/2016	S68-PMC5155676	['maternal characteristics at baseline according to randomization groupplacebo1000-iu/d Cholecalciferoln422407Gestation (wk), mean (sd)15.9 (1.5)15.9 (1.5)maternal age (y), mean (sd)30.7 (5.4)30.7 (5.0)nulliparous (%)44.842.7current smoker (%)7.77.7bmi (kg/m2), median (iqr)25.4 (22.7–29.7)24.6 (22.2–28.6)height (cm), mean (sd)165.6 (6.6)165.5 (6.3)white ethnicity (%)94.895.625(Oh)D (nmol/l), median (iqr)44.4 (33.2–57.0)45.7 (34.3–57.8)\n\nmaternal 25(Oh)D status at 34 weeks of Gestation by randomization group\nmaternal 25(Oh)D at 34 weeks of Gestation was greater in the women randomized to Cholecalciferol (mean 67.7 nmol/l [sd 21.3 nmol/l]) compared with the placebo group (mean 43.1 nmol/l [sd 22.5 nmol/l], p< .0001); 83.3% of women randomized to Cholecalciferol achieved Vitamin D replete status at 34 weeks of Gestation (>50 nmol/l) compared with 35.6% in the placebo group ( p< .001).']	N/A	N/A	[('CHEBI_52815', 'cresyl violet', 86, 'Cholecalciferoln422407Gestation'), ('CHEBI_33010', 'chromide(1-)', 377, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 451, 'OH)D'), ('GO_0007565', 'female pregnancy', 478, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 520, '25(OH)D'), ('GO_0007565', 'female pregnancy', 543, 'gestation'), ('CHEBI_52550', 'theopalauamide', 592, 'cholecalciferol'), ('CHEBI_52550', 'theopalauamide', 752, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 777, 'vitamin D'), ('GO_0007565', 'female pregnancy', 817, 'gestation')]
S71-PMC5155676	PMC5155676	12/2016	S71-PMC5155676	['in both treatment groups, the proportion of women who were Vitamin D replete at 34 weeks of Gestation was lower in those who Delivered in winter (table 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 92, 'gestation'), ('GO_0007567', 'parturition', 125, 'delivered')]
S93-PMC5155676	PMC5155676	12/2016	S93-PMC5155676	['sensitivity analyses\nas participants were permitted to continue taking daily Vitamin D supplements containing up to 400 iu, in the sensitivity analysis we excluded 229 women (n = 117 randomized to Cholecalciferol) who reported taking other Vitamin D containing dietary supplements at the late Pregnancy interview.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 197, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D'), ('GO_0007565', 'female pregnancy', 293, 'pregnancy')]
S94-PMC5155676	PMC5155676	12/2016	S94-PMC5155676	['similarly, 81.0% of women randomized to Cholecalciferol were Vitamin D replete at 34 weeks of Gestation, compared with 29.4% of women randomized to placebo ( p< .001).']	N/A	N/A	[('CHEBI_52550', 'theopalauamide', 40, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'gestation')]
S45-PMC5167470	PMC5167470	12/2016	S45-PMC5167470	['a strict monitoring and biochemical follow-up of Pregnant women taking high doses of Vitamins A and D significantly minimizes the risk for developing adverse events.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 49, 'pregnant'), ('CHEBI_27300', 'vitamin D', 85, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 94, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 100, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 100, 'D')]
S58-PMC5318550	PMC5318550	2/2017	S58-PMC5318550	['these sd scores were constructed based on distributions in the generation r cohort.17\n\nassessment of Vitamin D status in maternal mid-Pregnancy and Cord Blood Plasma samples\ntotal Vitamin D was reported as the sum of 25-Hydroxyvitamin D2 (25ohd2) and 25-Hydroxyvitamin D3 (25ohd3) species measured in maternal Plasma and Cord Blood samples using a modification of a method previously described.18in mid-Pregnancy (mean 20.6\u2005weeks; sd 1.0, iqr 1.14), Venous Blood samples were collected and directly after Delivery (mean Gestational duration 39.8\u2005weeks; sd 1.8, iqr 2.0), midwives or obstetricians collected Cord Blood from the Umbilical Vein.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 148, 'cord'), ('UBERON_0000178', 'blood', 153, 'blood'), ('UBERON_0001969', 'blood plasma', 159, 'plasma'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('CHEBI_86319', '25-hydroxyvitamin D2', 217, '25-hydroxyvitamin D2'), ('PR_000002019', 'MHC class II histocompatibility antigen beta chain DRB1', 235, 'D2'), ('CHEBI_63991', '15-epi-lipoxin B4', 251, '25-hydroxyvitamin D3'), ('UBERON_0001969', 'blood plasma', 310, 'plasma'), ('UBERON_0002240', 'spinal cord', 321, 'cord'), ('UBERON_0000178', 'blood', 326, 'blood'), ('GO_0007565', 'female pregnancy', 403, 'pregnancy'), ('UBERON_0001638', 'vein', 450, 'venous'), ('UBERON_0000178', 'blood', 457, 'blood'), ('GO_0007567', 'parturition', 505, 'delivery'), ('GO_0007565', 'female pregnancy', 520, 'gestational'), ('UBERON_0002240', 'spinal cord', 607, 'cord'), ('UBERON_0000178', 'blood', 612, 'blood'), ('UBERON_0002066', 'umbilical vein', 627, 'umbilical vein')]
S85-PMC5318550	PMC5318550	2/2017	S85-PMC5318550	['next, the following variables were added stepwise to this basic model; (2) sociodemographic factors and maternal iq; (3) child Birth weight and Gestational duration; (4) maternal mid-Pregnancy and Cord Blood Vitamin D Plasma concentrations; (5) maternal nutritional intake; (6) maternal exposure to fever during Pregnancy; and (7) child relative age in class.']	N/A	N/A	[('GO_0007567', 'parturition', 127, 'birth'), ('GO_0007565', 'female pregnancy', 144, 'gestational'), ('GO_0007565', 'female pregnancy', 183, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 197, 'cord'), ('UBERON_0000178', 'blood', 202, 'blood'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 218, 'plasma'), ('GO_0007565', 'female pregnancy', 312, 'pregnancy')]
S110-PMC5318550	PMC5318550	2/2017	S110-PMC5318550	"[""caption (table-wrap): table\xa02\n\nchange of the association between child's season of Birth and iq at age 6\u2005years with stepwise addition of covariates (n=6034)\xa0child iq at age 6\u2005yearsseason of Birthadjusted forbasic model: child gender and age at iq assessmentmodel 2: +maternal sociodemographic characteristicsmodel 3: +maternal iqmodel 4: +maternal nutritional Intake and one-carbon biomarkersmodel 5: +child relative age in class and season at iq assessmentmodel 6: +Vitamin D Plasma levelsmodel 7: +Gestational duration and Birth weightmodel 8: +fever during Pregnancy and crp levelsspringβ (95% ci) p value−1.24 (−2.31 to −0.17) 0.02−1.14 (−2.17 to −0.12) 0.03−0.87 (−1.87 to 0.14) 0.09−0.86 (−1.87 to 0.14) 0.09−0.75 (−1.91 to 0.40) 0.20−0.68 (−1.89 to 0.52) 0.27−0.59 (−1.80 to 0.61) 0.33−0.57 (−1.78 to 0.64) 0.35summer\xa0 referencereferencereferencereferencereferencereferencereferencereference autumnβ (95% ci) p value−0.52 (−1.56 to 0.51) 0.32−0.75 (−1.74 to 0.24) 0.14−0.63 (−1.60 to 0.34) 0.20−0.64 (−1.61 to 0.34) 0.20−0.53 (−2.25 to 1.18) 0.54−0.66 (−2.41 to 1.09) 0.46−0.63 (−2.37 to 1.12) 0.48−0.63 (−2.37 to 1.12) 0.48winterβ (95% ci) p value−0.84 (−1.93 to 0.26) 0.13−0.89 (−1.94 to 0.15) 0.09−0.66 (−1.69 to 0.36) 0.21−0.71 (−1.74 to 0.32) 0.18−0.76 (−2.28 to 0.77) 0.33−0.84 (−2.47 to 0.79) 0.31−0.76 (−2.39 to 0.86) 0.36−0.75 (−2.38 to 0.88) 0.37seasonal trendβ (95% ci) p value−0.40 (−0.74 to −0.07) 0.02−0.36 (−0.68 to −0.04) 0.03−0.27 (−0.58 to 0.05) 0.10−0.27 (0.59 to 0.05) 0.10−0.23 (−0.55 to 0.10) 0.18−0.18 (−0.53 to 0.17) 0.31−0.15 (−0.50 to 0.20) 0.39−0.14 (−0.49 to 0.21) 0.42effect estimate change of seasonal trend (%) reference 10.032.532.542.555.062.565.0r2(change)*0.0200.0880.0360.0030.0010.0010.010.001p value<0.001<0.001<0.001<0.0010.020.02<0.0010.001\nresults from linear regression analyses.""]"	N/A	N/A	[('GO_0007567', 'parturition', 83, 'birth'), ('GO_0007608', 'sensory perception of smell', 190, 'birthAdjusted'), ('GO_0007631', 'feeding behavior', 360, 'intake'), ('CHEBI_27300', 'vitamin D', 467, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 477, 'plasma'), ('GO_0007565', 'female pregnancy', 500, 'gestational'), ('GO_0007567', 'parturition', 525, 'birth'), ('GO_0007565', 'female pregnancy', 560, 'pregnancy')]
S135-PMC5318550	PMC5318550	2/2017	S135-PMC5318550	['we did not observe a meaningful effect of maternal nutritional intake, Vitamin D status or maternal exposure to fever during Pregnancy on the association between child season of Birth and iq.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnancy'), ('GO_0007567', 'parturition', 178, 'birth')]
S22-PMC5322422	PMC5322422	2/2017	S22-PMC5322422	['the infant did not receive Vitamin K prophylaxis at Birth, though his mother was taking oral Vitamin K, a Prenatal Vitamin, and herbal supplements daily.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin K'), ('GO_0007567', 'parturition', 52, 'birth'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin K'), ('GO_0007565', 'female pregnancy', 106, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 115, 'vitamin')]
S159-PMC5351212	PMC5351212	3/2017	S159-PMC5351212	['1\n\nelevated plus maze behaviors in juvenile offspring who were exposed to Prenatal Immune challenge (pol) or Prenatal Vitamin D treatment (vitd).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 74, 'prenatal'), ('UBERON_0002405', 'immune system', 83, 'immune'), ('GO_0007565', 'female pregnancy', 109, 'prenatal'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
S171-PMC5351212	PMC5351212	3/2017	S171-PMC5351212	['2\n\nsocial approach behavior in juvenile offspring who were exposed to Prenatal Immune challenge (pol) or Prenatal Vitamin D treatment (vitd).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 70, 'prenatal'), ('UBERON_0002405', 'immune system', 79, 'immune'), ('GO_0007565', 'female pregnancy', 105, 'prenatal'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]
S183-PMC5351212	PMC5351212	3/2017	S183-PMC5351212	['3\n\nmarble burying behavior in juvenile offspring who were exposed to Prenatal Immune challenge (pol) or Prenatal Vitamin D treatment (vitd).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 69, 'prenatal'), ('UBERON_0002405', 'immune system', 78, 'immune'), ('GO_0007565', 'female pregnancy', 104, 'prenatal'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
S194-PMC5351212	PMC5351212	3/2017	S194-PMC5351212	['4\n\nacquisition of Fear Memory, association with context and fear Memory behavior in juvenile offspring who were exposed to Prenatal Immune challenge (pol) or Prenatal Vitamin D treatment (vitd).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 18, 'fear'), ('GO_0007613', 'memory', 23, 'memory'), ('GO_0007613', 'memory', 65, 'memory'), ('GO_0007565', 'female pregnancy', 123, 'prenatal'), ('UBERON_0002405', 'immune system', 132, 'immune'), ('GO_0007565', 'female pregnancy', 158, 'prenatal'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
S28-PMC5372933	PMC5372933	3/2017	S28-PMC5372933	['canadian sample\nparticipants in the canadian sample were enrolled as part of a randomized control trial from june 2010 through march 2013, investigating the efficacy of three doses of maternal Perinatal Vitamin D to improve infant 25-Hydroxyvitamin D concentrations at 8 weeks Postpartum; results are published elsewhere [13].']	N/A	N/A	[('GO_0036268', 'swimming', 193, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 193, 'perinatal'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 231, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 277, 'postpartum')]
S92-PMC5379504	PMC5379504	4/2017	S92-PMC5379504	['caption (table-wrap): table 2\n\nFeeding practice, Micronutrient supplementation and morbidity related characteristics of study participants, dabat district, northwest ethiopia, 2015characteristicsfrequencypercentfeeding during Pregnancy\u2003less than before/usual35660.6\u2003as usual22137.6\u2003greater than usual/extra foods101.7prenatal Iron-Folate supplementation\u2003yes30852.5\u2003no27947.5colostrum\u2003given to the child32455.2\u2003discarded26344.8ever breastfeeding\u2003yes58499.5\u2003no30.5initiation of breastfeeding\u2003early initiation33357.0\u2003late initiation25143.0exclusive breastfeeding\u2003yes36161.5\u2003no22638.5pre-lacteal Feeding\u2003yes13723.3\u2003no45076.7complementary Feeding initiation\u2003early initiation10918.6\u2003timely initiation31453.5\u2003lately initiation16427.9bottle Feeding in the previous 24\xa0h\u2003yes406.8\u2003no54793.2dietary diversity score\u2003<\xa04 Food groups56295.7\u2003≥\xa04 Food groups254.3maternal vitamin a supplementation\u2003yes14524.7\u2003no44275.3history of fever in the previous 2\xa0weeks\u2003yes23740.4\u2003no35059.6history of diarrheal disease in the previous 2\xa0weeks\u2003yes14324.4\u2003no44475.6child Vitamin A supplementation in the previous 12\xa0months\u2003yes46378.9\u2003no12421.1\n\ncaption (table-wrap): table 3\n\nenvironmental health related characteristics of the households, dabat district, northwest ethiopia, 2015characteristicsfrequencypercent (%)source of drinking Water\u2003safe sourcea21236.1\u2003unsafe sourceb37563.9water treatment habit\u2003not at all55093.7\u2003sometimes233.9\u2003always142.4availability of latrine71.9\u2003yes16528.1\u2003no42271.9waste disposal\u2003appropriatec7412.6\u2003inappropriated51387.4hand washing habit after toilet\u2003not at all7112.1\u2003sometimes11118.9\u2003always40569\napiped, protected well and spring Water\nbunprotected well, spring and surface Water\nccollected by municipality, buried and burned\nddumped in street/open space, compound and river\nthe prevalence of stunting and wasting among children aged 6–24\xa0months were 58.1% [95% ci; 50.3, 65.9%] and 17.0% [95% ci; 11.1, 22.9%], respectively.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 31, 'Feeding'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 49, 'micronutrient'), ('GO_0007565', 'female pregnancy', 226, 'pregnancy'), ('CHEBI_24870', 'ion', 326, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 331, 'folate'), ('GO_0007631', 'feeding behavior', 592, 'feeding'), ('GO_0007631', 'feeding behavior', 634, 'feeding'), ('GO_0007631', 'feeding behavior', 733, 'feeding'), ('CHEBI_33290', 'food', 808, 'food'), ('CHEBI_33290', 'food', 831, 'food'), ('CHEBI_27300', 'vitamin D', 1042, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 1050, 'A'), ('CHEBI_15377', 'water', 1305, 'water'), ('CHEBI_15377', 'water', 1633, 'water'), ('CHEBI_15377', 'water', 1677, 'water')]
S70-PMC5385921	PMC5385921	4/2017	S70-PMC5385921	['to remove the effect of family relatedness in the sample, we removed one of each pair of siblings, prioritising siblings with valid Vitamin D measurements from both mid-Gestation and Cord Serum to maximise sample size.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'gestation'), ('UBERON_0002240', 'spinal cord', 183, 'cord'), ('UBERON_0001977', 'blood serum', 188, 'serum')]
S88-PMC5385921	PMC5385921	4/2017	S88-PMC5385921	['in total, 4334 children and their mothers were available with measures of Vitamin D concentrations drawn from maternal Blood at mid-Gestation or drawn from Cord Blood at time of Birth as well as data on the srs and asd status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('UBERON_0000178', 'blood', 119, 'blood'), ('GO_0007565', 'female pregnancy', 132, 'gestation'), ('UBERON_0002240', 'spinal cord', 156, 'cord'), ('UBERON_0000178', 'blood', 161, 'blood'), ('GO_0007567', 'parturition', 178, 'birth')]
S118-PMC5385921	PMC5385921	4/2017	S118-PMC5385921	['the prevalence of Vitamin D deficiency was high in this cohort (17% of the mothers had mid-Gestational 25Ohd concentrations <25 nmol/l).']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'gestational'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 103, '25OHD')]"
S61-PMC5405075	PMC5405075	4/2017	S61-PMC5405075	['(75)denmark 2009–2010623 mother–child pairs recruited from copsac2010cohort study double-blinded Placebo\u2009+\u2009400\u2009iu ( n \u2009=\u2009308)Cholecalciferol 2,400\u2009+\u2009400\u2009iu ( n \u2009=\u2009315)581/3\u2009yearsmothers: 24\u2009weeks of Gestation to 1\u2009week after deliveryincrease in maternal Serum vitd level in treatment group (mean sd at randomization vs Postpartum: 31 vs 43; control group 31 vs 29)mean group difference 13 [95% ci 11–16, p \u2009<\u20090.001]persistent wheeze, asthma, urti, lrti, episodes of Lung symptoms, spt, specific igeno significant reduction in the risk of persistent wheezing per 4\u2009ng/ml increase in maternal Serum Vitamin D level (hr: 0.86, 95% ci 0.89–0.99 p \u2009=\u20090.03)reduced number of troublesome Lung episodes (irr: 0.83, 95% ci 0.71–0.97 p \u2009=\u20090.02)upregulation or Airway Immune profile (principal component analysis p \u2009=\u20090.04)no effect on additional end pointslitonjua et al.']	N/A	N/A	[('CHEBI_8246', 'Pirbuterol acetate', 97, 'Placebo'), ('CHEBI_16113', 'cholesterol', 125, 'Cholecalciferol'), ('GO_0007565', 'female pregnancy', 199, 'gestation'), ('UBERON_0001977', 'blood serum', 254, 'serum'), ('GO_0007565', 'female pregnancy', 319, 'postpartum'), ('UBERON_0002048', 'lung', 466, 'lung'), ('UBERON_0001977', 'blood serum', 591, 'serum'), ('CHEBI_27300', 'vitamin D', 597, 'vitamin D'), ('UBERON_0002048', 'lung', 681, 'lung'), ('UBERON_0001005', 'respiratory airway', 750, 'airway'), ('UBERON_0002405', 'immune system', 757, 'immune')]
S66-PMC5405075	PMC5405075	4/2017	S66-PMC5405075	['recruited 623 unselected women who were randomized to receive either 2,800 or 400\u2009iu (as part of routine care) of Vitamin D daily from 24\u2009weeks of Gestation until the first Postpartum week.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'gestation'), ('GO_0007565', 'female pregnancy', 173, 'postpartum')]
S55-PMC5410409	PMC5410409	4/2017	S55-PMC5410409	['supplementation with Vitamin A and Vitamin C during Pregnancy had no preventive effect on the development Of Wheezing in the child [7].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin C'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('GO_0001503', 'ossification', 106, 'of wheezing')]
S40-PMC5418719	PMC5418719	5/2017	S40-PMC5418719	['data on maternal age, Gestational diabetes mellitus, Antenatal Steroid use, histologic chorioamnionitis, maternal education, Birth during Vitamin D synthetizing period, Gestational age, Birth weight, small Gestational age, sex, type of Delivery, and apgar scores at 1 and 5\xa0min were retrieved for each infant.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 22, 'gestational'), ('GO_0007567', 'parturition', 53, 'antenatal'), ('CHEBI_35341', 'steroid', 63, 'steroid'), ('GO_0007567', 'parturition', 125, 'birth'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'gestational'), ('GO_0007567', 'parturition', 186, 'birth'), ('GO_0007565', 'female pregnancy', 206, 'gestational'), ('GO_0007567', 'parturition', 236, 'delivery')]
S71-PMC5418719	PMC5418719	5/2017	S71-PMC5418719	['caption (table-wrap): table 1\n\ndemographic characteristicscharacteristicsall patients( n \u2009=\u200952)Cord 25(Oh)D concentrations <10\xa0ng/ml ( n \u2009=\u200920)Cord 25(Oh)D concentrations ≥10\xa0ng/ml ( n \u2009=\u200929)maternal age, years34.3\u2009±\u20093.432.4\u2009±\u20093.133.8\u2009±\u20094.0gdm6 (12%)5 (25%)1 (3%)*preeclampsia4 (8%)0 (0%)3 (10%)antenatal Steroid44 (85%)19 (95%)22 (79%)histological chorioamnionitis33 (64%)11 (55%)21 (72%)completed college38 (73)13 (65%)24 (83%)Birth during Vitamin D Synthesizing period30 (58%)7 (35%)20 (69%)†Gestational age (weeks)27.1\u2009±\u20092.527.5\u2009±\u20092.526.8\u2009±\u20092.6small Gestational age8 (15%)2 (10%)5 (17%)Birth weight (g)971.2\u2009±\u2009252.41045.5\u2009±\u2009271.8933.5\u2009±\u2009203.6birth length (cm)34.1\u2009±\u20093.534.3\u2009±\u20093.434.1\u2009±\u20093.6birth Head circumference (cm)24.6\u2009±\u20092.224.8\u2009±\u20092.324.5\u2009±\u20092.2male sex26 (50%)7 (35%)16 (55%)cesarean section40 (77%)18 (90%)20 (71%)apgar score at 5\xa0min5.1\u2009±\u20091.55.3\u2009±\u20091.74.9\u2009±\u20091.3rds47 (90%)17 (85%)27 (96%)pda35 (67%)15 (79%)19 (66%)Nec3 (6%)0 (0%)2 (7%)culture-proven sepsis17 (33%)5 (26%)11 (38%)bpd (≥ moderate)25 (48%)7 (37%)16 (55%)rop (≥ stage 2)24 (46%)8 (40%)14 (50%)ivh (≥ grade 2)6 (12%)4 (20%)2 (7%)Breast Milk with/without formula38 (73%)13 (65%)22 (76%)exclusively fortified Breast Milk13 (25%)5 (25%)8 (28%)ventilation days (d)24.1\u2009±\u200918.420.9\u2009±\u200918.120.9\u2009±\u200918.1hospital days (d)85.5\u2009±\u200933.277.6\u2009±\u200924.886.6\u2009±\u200928.3tpn days (d)47.1\u2009±\u200932.537.2\u2009±\u200922.747.2\u2009±\u200922.4\ndata are presented as n (%), median (range), or mean\u2009±\u2009sd\ngdm Gestational diabetes mellitus, rds Respiratory Distress syndrome, pda patent Ductus Arteriosus, nec necrotizing enterocolitis, bpd bronchopulmonary dysplasia, rop retinopathy of prematurity, Ivh Intraventricular hemorrhage, tpn total parenteral nutrition\n*p \u2009=\u20090.035 for the difference between cord 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml vs. ≥ 10\xa0ng/ml\n†p \u2009=\u20090.023 for the difference between Cord 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml vs. ≥ 10\xa0ng/ml\nall neonates received 800\xa0iu 25(Oh)D per day from first 2\xa0weeks of age.']	N/A	N/A	[('CHEBI_33252', 'atomic nucleus', 95, 'Cord'), ('UBERON_0000948', 'heart', 95, 'Cord'), ('CHEBI_71657', 'versiconol acetate', 100, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 100, '25'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 103, 'OH ... D'), ('CHEBI_33252', 'atomic nucleus', 143, 'Cord'), ('UBERON_0000948', 'heart', 143, 'Cord'), ('CHEBI_71657', 'versiconol acetate', 148, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 148, '25(OH ... D'), ('CHEBI_75977', '(S)-2-hydroxyhexadecanoic acid', 305, 'steroid44'), ('GO_0007567', 'parturition', 429, 'Birth'), ('CHEBI_27300', 'vitamin D', 442, 'vitamin D'), ('GO_0031319', 'detection of cAMP', 450, 'D synthesizing'), ('GO_0007565', 'female pregnancy', 495, 'Gestational'), ('GO_0007565', 'female pregnancy', 554, 'gestational'), ('GO_0007567', 'parturition', 590, 'Birth'), ('UBERON_0000033', 'head', 699, 'head'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 924, 'NEC3'), ('UBERON_0013538', 'Brodmann (1909) area 7', 1101, 'Breast milk'), ('UBERON_0013558', 'Brodmann (1909) area 27', 1179, 'breast milk13'), ('GO_0007565', 'female pregnancy', 1423, 'gestational'), ('UBERON_0003495', 'respiratory system arteriole', 1458, 'respiratory distress'), ('UBERON_0002254', 'thyroglossal duct', 1500, 'ductus arteriosus'), ('UBERON_2005050', 'palatocerebral artery', 1614, 'IVH'), ('UBERON_0006250', 'infundibular recess of 3rd ventricle', 1618, 'intraventricular'), ('CHEBI_71657', 'versiconol acetate', 1722, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1722, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 1810, 'cord'), ('CHEBI_33010', 'chromide(1-)', 1817, '(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1821, 'D'), ('CHEBI_71657', 'versiconol acetate', 1893, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 1896, 'OH)D')]
S87-PMC5424337	PMC5424337	10/2016	S87-PMC5424337	['overall, Vitamins were considered beneficial, including Prenatal Vitamins (88.3\xa0%), multivitamins (81.6\xa0%), Vitamin C (66.1\xa0%), Vitamin E (65.2\xa0%), and Vitamin D (68.1\xa0%).']	N/A	N/A	[('CHEBI_33277', 'gamma-tocotrienol', 9, 'vitamins'), ('GO_0007565', 'female pregnancy', 56, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 65, 'vitamins'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D')]
S12-PMC5489519	PMC5489519	6/2017	S12-PMC5489519	['various factors such as less sunlight exposure due to indoor activity during the day or use of sunscreen, darker skin pigmentation, and health conditions such as Pregnancy and obesity result in Vitamin D deficiency in People6.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 162, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 218, 'people6')]
S118-PMC5489519	PMC5489519	6/2017	S118-PMC5489519	['all subjects were taking a Prenatal Vitamin with 400\u2009iu of Vitamin D. Blood samples were collected by venipuncture at the time of the study visit; then placed in a Serum separator tube, centrifuged, and Serum stored at −20\u2009°c until later analysis.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 36, 'vitamin'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('UBERON_0000178', 'blood', 70, 'Blood'), ('UBERON_0001977', 'blood serum', 164, 'serum'), ('UBERON_0001977', 'blood serum', 203, 'serum')]
S30-PMC5504744	PMC5504744	7/2017	S30-PMC5504744	['caption (table-wrap): table 1\n\ningredients and calculated Nutrient composition of the Gestation diet1itemgestation dietingredients, % as-Fed\u2003barley25.0\u2003oat20.0\u2003dried sugar Beet pulp14.3\u2003Wheat bran10.0\u2003soybean meal5.7\u2003dried Apple pomace5.6\u2003dried whole Maize Plant5.0\u2003Animal fat (70% lard and 30 % tallow)3.0\u2003linseed meal2.0\u2003potato protein2.0\u2003rapeseed meal2.0\u2003molasses2.0\u2003Dicalcium Phosphate1.16\u2003Calcium Carbonate0.75\u2003Sodium Chloride0.56\u2003pellan20.40\u2003Vitamin-Mineral premix30.40\u2003Amino acids4, %\u2003\u2003l-lysine Hcl0.08\u2003\u2003l-threonine0.06calculated composition, % dm\u2003dry matter, % of wet weight88.35\u2003total ash7.20\u2003Ether extract6.80\u2003crude protein15.10\u2003digestible energy, mj/kg dm13.70\n1in the arg group, the pellets were top dressed with 25 gl-Arginine Hcl/(sow·d), and in the ctrl group, the pellets were top dressed with 43 gl-alanine/(sow·d)\n2binder that aids in pellet formation (mikro-technik, gmbh & co. kg, germany)\n3contains: Vitamin A: 2,000,000 u/kg; Vitamin D3: 200,000 u/kg; Vitamin E: 10 g/kg; i: 137.4 mg/kg; Mn: 5 g/kg; Cu: 1.75 g/kg; zn: 1.4 g/kg; Se: 50 mg/kg\n4calculated amino acid composition, g/kg dm: alanine: 6.42; arginine: 8.51; aspartate plus asparagine: 12.70; cystine: 3.15; glutamate plus glutamine: 27.50; glycine: 6.54; histidine: 3.42; isoleucine: 5.74; leucine: 10.72; lysine: 7.90; methionine: 2.46; phenylalanine: 7.00; proline: 9.59; serine: 6.73; threonine: 6.30; tryptophan: 1.83; tyrosine: 5.03; valine: 7.38\n\ndata and Tissue sample collection at farrowing\nat the end of farrowing, litter characteristics including the number of piglets Born alive and stillborn and their individual body weights were recorded.']	N/A	N/A	"[('CHEBI_33284', 'nutrient', 58, 'nutrient'), ('GO_0007565', 'female pregnancy', 86, 'gestation'), ('GO_0007631', 'feeding behavior', 137, 'fed'), ('NCBITaxon_33208', 'Metazoa', 172, 'beet'), ('NCBITaxon_10088', 'Mus <genus>', 186, 'Wheat'), ('NCBITaxon_33208', 'Metazoa', 223, 'apple'), ('NCBITaxon_40674', 'Mammalia', 251, 'maize'), ('NCBITaxon_10088', 'Mus <genus>', 257, 'plant5'), ('NCBITaxon_33208', 'Metazoa', 266, 'Animal'), ('CHEBI_4509', 'diclofenac sodium', 370, 'Dicalcium phosphate1'), ('CHEBI_553473', 'ceftizoxime', 394, 'Calcium carbonate0'), ('CHEBI_70124', ""(2'S)-Hydroxy-(11S,12R)-dihydrostemofoline, (rel)-"", 416, 'Sodium chloride0'), ('CHEBI_33229', 'vitamin (role)', 448, 'Vitamin'), ('CHEBI_46662', 'mineral', 456, 'mineral'), ('CHEBI_29318', 'aminyl', 476, 'Amino'), ('CHEBI_17883', 'hydrogen chloride', 502, 'HCl0'), ('CHEBI_25698', 'ether', 602, 'Ether'), ('CHEBI_22654', 'asparagine derivative', 731, 'arginine'), ('CHEBI_17883', 'hydrogen chloride', 740, 'HCl'), ('CHEBI_27300', 'vitamin D', 921, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 948, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 948, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 974, 'vitamin E'), ('CHEBI_25614', 'nylons', 1010, 'Mn'), ('CHEBI_17996', 'chloride', 1022, 'Cu'), ('CHEBI_37972', 'phosphorus-32 atom', 1051, 'Se'), ('UBERON_0000479', 'tissue', 1444, 'tissue'), ('GO_0007567', 'parturition', 1562, 'born')]"
S126-PMC5513133	PMC5513133	7/2017	S126-PMC5513133	['caption (table-wrap): table 2\n\ncharacteristics of included reportsauthor, location, yeardesignsubjectstime of Vitamin D measurementcross-sectional studies\u2003august et al., usa, 1992 [88]cross-sectional11 – women with pe3rd trimester9 – chronic Htn12 – normotensive Pregnant controls\u2003fernandez- alonzo et al., spain, 2012 [97]cross-sectional466 – Pregnant women (7 had pe)1st Trimester\u2003pena hr, et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('PR_000008832', 'histatin-3', 242, 'HTN12'), ('GO_0007565', 'female pregnancy', 263, 'pregnant'), ('GO_0007565', 'female pregnancy', 344, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 373, 'trimester')]
S252-PMC5513133	PMC5513133	7/2017	S252-PMC5513133	['in the vdaart, frequency of pe among Pregnant women with a high risk for atopic disease was not lower when a supplementation of 4400\xa0iu Vitamin D daily was given in early Pregnancy (10–18\xa0weeks).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 37, 'pregnant'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy')]
S20-PMC5521778	PMC5521778	7/2017	S20-PMC5521778	['in Mammals, Pulmonary Vitamin A is accumulated in Lipid Interstitial Cells (Lipofibroblasts) located in the Periacinar fetal Lung during late Gestation and is mobilized during the Perinatal burst in Air Sac (Alveolar) remodeling and differentiation [12].']	N/A	N/A	[('NCBITaxon_40674', 'Mammalia', 3, 'mammals'), ('UBERON_0002048', 'lung', 12, 'pulmonary'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('CHEBI_18059', 'lipid', 50, 'lipid'), ('CL_0002295', 'type-6 epithelial cell of thymus', 50, 'lipid interstitial cells'), ('UBERON_0005169', 'interstitial tissue', 56, 'interstitial'), ('CL_0000057', 'fibroblast', 76, 'lipofibroblasts'), ('UBERON_0001179', 'peritoneal cavity', 108, 'periacinar'), ('UBERON_0002048', 'lung', 125, 'lung'), ('GO_0007565', 'female pregnancy', 142, 'gestation'), ('GO_0036268', 'swimming', 180, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 180, 'perinatal'), ('UBERON_0001005', 'respiratory airway', 199, 'air sac'), ('UBERON_0003215', 'alveolus', 208, 'alveolar')]
S23-PMC5521778	PMC5521778	7/2017	S23-PMC5521778	['neonatal or Antenatal Vitamin A supplementation either for preterm infants or Vitamin A deficient Pregnant women improves Vitamin A status and Pulmonary function and mitigates chronic Lung disease [16,17].']	N/A	N/A	[('GO_0007567', 'parturition', 12, 'antenatal'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin A'), ('GO_0007565', 'female pregnancy', 98, 'pregnant'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin A'), ('UBERON_0002048', 'lung', 143, 'pulmonary'), ('UBERON_0002048', 'lung', 184, 'lung')]
S3-PMC5537904	PMC5537904	7/2017	S3-PMC5537904	['Prenatal Vitamin D intake was assessed with diet recalls and questionnaires, and offspring body composition was measured via air displacement plethysmography at Birth and 5 months.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007567', 'parturition', 161, 'birth')]
S39-PMC5537904	PMC5537904	7/2017	S39-PMC5537904	['assessment of maternal Vitamin D intake\nprospective data on Vitamin D intake from Food and dietary supplements was collected from early Pregnancy through 5 months Postnatally.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 23, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_33290', 'food', 82, 'food'), ('GO_0007565', 'female pregnancy', 136, 'pregnancy'), ('GO_0007565', 'female pregnancy', 163, 'postnatally')]
S56-PMC5537904	PMC5537904	7/2017	S56-PMC5537904	['daily Vitamin D from dietary supplements was combined with daily Vitamin D from Food sources to estimate total oral intake of Vitamin D in Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_33290', 'food', 80, 'food'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy')]
S94-PMC5537904	PMC5537904	7/2017	S94-PMC5537904	['mother-offspring dyads were eligible for the analyses if offspring were Born ≥37 weeks Gestation, had 25(Oh)D measured in Cord Blood, and had at least one of the following: complete data on maternal Intake of Vitamin D during Pregnancy from Food and dietary supplements, body composition measured at Birth, or body composition measured Postnatally.']	N/A	N/A	[('GO_0007567', 'parturition', 72, 'born'), ('GO_0007565', 'female pregnancy', 87, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 102, '25(OH ... D'), ('UBERON_0002240', 'spinal cord', 122, 'cord'), ('UBERON_0000178', 'blood', 127, 'blood'), ('GO_0007631', 'feeding behavior', 199, 'intake'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('GO_0007565', 'female pregnancy', 226, 'pregnancy'), ('CHEBI_33290', 'food', 241, 'food'), ('GO_0007567', 'parturition', 300, 'birth'), ('GO_0007565', 'female pregnancy', 336, 'postnatally')]
S28-PMC5546866	PMC5546866	8/2017	S28-PMC5546866	['materials and methods\n\nthe maternal Vitamin d osteoporosis study\nthe maternal Vitamin d osteoporosis study is a multicenter, double-blind, randomized, placebo-controlled trial of Vitamin D supplementation in Pregnancy.']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 36, 'Vitamin'), ('CHEBI_33229', 'vitamin (role)', 78, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D'), ('GO_0007565', 'female pregnancy', 208, 'pregnancy')]
S42-PMC5546866	PMC5546866	8/2017	S42-PMC5546866	['all participants received standard Antenatal care and could continue self-administration of dietary supplements containing up to 400 iu/d Vitamin D.\n\nmaternal assessments during Pregnancy\nprior to commencing the study Medication and again at 34 weeks of Gestation, the women attended the research center for a detailed assessment of diet (including supplement use), lifestyle (smoking, physical activity participation, employment), and health (medical history, current medication use) using interviewer-led questionnaires.']	N/A	N/A	[('GO_0007567', 'parturition', 35, 'antenatal'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('CHEBI_60211', 'compound Z', 218, 'medication'), ('GO_0007565', 'female pregnancy', 254, 'gestation')]
S65-PMC5546866	PMC5546866	8/2017	S65-PMC5546866	['in addition, in women randomized to Cholecalciferol, we assessed the relationship between the Snps and the change in Vitamin D using the residuals of 25(Oh)D at 34 weeks of Gestation Regressed on 25(Oh)D at 14 weeks of Gestation as the outcome.']	N/A	N/A	[('CHEBI_52550', 'theopalauamide', 36, 'cholecalciferol'), ('SO_0000694', 'SNP', 94, 'SNPs'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 150, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 156, 'D'), ('GO_0007565', 'female pregnancy', 173, 'gestation'), ('GO_0060033', 'anatomical structure regression', 183, 'regressed'), ('CHEBI_71657', 'versiconol acetate', 196, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 202, 'D'), ('GO_0007565', 'female pregnancy', 219, 'gestation')]
S71-PMC5546866	PMC5546866	8/2017	S71-PMC5546866	['we also undertook sensitivity analysis in which women who reported having taken any additional Vitamin D–containing Supplements within 90 days of the late-Pregnancy Blood sampling were excluded.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 116, 'supplements'), ('GO_0007565', 'female pregnancy', 155, 'pregnancy'), ('UBERON_0000178', 'blood', 165, 'blood')]
S116-PMC5546866	PMC5546866	8/2017	S116-PMC5546866	['sensitivity analysis\nas the women were allowed to continue taking Vitamin D supplements containing up to 400 iu/d, in sensitivity analyses, we included only women who were not taking additional Vitamin D–containing supplements at 34 weeks of Gestation (n = 224, 67.7%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('GO_0007565', 'female pregnancy', 242, 'gestation')]
S150-PMC5576377	PMC5576377	8/2017	S150-PMC5576377	['newborns will be given the routine vaccinations, weights taken and Prenatal and Vitamin A provided including all the relevant services as outlined in the ehc package.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 67, 'prenatal'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin A')]
S54-PMC5587553	PMC5587553	9/2017	S54-PMC5587553	['antenatal nutritional supplements given to mothers during Pregnancy included zinc (15), iron (10), Vitamin A (10), Vitamins b1, b2, b3, b12(10), Vitamin C (9), and Iodine and Selenium (8).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin A'), ('CHEBI_33277', 'gamma-tocotrienol', 115, 'vitamins'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin C'), ('CHEBI_24859', 'iodine atom', 164, 'iodine'), ('CHEBI_27568', 'selenium atom', 175, 'selenium')]
S62-PMC5638722	PMC5638722	8/2017	S62-PMC5638722	['using variables significant on univariate analyses, (Gestational age at Birth, Birth weight, cord-Blood Vitamin D level) multivariable logistic regression analysis was done for determining the risk of eos and los.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 53, 'gestational'), ('GO_0007567', 'parturition', 72, 'birth'), ('GO_0007567', 'parturition', 79, 'birth'), ('UBERON_0000178', 'blood', 98, 'blood'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
S86-PMC5638722	PMC5638722	8/2017	S86-PMC5638722	['using variables significant on univariate analyses, (Gestational age at Birth, Birth weight, cord-Blood Vitamin D level) multivariable logistic regression analysis was done for determining the risk of eos and los.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 53, 'gestational'), ('GO_0007567', 'parturition', 72, 'birth'), ('GO_0007567', 'parturition', 79, 'birth'), ('UBERON_0000178', 'blood', 98, 'blood'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
S115-PMC5638722	PMC5638722	8/2017	S115-PMC5638722	['premature deliveries are also found to be increased in case of Gestational Vitamin D insufficiency22).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 63, 'gestational'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
S28-PMC5659607	PMC5659607	10/2017	S28-PMC5659607	['vdaart Vitamin D intervention\nthe women were randomized 1:1, between 10–18 weeks of Gestation, to a daily intake of 4,000 iu vitamin d3plus a multivitamin containing 400 iu Vitamin D3Or a matching placebo tablet plus a multivitamin containing 400 iu Vitamin D3, i.e.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'gestation'), ('CHEBI_76020', 'poly[d(TTC)]', 173, 'vitamin D3or'), ('PR_000025569', 'amyloid-beta precursor protein sequence variant T714I (human)', 173, 'vitamin D3or'), ('CHEBI_33279', 'vitamin D5', 250, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 250, 'vitamin D3')]
S34-PMC5659607	PMC5659607	10/2017	S34-PMC5659607	['exclusion criteria were Gestational age >26thweek, any endocrine, Cardiovascular, or Nephrological disorders or Vitamin D intake >600 iu/day[8].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 24, 'gestational'), ('UBERON_0004535', 'cardiovascular system', 66, 'cardiovascular'), ('UBERON_0001288', 'loop of Henle', 85, 'nephrological'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
S119-PMC5659607	PMC5659607	10/2017	S119-PMC5659607	['the vdaart and copsac2010trials used different doses of Vitamin D, initiated the supplementation at different Pregnancy stages ranging from 10 to 26 weeks of Gestation, and enrolled pregnant women with divergent 25(Oh)D levels at entry into the trials.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007565', 'female pregnancy', 158, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 212, '25 ... OH ... D')]
S71-PMC5664622	PMC5664622	9/2017	S71-PMC5664622	['dietary intake of Vitamin D (without supplementation) by Pregnant women was significantly below recommendations (median 2.1 µg/day) and was not significantly associated with Blood Vitamin D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('UBERON_0000178', 'blood', 174, 'blood'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D')]
S65-PMC5679631	PMC5679631	11/2017	S65-PMC5679631	['the analyses regarding maternal Vitamin D supplementation and maternal 25(Oh)D quintiles were performed on the entire population because the exposure of interest was Prenatal, i .']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('GO_0007565', 'female pregnancy', 166, 'prenatal')]
S86-PMC5679631	PMC5679631	11/2017	S86-PMC5679631	['finally, there was an expected difference among the quintiles in terms of season of Blood sampling in that the higher quintiles included a lower percentage of mothers giving blood during the winter season and a higher percentage in the summer.10.1371/journal.pone.0188011.t001\n\ncaption (table-wrap): table 1\ncharacteristics of the study population (n = 913).maternal multivitamin supplementation containing Vitamin D (n = 913)maternal Plasma 25(Oh)D nmol/l (n = 892)infant Vitamin D supplementation§(n = 616)none< 10 μg≥ 10 μgq 1q 2q 3q 4q 5yesno7.7–27.3#27.4–37.3#37.4–47.8#47.9–59.9#60.0–126.4#n = 350n = 144n = 41921.4 (4.3)&32.3 (2.9)&43.0 (3.2)&53.3 (3.5)&71.9 (10.9)&n = 441n = 165n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%) mode and place of Delivery Vaginal / home171 (48.9)71 (49.3)188 (44.9)80 (44.9)87 (48.6)80 (44.7)92 (51.7)78 (43.8)245 (55.6)93 (56.3)Vaginal / hospital137 (39.1)56 (38.9)174 (41.5)68 (38.2)74 (41.3)77 (43.0)63 (35.4)78 (43.8)157 (35.6)58 (35.2)c-section / hospital36 (10.3)12 (8.3)47 (11.2)21 (11.8)15 (8.4)19 (10.6)21 (11.8)18 (10.1)39 (8.8)14 (8.5)missing6 (1.7)5 (3.5)10 (2.4)9 (5.1)3 (1.7)3 (1.7)2 (1.1)4 (2.2)00 number of siblings none130 (37.1)68 (47.2)166 (39.6)71 (39.9)71 (39.7)73 (40.8)83 (46.7)61 (34.3)185 (42)46 (27.9)1153 (43.7)51 (35.4)197 (47.0)79 (44.4)79 (44.1)82 (45.8)72 (40.4)77 (43.2)189 (42.8)76 (46.1)2 or more66 (18.9)25 (17.4)56 (13.4)28 (15.7)28 (15.6)24 (13.4)23 (12.9)40 (22.5)66 (15)43 (26)missing1 (0.3)0001 (0.6)0001 (0.2)0 recruitment group conventional233 (66.6)66 (45.8)322 (76.8)114 (64)117 (65.4)121 (67.6)129 (72.5)132 (74.2)298 (67.6)54 (32.7)alternative117 (33.4)78 (54.2)97 (23.2)64 (36)62 (34.6)58 (32.4)49 (27.5)46 (25.8)143 (32.4)111 (67.3) maternal Vitamin D quintile 1104 (29.7)30 (20.8)44 (10.5)64 (14.5)40 (24.2)283 (23.7)30 (20.8)66 (15.8)87 (19.7)38 (23)359 (16.9)25 (17.4)95 (22.7)88 (20)24 (14.5)460 (17.1)22 (15.3)96 (22.9)98 (22.2)28 (17)538 (10.9)30 (20.8)110 (26.2)96 (21.8)29 (17.7)missing6 (1.7)7 (4.9)8 (1.9)8 (1.8)6 (3.6) sex male196 (56)63 (43.8)200 (47.7)102 (57.3)87 (48.6)93 (52)78 (43.8)89 (50)219 (49.7)81 (49.1)female154 (44)81 (56.2)219 (52.3)76 (42.7)92 (51.4)86 (48)100 (56.2)89 (50)222 (50.3)84 (50.9) vaginitis (last month of Pregnancy) no319 (91.2)123 (85.4)372 (88.8)156 (87.6)161 (89.9)163 (91)162 (91)153 (86)409 (92.7)143 (86.7)yes25 (7.1)16 (11.1)37 (8.8)13 (7.3)15 (8.4)13 (7.3)14 (7.9)21 (11.8)32 (7.3)22 (13.3)missing6 (1.7)5 (3.5)10 (2.4)9 (5.1)3 (1.7)3 (1.7)2 (1.1)4 (2.2)00 mode of infant Feeding Breast Feeding243 (69.4)105 (72.9)268 (64.0)107 (60.1)125 (69.8)114 (63.7)128 (71.9)128 (71.9)bottle feeding80 (22.9)25 (17.4)103 (24.6)52 (29.2)39 (21.8)50 (27.9)29 (16.3)34 (19.1)combination feeding26 (7.4)14 (9.7)47 (11.2)19 (10.7)15 (8.4)15 (8.4)21 (11.8)15 (8.4)missing1 (0.3)01 (0.2)00001 (0.6) season of maternal Blood sampling winter89 (50)69 (38.6)49 (27.4)41 (23)22 (12.4)spring54 (30.3)51 (28.5)46 (25.7)31 (17.4)16 (8.9)summer8 (4.5)23 (12.8)40 (22.3)66 (37.1)82 (46.1)autumn27 (15.2)36 (20.1)44 (24.6)40 (22.5)58 (32.6)\n§only Breast Fed children;\n#range;\n&mean (sd)\n\nmaternal 25(Oh)D and use of multivitamin supplements containing Vitamin D\nmaternal 25(Oh)D concentrations of the entire group ranged from 7.7 to 126.3 nmol/l with a mean of 44.3, sd 18.3 nmol/l.']	N/A	N/A	"[('UBERON_0000178', 'blood', 84, 'blood'), ('CHEBI_27300', 'vitamin D', 407, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 435, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 442, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 442, '25(OH ... D'), ('CHEBI_28384', 'vitamin K', 473, 'Vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 481, 'D'), ('GO_0007586', 'digestion', 756, 'Delivery'), ('UBERON_0000970', 'eye', 765, 'Vaginal'), ('UBERON_0000970', 'eye', 872, 'Vaginal'), ('CHEBI_28384', 'vitamin K', 1733, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 2237, 'Pregnancy'), ('GO_0007631', 'feeding behavior', 2512, 'Feeding'), ('UBERON_0000310', 'breast', 2520, 'Breast'), ('GO_0070479', ""nuclear-transcribed mRNA catabolic process, 5'-3' exonucleolytic nonsense-mediated decay"", 2527, 'Feeding243'), ('UBERON_0000178', 'blood', 2840, 'Blood'), ('GO_0007567', 'parturition', 3059, 'breast'), ('UBERON_0000310', 'breast', 3059, 'breast'), ('GO_0007631', 'feeding behavior', 3066, 'fed'), ('CHEBI_71657', 'versiconol acetate', 3109, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 3109, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 3164, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 3183, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 3189, 'D')]"
S26-PMC5685050	PMC5685050	10/2014	S26-PMC5685050	['[17]demonstrated that 83.3% of Pregnant thai women, especially in the 1st Trimester of Pregnancy, had Vitamin D insufficiency but without association with adverse Pregnancy outcomes such as spontaneous Abortion, Gestational diabetes, cesarean section rate and Preterm labor.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 31, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 74, 'trimester'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy'), ('GO_0007569', 'cell aging', 202, 'abortion'), ('GO_0007565', 'female pregnancy', 212, 'gestational'), ('GO_0007565', 'female pregnancy', 260, 'preterm')]
S27-PMC5685050	PMC5685050	10/2014	S27-PMC5685050	['they also demonstrated that Intake of Prenatal Vitamins at the Vitamin D dose of 400\xa0iu/day was sufficient to prevent Vitamin D deficiency but was not high enough to prevent Vitamin D insufficiency.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 28, 'intake'), ('GO_0007565', 'female pregnancy', 38, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 47, 'vitamins'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D')]
S147-PMC5697969	PMC5697969	12/2017	S147-PMC5697969	['caption (table-wrap): table 4\n\ndiversity and quantity of Food groups consumed during past 24 h by Pregnant women, by program group and survey round1baseline2endlinestandard mnchnutrition-focused mnchstandard mnchnutrition-focused mnchdifference-in-difference effect estimates3n 300300300300type of Food groups Consumed, %\u2003all Starchy staple foods100100100100—\u2003pulses37.734.737.065.729.3∗∗∗\u2003nuts and seeds3.71.63.73.01.4\u2003dairy40.334.339.367.033.7∗∗\u2003Flesh foods82.785.790.393.0−0.30\u2003\u2003meat23.020.716.030.717.0∗∗\u2003\u2003fish73.079.085.384.3−6.70\u2003eggs26.724.325.761.338.0∗∗∗\u2003dark-green leafy vegetables44.749.739.067.323.3∗\u2003other Vitamin A–rich fruit and vegetables28.0∗20.717.046.036.0∗∗∗\u2003other vegetables90.093.098.393.7−7.70∗\u2003other fruit62.7∗52.758.753.34.70number of Food groups Consumed, n 5.1 ± 1.445.0 ± 1.45.1 ± 1.36.5 ± 1.61.6∗∗∗consumed ≥5 Food groups, %67.060.765.088.730.0∗∗∗quantity of Food groups consumed, g\u2003all Starchy staple foods574 ± 210574 ± 225637 ± 399611 ± 276−26.3\u2003pulses89.9 ± 79.787.9 ± 77.8121 ± 96.9208 ± 12188.7∗∗∗\u2003nuts and seeds1.9 ± 10.93.8 ± 20.23.8 ± 14.62.6 ± 12.1−3.0\u2003dairy93.0 ± 17177.8 ± 14193.2 ± 137171 ± 15593.1∗∗\u2003Flesh foods89.6 ± 92.083.0 ± 91.7116 ± 120196 ± 18687.4∗∗\u2003\u2003meat22.2 ± 61.421.0 ± 57.723.1 ± 63.349.1 ± 11427.2∗∗\u2003\u2003fish67.4 ± 77.562.4 ± 73.197.9 ± 111151 ± 15158.1∗\u2003Eggs14.3 ± 32.112.9 ± 25.619.1 ± 36.337.7 ± 37.720.1∗∗\u2003dark-green leafy vegetables127 ± 185138 ± 174123 ± 145334 ± 272200∗∗∗\u2003other Vitamin A–rich fruit and vegetables36.3 ± 97.433.3 ± 91.826.6 ± 92.891.7 ± 17468.0∗∗\u2003other vegetables139 ± 111128 ± 112167 ± 129212 ± 14156.1∗∗\u2003other fruit185 ± 233∗∗131 ± 272141 ± 197160 ± 20172.4\n∗p< 0.05,∗∗p< 0.01,∗∗∗p< 0.001.']	N/A	N/A	[('CHEBI_33290', 'food', 57, 'food'), ('GO_0007565', 'female pregnancy', 98, 'pregnant'), ('CHEBI_33290', 'food', 298, 'food'), ('GO_0007631', 'feeding behavior', 310, 'consumed'), ('CHEBI_26738', 'sphingenine', 326, 'starchy'), ('UBERON_0007381', 'epidermal scale', 448, 'Flesh'), ('CHEBI_27300', 'vitamin D', 619, 'vitamin A'), ('CHEBI_33290', 'food', 760, 'food'), ('GO_0007631', 'feeding behavior', 772, 'consumed'), ('CHEBI_33290', 'food', 839, 'food'), ('CHEBI_33290', 'food', 888, 'food'), ('CHEBI_26738', 'sphingenine', 916, 'starchy'), ('UBERON_0007381', 'epidermal scale', 1143, 'Flesh'), ('CL_0002425', 'early T lineage precursor', 1308, 'Eggs14'), ('CHEBI_27300', 'vitamin D', 1439, 'vitamin A')]
S3-PMC5706533	PMC5706533	11/2017	S3-PMC5706533	['eligibility criteria for study selection \xa0trials of Prenatal Vitamin D supplementation with randomised allocation and control groups administered placebo, no Vitamin D, or Vitamin D ≤600 iu/day (or its equivalent), and published in a peer reviewed journal.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 52, 'prenatal'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D')]
S8-PMC5706533	PMC5706533	11/2017	S8-PMC5706533	['overall, Vitamin D increased mean Birth weight of 58.33 g (95% confidence interval 18.88 g to 97.78 g; 37 comparisons) and reduced the risk of small for Gestational age Births (risk ratio 0.60, 95% confidence interval 0.40 to 0.90; seven comparisons), but findings were not robust in sensitivity and subgroup analyses.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007567', 'parturition', 34, 'birth'), ('GO_0007565', 'female pregnancy', 153, 'gestational'), ('GO_0007567', 'parturition', 169, 'births')]
S23-PMC5706533	PMC5706533	11/2017	S23-PMC5706533	['eligibility criteria\nwe included trials of Prenatal Vitamin D supplementation in which\nsupplementation was Vitamin D given alone or in combination with a cointervention that was similar across multiple arms\nparticipants were Pregnant at enrolment or enrolled before Pregnancy and then followed-up in Pregnancy\nallocation into the parallel intervention groups at or after enrolment was randomised\nat least one trial group received placebo, no Vitamin D, or up to 600 iu/day (or a less frequent dose that would be about equivalent to 600 iu/day—for example, 4200 iu/week) during Pregnancy\nat least one of the articles describing the trial was a full text report published in a scientific journal or in another peer reviewed format.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('GO_0007565', 'female pregnancy', 225, 'pregnant'), ('GO_0007565', 'female pregnancy', 266, 'pregnancy'), ('GO_0007565', 'female pregnancy', 300, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 442, 'vitamin D'), ('GO_0007565', 'female pregnancy', 577, 'pregnancy')]
S68-PMC5706533	PMC5706533	11/2017	S68-PMC5706533	['results\n\nliterature search results and study selection\namong 3810 articles identified from the literature search, 43 Prenatal Vitamin D trials were eligible for inclusion in meta-analyses based on data in 77 publications (fig 1; table a in appendix 5).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 117, 'prenatal'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]
S71-PMC5706533	PMC5706533	11/2017	S71-PMC5706533	['caption (fig)\n\nfig 1 \xa0screening and selection of studies for systematic review and meta-analysis of Vitamin D supplementation during Pregnancy\n\ncharacteristics and quality of trials included in meta-analyses\nthe 43 eligible trials comprised 55 intervention-control arm comparisons and a total of 8406 enrolled women (table 1; tables a and b in Appendix 5).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('UBERON_0001154', 'vermiform appendix', 344, 'appendix')]
S79-PMC5706533	PMC5706533	11/2017	S79-PMC5706533	['caption (table-wrap): table 1\n\ncharacteristics of Prenatal Vitamin D trials included in systematic review and meta-analyses.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 50, 'prenatal'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
S85-PMC5706533	PMC5706533	11/2017	S85-PMC5706533	['caption (fig)\n\nfig 2 \xa0accumulation of Prenatal Vitamin D supplementation trials 1980-2024.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 38, 'prenatal'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D')]
S100-PMC5706533	PMC5706533	11/2017	S100-PMC5706533	['caption (table-wrap): table 3\n\nweighted mean differences (wmd) from primary meta-analyses of effects of Vitamin D supplementation during Pregnancy on maternal and neonatal/infant outcomesoutcomestrialsintervention-control comparisonsparticipantswmd (intervention versus control) (95% ci)i2(%) maternal Serum 25(Oh)D concentration at/near Delivery (nmol/l)3242570632.91*(27.19 to 38.62)96*neonatal/infant Birth weight (g ) 3037527358.33*(18.88 to 97.78)43*Birth length (cm)192138990.19 (−0.08 to 0.47)62*Head circumference at Birth (cm)171837910.13 (−0.05 to 0.30)63*Cord Serum 25(Oh)D concentration (nmol/l)2028298827.73*(21.57 to 33.88)96*Gestational age at Birth (weeks)19233214−0.01 (−0.19 to 0.16)54*neonatal bone Mineral content (g)226901.09 (−0.64 to 2.81)0infant bone Mineral content (g)1252−43.00*(−67.25 to −18.75)0neonatal bone Mineral density (g/cm2)226900.00 (−0.003 to 0.004)0infant bone Mineral density (g/cm2)1252−0.04*(−0.06 to −0.03)0length at age 1 year (cm)222511.30*(0.54 to 2.06)40weight at age 1 year (g)22252290.62 (−5.04 to 586.29)47head circumference at age 1 year (cm)222480.09 (−0.28 to 0.45)0length for age z score at 1 year†231860.31 (−0.04 to 0.66)0weight for age z score at 1 year†231870.13 (−0.19 to 0.45)0head circumference for age z score at 1 year†231830.12 (−0.18 to 0.42)0\n*p<0.05.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0001977', 'blood serum', 302, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 308, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 308, '25 ... OH ... D'), ('GO_0007567', 'parturition', 338, 'delivery'), ('GO_0007567', 'parturition', 404, 'Birth'), ('GO_0007567', 'parturition', 455, 'Birth'), ('UBERON_0000033', 'head', 503, 'Head'), ('GO_0007567', 'parturition', 525, 'birth'), ('UBERON_0000948', 'heart', 566, 'Cord'), ('UBERON_0001977', 'blood serum', 571, 'serum'), ('CHEBI_71657', 'versiconol acetate', 577, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 583, 'D'), ('GO_0007565', 'female pregnancy', 640, 'Gestational'), ('GO_0007567', 'parturition', 659, 'birth'), ('CHEBI_46662', 'mineral', 718, 'mineral'), ('CHEBI_46662', 'mineral', 775, 'mineral'), ('CHEBI_46662', 'mineral', 838, 'mineral'), ('CHEBI_46662', 'mineral', 901, 'mineral')]
S66-PMC5732505	PMC5732505	12/2017	S66-PMC5732505	['we calculated the average daily intake of Vitamin D from supplementation during the last two months of Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy')]
S87-PMC5732505	PMC5732505	12/2017	S87-PMC5732505	['p -values refer to differences between the groupsmaternal characteristics n non-gdm n gdm p valueage at Delivery (y)64231.4\xa0±\xa04.38132.7\xa0±\xa04.50.018level of educationa6325.0\xa0±\xa01.3794.7\xa0±\xa01.40.051parity6401.5\xa0±\xa00.7811.5\xa0±\xa00.70.275prepregnancy smoking, number of cigarettes daily6251.2\xa0±\xa03.7762.0\xa0±\xa04.60.064alcohol consumption before Pregnancy, portion/wk.6251.9\xa0±\xa02.0782.3\xa0±\xa03.50.755prepregnancy height (cm)642166.3\xa0±\xa06.081165.9\xa0±\xa05.40.398prepregnancy weight (kg)63163.5\xa0±\xa010.28172.1\xa0±\xa013.5<0.001prepregnancy bmi (kg/m2)63923.0\xa0±\xa03.58126.2\xa0±\xa04.8<0.001duration of Gestation at ogtt (wk)32326.3\xa0±\xa04.38025.9\xa0±\xa05.90.774duration of Gestation at Pregnancy Blood sampling (wk)64211.3\xa0±\xa01.98111.2\xa0±\xa02.20.089duration of Gestation at Delivery (wk)64240.2\xa0±\xa01.18140.1\xa0±\xa01.10.410pregnancy 25(Oh)D (nmol/l)64281.9\xa0±\xa019.58180.0\xa0±\xa021.20.417ucb 25(Oh)D (nmol/l)64280.1\xa0±\xa020.08178.4\xa0±\xa018.80.448supplemental Vitamin D intake during Pregnancy ( μ g/d)62115.5\xa0±\xa016.67613.5\xa0±\xa010.80.162cumulative Gestational weight gain atb(kg)0.093\u2003first measurement5801.7\xa0±\xa00.5741.6\xa0±\xa00.5\u200312th Gestational week5803.8\xa0±\xa01.0743.6\xa0±\xa01.1\u200320th Gestational week5806.3\xa0±\xa00.8746.2\xa0±\xa00.8\u200330th Gestational week5809.7\xa0±\xa00.5749.7\xa0±\xa00.4\u2003last measurement58013.8\xa0±\xa00.47413.7\xa0±\xa00.3\ngdm Gestational diabetes mellitus, 25(Oh)D 25-Hydroxy Vitamin D, ucb Umbilical cord Blood\nvalues are means ± sd\nascale from 1\u2009=\u2009lower secondary education to 6\u2009=\u2009first or second stage of tertiary education\nbvalues are adjusted for duration of Gestation\nindependent sample t-tests, mann-whitney u-tests, repeated measures anova or the pearson chi-square test, when appropriate, were applied to compare maternal characteristics between gdm and non-gdm mothers.']	N/A	N/A	[('GO_0007567', 'parturition', 104, 'delivery'), ('GO_0007565', 'female pregnancy', 330, 'pregnancy'), ('GO_0007565', 'female pregnancy', 560, 'gestation'), ('GO_0007565', 'female pregnancy', 624, 'gestation'), ('GO_0007565', 'female pregnancy', 637, 'pregnancy'), ('UBERON_0000178', 'blood', 647, 'blood'), ('GO_0007565', 'female pregnancy', 708, 'gestation'), ('GO_0007567', 'parturition', 721, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 774, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 826, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 832, 'D'), ('CHEBI_27300', 'vitamin D', 887, 'vitamin D'), ('GO_0007565', 'female pregnancy', 911, 'pregnancy'), ('GO_0007565', 'female pregnancy', 972, 'gestational'), ('GO_0007565', 'female pregnancy', 1055, 'gestational'), ('GO_0007565', 'female pregnancy', 1100, 'gestational'), ('GO_0007565', 'female pregnancy', 1145, 'gestational'), ('GO_0007565', 'female pregnancy', 1231, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 1262, '25(OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 1270, '25-hydroxy vitamin D'), ('UBERON_0007118', 'umbilicus', 1296, 'umbilical'), ('UBERON_0000178', 'blood', 1311, 'blood'), ('GO_0007565', 'female pregnancy', 1469, 'gestation')]
S111-PMC5732505	PMC5732505	12/2017	S111-PMC5732505	['1\n\nmaternal Vitamin D status and Gestational diabetes mellitus.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'gestational')]
S39-PMC5741981	PMC5741981	12/2018	S39-PMC5741981	['presented Drug classes were Paracetamol, nonsteroidal Anti-Inflammatory Drugs (Nsaids), Vitamins other than Folic Acid and Vitamin D, Drugs against a cold, Acid-suppressive medication, Antibiotics, antifungal medication, Drugs against nausea and vomiting (nvp), Sedatives/anxiolytics, anti-asthma medication, anti-diabetes medication, medication against high Blood pressure, and homeopathic medication.19\nFolic Acid and Vitamin D are Vitamins which are advised in the netherlands during Pregnancy.20therefore, women who only used these Vitamins were categorized as non-medication users.']	N/A	N/A	[('CHEBI_23888', 'drug', 10, 'drug'), ('CHEBI_46195', 'paracetamol', 28, 'paracetamol'), ('CHEBI_35472', 'anti-inflammatory drug', 54, 'anti-inflammatory drugs'), ('CHEBI_16039', 'ITP', 79, 'NSAIDs'), ('CHEBI_33277', 'gamma-tocotrienol', 88, 'vitamins'), ('CHEBI_30751', 'formic acid', 108, 'folic acid'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_23888', 'drug', 134, 'drugs'), ('CHEBI_37527', 'acid', 156, 'acid'), ('CHEBI_33282', 'antibacterial agent', 185, 'antibiotics'), ('CHEBI_23888', 'drug', 221, 'drugs'), ('CHEBI_46670', 'serpentine mineral', 262, 'sedatives'), ('UBERON_0000178', 'blood', 359, 'blood'), ('CHEBI_30751', 'formic acid', 405, 'Folic acid'), ('CHEBI_27300', 'vitamin D', 420, 'vitamin D'), ('CHEBI_33277', 'gamma-tocotrienol', 434, 'vitamins'), ('GO_0007565', 'female pregnancy', 487, 'pregnancy'), ('CHEBI_33277', 'gamma-tocotrienol', 536, 'vitamins')]
S70-PMC5741981	PMC5741981	12/2018	S70-PMC5741981	['of the respondents, 56 (48%) reported Folic Acid and/or Vitamin D use during Pregnancy.']	N/A	N/A	[('CHEBI_30751', 'formic acid', 38, 'folic acid'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy')]
S3-PMC5784894	PMC5784894	1/2018	S3-PMC5784894	['a Murine model was created in which Pregnant dams were either Vitamin D deficient or replete, and their offspring moved to a Vitamin D replete diet at weaning.']	N/A	N/A	[('NCBITaxon_39107', 'Murinae', 2, 'murine'), ('GO_0007565', 'female pregnancy', 36, 'pregnant'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
S89-PMC5812027	PMC5812027	2/2018	S89-PMC5812027	['1\n\nflow chart of the study inclusion\n\ncaption (table-wrap): table 1\n\ncharacteristics of the Pregnant women and their infants at Birthmeansdbirth weight (grams)a3542537.7birth length (cm)a502.3gestational age at Delivery (days)28012.4gestational age t1 (days)7613.8gestational age t3 (days)23412.9maternal s-25Ohd t1 (nmol/l)6424.4maternal s-25Ohd t3 (nmol/l)7534.4n (%)male gender of infanta976 (49.8)small for Gestational age (weight or length)93 (4.5)low Birth weight (<\u20092500\xa0g)58 (2.8)Preterm Delivery (<\u200937\xa0weeks)78 (3.8)spontaneous Preterm Delivery (<\u200937\xa0weeks)55 (2.7)Pregnancy loss97 (4.7)Intrauterine fetal death (≥\u200922\xa0weeks)9 (0.5)\nt1 first trimester, t3 third trimester, 25Ohd 25-Hydroxyvitamin D\nalive Born infants only\n\ncaption (table-wrap): table 2\n\nthe Pregnant women’s Vitamin D status in the first (t1) and third (t3) Trimester of Pregnancy, and their characteristics (mean or percent) grouped by 25Ohd concentration in (t1)t1 25Ohd (nmol/l)<\u20093030–49.950–74.975–99.9≥\u2009100n198291788565125%10.114.840.128.76.4bmi t1 (kg/m2)25.124.924.423.924.4age t1 (years)29.430.931.632.032.4born in sweden (%)14.154.683.387.893.5tobacco use t1 (%)6.84.64.04.61.6nulliparous t1 (%)34.842.042.643.142.7vitamin D supplement use t1 (%)10.628.245.256.662.9university level education (%)32.354.961.367.366.1small for Gestational age (%)5.74.25.34.14.0preterm Delivery (%)4.15.23.83.91.6low Birth weight (%)3.04.53.12.11.6pregnancy loss (%)6.35.64.55.10t3 25Ohd (nmol/l)<\u20093030–49.950–74.975–99.9≥\u2009100n163330473409443%9.018.226.022.524.4small for Gestational age (%)7.55.54.74.62.3preterm Delivery (%)4.31.23.62.21.6low Birth weight (%)4.30.32.71.21.4\nt1 first trimester, t3 third trimester, 25Ohd 25-hydroxyvitamin d\n\nBirth size and Preterm Delivery\nin total, 93 (4.5%) infants were Born sga.']	N/A	N/A	"[('GO_0007565', 'female pregnancy', 92, 'pregnant'), ('GO_0002211', 'behavioral defense response to insect', 128, 'birthMeanSDBirth'), ('GO_0007567', 'parturition', 211, 'delivery'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 307, '25OHD'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 341, '25OHD'), ('GO_0007565', 'female pregnancy', 411, 'gestational'), ('GO_0007567', 'parturition', 457, 'birth'), ('GO_0007128', 'meiotic prophase I', 488, 'Preterm'), ('GO_0007567', 'parturition', 496, 'delivery'), ('GO_0007565', 'female pregnancy', 537, 'preterm'), ('GO_0007567', 'parturition', 545, 'delivery'), ('GO_0007565', 'female pregnancy', 574, 'Pregnancy'), ('UBERON_0035108', 'temporalis fascia', 596, 'Intrauterine'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 681, '25OHD'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 687, '25-hydroxyvitamin D'), ('GO_0007567', 'parturition', 713, 'born'), ('GO_0007565', 'female pregnancy', 767, 'pregnant'), ('CHEBI_27300', 'vitamin D', 784, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 834, 'trimester'), ('GO_0007565', 'female pregnancy', 847, 'pregnancy'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 913, '25OHD'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 943, '25OHD'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1208, 'D'), ('GO_0007565', 'female pregnancy', 1311, 'gestational'), ('GO_0007567', 'parturition', 1353, 'delivery'), ('GO_0007567', 'parturition', 1384, 'birth'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 1449, '25OHD'), ('GO_0007565', 'female pregnancy', 1539, 'gestational'), ('GO_0007567', 'parturition', 1581, 'delivery'), ('GO_0007567', 'parturition', 1612, 'birth'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 1684, '25OHD'), ('GO_0007567', 'parturition', 1711, 'Birth'), ('GO_0007565', 'female pregnancy', 1726, 'preterm'), ('GO_0007567', 'parturition', 1734, 'delivery'), ('GO_0007567', 'parturition', 1776, 'born')]"
S99-PMC5812027	PMC5812027	2/2018	S99-PMC5812027	['caption (table-wrap): table 3\n\nassociation between Vitamin D status in Pregnancy with Birth size and Pregnancy loss (adjusted logistic regression analysis)small for Gestational ageapreterm Delivery (<\u200937\xa0weeks)blow Birth weight (<\u20092500\xa0g)cpregnancy lossdorci 95%orci 95%orci 95%orci 95%t1 25Ohde\u2003continuous nmol/l1.0030.99–1.010.9960.99–1.010.9990.99–1.010.989*0.98–1.00\u2003\u2003<\u200930 (ref)1.01.01.01.0\u2003\u200330–49.91.0780.44–2.661.6470.63–4.332.5490.88–7.381.0300.44–2.41\u2003\u200350–74.91.6320.69–3.851.2600.47–3.362.2870.77–6.830.6880.29–1.62\u2003\u200375–99-91.2920.51–3.271.3320.48–3.731.6650.51–5.490.8090.33–1.96\u2003\u2003≥\u20091001.2940.38–4.420.5020.09–2.721.2550.22–7.270.000ft3 25Ohde\u2003\u2003<\u200930 (ref)1.01.01.0\u2003\u200330–49.90.7710.34–1.750.3020.08–1.140.071*0.01–0.63\u2003\u200350–74.90.6230.27–1.450.9330.31–2.790.5840.17–1.98\u2003\u200375–99-90.6570.27–1.610.6140.18–2.140.2370.06–1.01\u2003\u2003≥\u20091000.318*0.11–0.900.4460.11–1.760.215*0.05–0.97δ25ohdg\u2003\u2003large increase (≥\u200930\xa0nmol/l) (ref)1.01.01.0\u2003\u2003small increase (0–30\xa0nmol/l)2.564*1.16–5.672.905*1.01–8.343.1220.97–10.09\u2003\u2003decrease (<\u20090\xa0nmol/l)3.679**1.60–8.442.8940.95–8.854.722*1.37–16.28\nt1 first trimester, t3 third trimester, 25Ohd 25-Hydroxyvitamin D\n* p \u2009<\u20090.05 ** p \u2009<\u20090.01\namodels include 92 (t1) and 80 (t3 and δ25ohd) cases of small for Gestational age\nbmodels include 77 (t1) and 43 (t3 and δ25ohd) cases of Preterm Delivery\ncmodels include 57 (t1) and 31 (t3 and δ25ohd) cases of low Birth weight\ndmodels include 96 cases of Pregnancy loss\neadjusted for education, origin, season of Conception and bmi at t1.']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('GO_0007567', 'parturition', 86, 'birth'), ('GO_0007565', 'female pregnancy', 101, 'pregnancy'), ('GO_0007565', 'female pregnancy', 165, 'gestational'), ('GO_0007567', 'parturition', 189, 'delivery'), ('GO_0007567', 'parturition', 215, 'birth'), ('CHEBI_63058', '(2R,3S)-EHNA', 289, '25OHDe'), ('CHEBI_63058', '(2R,3S)-EHNA', 647, '25OHDe'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 1116, '25OHD'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 1122, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 1233, 'gestational'), ('GO_0019230', 'proprioception', 1305, 'preterm delivery'), ('GO_0007567', 'parturition', 1382, 'birth'), ('GO_0007565', 'female pregnancy', 1423, 'pregnancy'), ('GO_0007620', 'copulation', 1481, 'conception')]"
S60-PMC5827025	PMC5827025	2/2018	S60-PMC5827025	['caption (table-wrap): table 3\n\nassociation between demographic characteristics and the risk of Gestational Vitamin D deficiency based on multiple logistic regression analyses.parametercrude modelsadjusted models rr (95% ci ) p values rr (95% ci) p valuespre-Pregnancy bmi [kg/m2]1\xa0\xa0<18.51.25 (1.06, 1.47)0.0071.26 (1.07, 1.48)0.006\xa0\xa018.5–22.91.001.00\xa0\xa0≥23.00.84 (0.67, 1.05)0.1160.84 (0.67, 1.06)0.135season of Blood sample2\xa0\xa0spring1.001.00\xa0\xa0summer1.11 (0.93, 1.33)0.2601.12 (0.94, 1.34)0.211\xa0\xa0fall1.06 (0.88, 1.27)0.5551.05 (0.87, 1.27)0.601\xa0\xa0winter1.45 (1.21, 1.74)<0.0011.45 (1.21, 1.74)<0.001periconceptional Multivitamin use3\xa0\xa0no1.001.00\xa0\xa0less than one month0.69 (0.51, 0.94)0.0190.68 (0.50, 0.93)0.016\xa0\xa0more than one month0.72 (0.58, 0.89)0.0020.72 (0.58, 0.90)0.003\n1adjusted for maternal age, periconceptional Multivitamin use, and season of sampling.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 95, 'gestational'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('GO_0007565', 'female pregnancy', 258, 'pregnancy'), ('UBERON_0000178', 'blood', 411, 'blood'), ('CHEBI_7025', 'mupirocin', 613, 'multivitamin'), ('CHEBI_7025', 'mupirocin', 818, 'multivitamin')]
S63-PMC5827025	PMC5827025	2/2018	S63-PMC5827025	['association between Gestational Vitamin D status and the risk of Preterm Delivery\nthe association between Gestational Vitamin D status and the risk of Preterm Delivery was analyzed.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 20, 'gestational'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'preterm'), ('GO_0007567', 'parturition', 73, 'delivery'), ('GO_0007565', 'female pregnancy', 106, 'gestational'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'preterm'), ('GO_0007567', 'parturition', 159, 'delivery')]
S66-PMC5827025	PMC5827025	2/2018	S66-PMC5827025	['caption (table-wrap): table 4\n\ncrude and adjusted rrs for Preterm Delivery in different groups.parametergestational Vitamin D statussufficiencyinsufficiencydeficiencygestational week (week)39.3\u2009±\u20091.739.0\u2009±\u20091.5**38.6\u2009±\u20092.5**††Preterm Delivery [n (%)]25 (2.66)48 (3.81)115 (8.23)crude rr (95% ci )1.001.45 (0.89, 2.37)3.28 (2.12, 5.11)**adjusted rr (95% ci )11.002.07 (1.16, 3.71)*4.02 (2.33, 6.92)**††early Preterm Delivery [n (%)]29 (0.97)6 (0.49)34 (2.59)crude rr (95% ci )1.000.50 (0.18, 1.42)2.70 (1.29, 5.66)**††adjusted rr (95% ci )11.000.54 (0.19, 1.51)2.97 (1.41, 6.24)**††late Preterm Delivery [n (%)]216 (1.69)42 (3.32)81 (5.64)crude rr (95% ci )1.001.98 (1.11, 3.55)*3.62 (2.10, 6.23)**††adjusted rr (95% ci )11.002.09 (1.17, 3.74)*3.90 (2.26, 6.72)**††\n1adjusted for pre-Pregnancy bmi, maternal age, Periconceptional multivitamin use, and season of sampling.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 58, 'preterm'), ('GO_0007567', 'parturition', 66, 'delivery'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007622', 'rhythmic behavior', 225, 'Preterm delivery'), ('GO_0019230', 'proprioception', 406, 'preterm delivery'), ('GO_0019230', 'proprioception', 585, 'preterm delivery'), ('GO_0007565', 'female pregnancy', 782, 'pregnancy'), ('GO_0007565', 'female pregnancy', 811, 'periconceptional')]
S69-PMC5827025	PMC5827025	2/2018	S69-PMC5827025	['the association between Gestational Vitamin D status and risk of early Preterm Delivery and late Preterm Delivery were then analyzed.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 24, 'gestational'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'preterm'), ('GO_0007567', 'parturition', 79, 'delivery'), ('GO_0007565', 'female pregnancy', 97, 'preterm'), ('GO_0007567', 'parturition', 105, 'delivery')]
S142-PMC5827025	PMC5827025	2/2018	S142-PMC5827025	['Gestational Vitamin D status was divided into three groups according to following criteria: 25(Oh)D <20\u2009ng/ml for vdd, 20\u2009≤\u200925(Oh)D <30\u2009ng/ml for vitamin insufficiency (vdi), and 25(Oh)D ≥30\u2009ng/ml for Vitamin D sufficiency (vds)5,14.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 92, '25'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 95, 'OH ... D'), ('CHEBI_33010', 'chromide(1-)', 126, '(OH)D'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 179, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 185, 'D'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D')]
S14-PMC5838372	PMC5838372	3/2018	S14-PMC5838372	['a new Vitamin D support programme was launched for Pregnant women by the ministry of health in 2011.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'pregnant')]
S25-PMC5838372	PMC5838372	3/2018	S25-PMC5838372	['after this success, a new nationwide Vitamin D support program was launched for Pregnant women by the ministry of health in 2011.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnant')]
S26-PMC5838372	PMC5838372	3/2018	S26-PMC5838372	['this program included 1200 iu Vitamin D replacement daily to all Pregnant women from the first Trimester of Pregnancy until six months after Delivery (15).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 95, 'trimester'), ('GO_0007565', 'female pregnancy', 108, 'pregnancy'), ('GO_0007567', 'parturition', 141, 'delivery')]
S103-PMC5838372	PMC5838372	3/2018	S103-PMC5838372	['the proportion of Pregnant women who received 1000-1200 iu/day of Vitamin D was 14.4% and this low value was statistically significant.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 18, 'pregnant'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
S246-PMC5941617	PMC5941617	5/2018	S246-PMC5941617	['besides the direct Regulation Of Calcium-Phosphorus Metabolism, Vitamin D also indirectly promotes bone mass accrual stimulating the Development Of Muscle Tissue [196–198].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 19, 'regulation of'), ('CHEBI_30272', 'arsonium', 33, 'calcium-phosphorus'), ('GO_0050655', 'dermatan sulfate proteoglycan metabolic process', 33, 'calcium-phosphorus metabolism'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0001503', 'ossification', 133, 'development of muscle tissue'), ('UBERON_0002385', 'muscle tissue', 148, 'muscle tissue')]
S543-PMC5941617	PMC5941617	5/2018	S543-PMC5941617	['another italian study [498] examined 24 women (light and dark skinned) at full-term Pregnancy: 23 out of 24 women had Vitamin D deficiency.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
S723-PMC5941617	PMC5941617	5/2018	S723-PMC5941617	['we suggest to start Vitamin D supplementation at the beginning of Pregnancy and continue for the entire duration of Pregnancy and Lactation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('GO_0007595', 'lactation', 130, 'lactation')]
S21-PMC5952272	PMC5952272	5/2018	S21-PMC5952272	['Micronutrient supplementation includes Folic Acid tablets 3\u2009months before Pregnancy and 3\u2009months Postnatal, Vitamin A and D drops for infant starting from Birth until 12\u2009months, and Iron and Folic Acid tablets for Pregnant women 3\u2009months after Conception until 3\u2009months Postnatal.']	N/A	N/A	[('CHEBI_6956', 'Mitragynine', 0, 'Micronutrient'), ('CHEBI_30751', 'formic acid', 39, 'folic acid'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007567', 'parturition', 97, 'postnatal'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 122, 'D'), ('GO_0007567', 'parturition', 155, 'birth'), ('CHEBI_24870', 'ion', 182, 'iron'), ('CHEBI_30751', 'formic acid', 191, 'folic acid'), ('GO_0007565', 'female pregnancy', 214, 'pregnant'), ('GO_0007620', 'copulation', 244, 'conception'), ('GO_0007567', 'parturition', 270, 'postnatal')]
S78-PMC5952272	PMC5952272	5/2018	S78-PMC5952272	['immunity-related Micronutrients\n\nVitamins E and D\n\nPregnant women\nalmost 1 in every 5 women had Vitamin E deficiency.']	N/A	N/A	[('CHEBI_33839', 'macromolecule', 17, 'micronutrients'), ('CHEBI_27306', 'vitamin B6', 33, 'Vitamins E'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 33, 'Vitamins E'), ('PR_000006444', 'diacylglycerol kinase delta', 48, 'D'), ('GO_0007565', 'female pregnancy', 51, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin E')]
S88-PMC5952272	PMC5952272	5/2018	S88-PMC5952272	['status of (a) Vitamin E and (b) Vitamin D in Pregnant women (18-43 years) by Trimester and province assessed through Serum levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 45, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 77, 'trimester'), ('UBERON_0001977', 'blood serum', 117, 'serum')]
S246-PMC5956785	PMC5956785	5/2018	S246-PMC5956785	['the use of Vitamin D and Fish Oil during Pregnancy in case mothers was not significantly different from controls following covariate adjustments [80].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_34766', 'Furamizole', 25, 'fish oil'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy')]
S24-PMC5995352	PMC5995352	6/2018	S24-PMC5995352	['in Pregnancy, an increase in the active Vitamin D Calcitriol (1,25(Oh)2D) ensures Calcium and Phosphate supply to the foetus.']	N/A	N/A	"[('GO_0007565', 'female pregnancy', 3, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 50, 'calcitriol'), ('CHEBI_17996', 'chloride', 63, ','), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 64, '25(OH)2D'), ('CHEBI_22313', 'alkaline earth metal atom', 82, 'calcium'), ('CHEBI_18367', 'phosphate(3-)', 94, 'phosphate')]"
S27-PMC5995352	PMC5995352	6/2018	S27-PMC5995352	['maternal 25Ohd crosses the Placenta and, as the Foetus has no endogenous synthesis of 25Ohd, maternal Vitamin D insufficiency during Pregnancy implies Vitamin D insufficiency in the new Born.']	N/A	N/A	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 9, '25OHD'), ('UBERON_0001987', 'placenta', 27, 'placenta'), ('UBERON_0000376', 'hindlimb stylopod', 48, 'foetus'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 86, '25OHD'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('GO_0007567', 'parturition', 186, 'born')]"
S60-PMC5995352	PMC5995352	6/2018	S60-PMC5995352	['time spent outdoors during Pregnancy and Vitamin D supplementation during Pregnancy was self-reported in a questionnaire at 28 weeks of Gestation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007565', 'female pregnancy', 136, 'gestation')]
S169-PMC5995352	PMC5995352	6/2018	S169-PMC5995352	['[45] observed no association between maternal 25Ohd sampled at 26–28 weeks Gestation and offspring length z-scores at 18 months in 596 children of mixed ethnicity from singapore with a lower rate of Vitamin D insufficiency (25%) and deficiency (6%) compared to our mothers (40% insufficient and 17% deficient).']	N/A	N/A	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 46, '25OHD'), ('GO_0007565', 'female pregnancy', 75, 'gestation'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D')]"
S7-PMC6011374	PMC6011374	6/2018	S7-PMC6011374	['a 53% decreased risk for Gestational diabetes mellitus (gdm) was observed with high (>\u200981\xa0nmol/l) “standardised” Vitamin D status when compared to moderate-high (63–81\xa0nmol/l, arr, 0.47; 95% ci: 0.23, 0.96).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 25, 'gestational'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
S76-PMC6011374	PMC6011374	6/2018	S76-PMC6011374	['using moderate-high as a reference (standardised Vitamin D 63–81\xa0nmol/l), there was no appreciable effect of having a low, low-moderate or high Vitamin D with the risk of developing any Pregnancy complication after adjusting for confounders.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 186, 'pregnancy')]
S78-PMC6011374	PMC6011374	6/2018	S78-PMC6011374	['when women were categorised based on clinical definitions of Vitamin D deficiency and Serum 25(Oh)D between 50 and 75\xa0nmol/l used as the reference, no significant relationship between Vitamin D status and adverse Pregnancy outcome was found (table2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('UBERON_0001977', 'blood serum', 86, 'serum'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 92, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007565', 'female pregnancy', 213, 'pregnancy')]
S124-PMC6011374	PMC6011374	6/2018	S124-PMC6011374	['adjusted relative risks (arr) of Pregnancy complications from any complication, preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaeous preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status and stratified by fetal sex.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('GO_0007565', 'female pregnancy', 99, 'gestational'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007567', 'parturition', 186, 'birth'), ('GO_0007565', 'female pregnancy', 213, 'gestational'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D')]
S6-PMC6043562	PMC6043562	7/2018	S6-PMC6043562	['feno levels were lower with higher intakes of Prenatal Vitamin D (−16.15%, 95% ci: −20.38 to −2.88%), Folate from Foods (−3.86%, 95% ci: −8.33 to 0.83%) and N-3 Pufas (−9.21%, 95% ci −16.81 to −0.92%).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 46, 'prenatal'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 102, 'folate'), ('CHEBI_33290', 'food', 114, 'foods'), ('CHEBI_30256', 'thiocarbonyl group', 157, 'n-3'), ('CHEBI_86926', 'S a S b S', 161, 'PUFAs')]
S72-PMC6043562	PMC6043562	7/2018	S72-PMC6043562	['the point estimate for Prenatal Vitamin E intake from Food and supplements combined was 6.94% (95% ci −2.36 to 12.24%) for the feno outcome (table\xa04), which was much larger than the Vitamin E estimate from diet alone (table\xa03).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'prenatal'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin E'), ('CHEBI_33290', 'food', 54, 'food'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin E')]
S223-PMC6043562	PMC6043562	7/2018	S223-PMC6043562	['Prenatal maternal exposures of interest were residence-specific Air Pollutants (3rdtrimester bc or Pm2.5,) and Nutrient intakes (1stand 2ndtrimester averaged energy-adjusted dietary intakes of Vitamins D, c, and e, Β-Carotene, Folate, Choline, and N-3 and N-6 polyunsaturated Fatty Acids).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_35086', 'm-Benzenesulfonium diazonium chloride', 64, 'air'), ('CHEBI_26199', 'polyprenol', 68, 'pollutants'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 99, 'PM2'), ('CHEBI_33284', 'nutrient', 111, 'nutrient'), ('CHEBI_27300', 'vitamin D', 193, 'vitamins D'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 215, 'β-carotene'), ('CHEBI_30863', '5-azaorotic acid', 227, 'folate'), ('CHEBI_15354', 'choline', 235, 'choline'), ('CHEBI_30256', 'thiocarbonyl group', 248, 'n-3'), ('CHEBI_18320', '1,4-dithiothreitol', 256, 'n-6'), ('CHEBI_35366', 'fatty acid', 276, 'fatty acids')]
